

LEGEMIDDELSTATISTIKK

2019:2

Reseptregisteret
2014–2018

The Norwegian
Prescription Database
2014–2018

Reseptregisteret 2014–2018

The Norwegian Prescription Database 2014–2018

Christian Lie Berg

Kristine Olsen

Solveig Sakshaug

Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health
Område for Helsedata og digitalisering
Avdeling for Legemiddelstatistikk
Juni 2019

Tittel/Title:

Legemiddelstatistikk 2019:2
Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018

Forfattere/Authors:

Christian Berg, redaktør/editor
Kristine Olsen
Solveig Sakshaug

Acknowledgement:

Julie D. W. Johansen (English text)

Bestilling/Order:

Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no /
The report can be downloaded from www.fhi.no

Grafisk design omslag:

Fete Typer

Ombrekking:

Houston911

Kontaktinformasjon / Contact information:

Folkehelseinstituttet / Norwegian Institute of Public Health
Postboks 222 Skøyen
N-0213 Oslo
Tel: +47 21 07 70 00

ISSN: 1890-9647

ISBN: 978-82-8406-014-9

Sitering/Citation:

Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018]
Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019.

Tidligere utgaver / Previous editions:

2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007

2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008

2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler /
The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs

2011: Legemiddelstatistikk 2011:2: Reseptregisteret 2006–2010 / The Norwegian Prescription Database 2006–2010

2012: Legemiddelstatistikk 2012:2: Reseptregisteret 2007–2011. Tema: Legemidler og eldre /
The Norwegian Prescription Database 2007–2011. Topic: Drug use in the elderly

2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008–2012 / The Norwegian Prescription Database 2008–2012

2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009–2013 / The Norwegian Prescription Database 2009–2013

2015: Legemiddelstatistikk 2015:2: Reseptregisteret 2010–2014. Tema: Antibiotika /
The Norwegian Prescription Database 2010–2014. Topic: Antibiotics

2016: Legemiddelstatistikk 2016:2: Reseptregisteret 2011–2015 / The Norwegian Prescription Database 2011–2015

2017: Legemiddelstatistikk 2017:2: Reseptregisteret 2012–2016 / The Norwegian Prescription Database 2012–2016

2018: Legemiddelstatistikk 2018:2: Reseptregisteret 2013–2017. Tema: Legemidler og eldre /
The Norwegian Prescription Database 2010–2014. Topic: Drug use in the elderly

Innhold

Sammendrag	7
1. Generelt om Reseptregisteret (NorPD) og legemiddelstatistikk	8
1.1 Reseptregisteret	8
1.2 Nordiske reseptregistre	11
1.3 Grossistbasert legemiddelstatistikk	12
1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifikasjon.....	12
1.5 Definert Døgdose (DDD).....	13
1.6 WHO Collaborating Centre for Drug Statistics Methodology	14
2. Reseptregisteret (NorPD) 2014–2018	15
2.1 Utvalgte nøkkeltall fra Reseptregisteret	15
2.2 Reseptkategorier og refusjon av utgifter til legemidler	19
2.3 Beskrivelse av hovedtabellene	20
2.4 ATC main groups.....	24
2.5 ATC group A – Alimentary tract and metabolism.....	25
2.6 ATC group B – Blood and bloodforming organs.....	36
2.7 ATC group C – Cardiovascular system	39
2.8 ATC group D – Dermatologicals	47
2.9 ATC group G – Genito urinary system and sex hormones.....	53
2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins	58
2.11 ATC group J – Antiinfectives for systemic use	61
2.12 ATC group L – Antineoplastic and immunomodulating agents	68
2.13 ATC group M – Musculo-skeletal system	71
2.14 ATC group N – Nervous system	74
2.15 ATC group P – Antiparasitic products, insecticides and repellents	84
2.16 ATC group R – Respiratory system	86
2.17 ATC group S – Sensory organs	91
2.18 ATC-group V – Various	95
Noen forkortelser og definisjoner	97
Folkemengde i Norge 2014–2018 (per 1. juli)	98
Folkemengde etter alder i 2018 (per 1. juli)	98
Liste over vitenskapelige publikasjoner basert på data fra Reseptregisteret per 21.02.2019	99

Contents

Summary	7
1. General information about the Norwegian Prescription Database (NorPD) and drug statistics	8
1.1 About the NorPD	8
1.2 Prescription statistics in the other Nordic countries	11
1.3 The Norwegian Drug Wholesales Statistics	12
1.4 The Anatomical Therapeutic Chemical (ATC) classification system	12
1.5 The Defined Daily Dose (DDD).....	13
1.6 WHO Collaborating Centre for Drug Statistics Methodology	14
2. The Norwegian Prescription Database (NorPD) 2014–2018	15
2.1 Selected key figures from the NorPD.....	15
2.2 Prescription categories and reimbursement of medicinal expenses	19
2.3 Description of the main tables	20
2.4 ATC main groups.....	24
2.5 ATC group A – Alimentary tract and metabolism.....	25
2.6 ATC group B – Blood and bloodforming organs.....	36
2.7 ATC group C – Cardiovascular system	39
2.8 ATC group D – Dermatologicals	47
2.9 ATC group G – Genito urinary system and sex hormones.....	53
2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins	58
2.11 ATC group J – Antiinfectives for systemic use	61
2.12 ATC group L – Antineoplastic and immunomodulating agents.....	68
2.13 ATC group M – Musculo-skeletal system	71
2.14 ATC group N – Nervous system	74
2.15 ATC group P – Antiparasitic products, insecticides and repellents	84
2.16 ATC group R – Respiratory system	86
2.17 ATC group S – Sensory organs	91
2.18 ATC-group V – Various	95
Some abbreviations and definitions	97
Population in Norway 2014–2018 (as of 1st July)	98
Population by age in 2018 (as of 1st July)	98
List of publications based on data from the Norwegian Prescription Database (NorPD) as of 21.02.2019	99

Sammendrag Summary

Siden Reseptregisteret ble opprettet 1. januar 2004 har i underkant av 5,8 millioner individer blitt inkludert i registeret med minst ett legemiddel utlevert på resept fra apotek. Antall legemiddelutleveringer etter resept til pasienter i samme periode er rundt 620 millioner.

Reseptregisteret inneholder opplysninger fra alle landets apotek om utlevering av legemidler på resept, til forskrivers egen praksis og til institusjoner. I 2018 ble rundt 97 % av legemidlene i Reseptregisteret (målt i DDD) utlevert til enkeltpersoner. Salg av reseptfrie legemidler er ikke inkludert i Reseptregisteret.

Generell informasjon om Reseptregisteret, legemiddelstatistikk, klassifikasjon av legemidler og målemetoder finnes i rapportens del 1. Del 2 inneholder nøkkeltall fra Reseptregisteret og et omfattende tabellverk med opplysninger om antall individer som har fått utlevert legemidler etter resept fra apotek i Norge i siste femårsperiode (2014–2018). I 2018 fikk 70 % av den norske befolkningen utlevert minst ett legemiddel på resept, 77 % av kvinnene og 64 % av mennene (tabell 2.1.a).

Ettårsprevalensen for å få utlevert minst ett legemiddel etter resept i 2018 var lavest i aldersgruppen 5–9 år for både kvinner og menn (figur 2.1). Mellom 92 % og 95 % av individene i alderen 70 år og eldre fikk utlevert medisiner etter resept. Tabell 2.1.b viser ettårsprevalens for hver av de 14 ATC-hovedgruppene; totalt og fordelt på kvinner og menn. De tre legemiddelgruppene som er mest brukt blant begge kjønn er midler mot infeksjoner til systemisk bruk (ATC-gruppe J), legemidler med virkning på nervesystemet (ATC-gruppe N) og legemidler som brukes for sykdommer i luftveiene (ATC-gruppe R).

Tabell 2.1.c viser en oversikt over legemidler med flest brukere i Norge i 2018 (antall og andel brukere definert som ATC 5. nivåer).

Reseptregisteret har en nettside der man kan finne kompletterende informasjon: www.norpd.no (engelsk versjon) eller www.reseptregisteret.no (norsk versjon).

Avdeling for legemiddelstatistikk,
Folkehelseinstituttet, juni 2019

Since the Norwegian Prescription Database (NorPD) was established on 1 January 2004 5.8 million individuals have been included in the database with at least one drug dispensed from a pharmacy. The number of drugs dispensed to patients in the same period is about 620 millions.

NorPD contains information from all Norwegian pharmacies regarding the dispensing of drugs to individuals, to prescribers' own practice and to institutions. In 2018, about 97% of the drugs registered in NorPD (measured in DDD) were dispensed to individuals. Sales of over-the-counter drugs are not included in NorPD.

General information about the NorPD, drug statistics, classification of drugs and measurement methods is included in part 1 of the report. Part 2 contains selected key figures from the NorPD and the main tables with information about the number of individuals who had drugs dispensed from pharmacies in Norway during the last five years (2014–2018). In 2018, 70% of the Norwegian population received at least one prescription drug, 77% of the women and 64% of the men (Table 2.1.a).

The one-year prevalence in the population who had at least one drug dispensed in 2018 was lowest in the age group 5–9 years for both women and men (Figure 2.1). Between 92% and 95% of the individuals aged 70 and older were dispensed at least one drug. Table 2.1.b shows the one-year prevalence in the population for each of the 14 ATC main groups; total and the distribution between women and men. The three drug groups most commonly used by both women and men are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R).

Table 2.1.c gives an overview of the most commonly used drugs (number of users/prevalence, defined as ATC 5th levels) in Norway in 2018.

The NorPD has a website where you can find additional information: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version).

Department of Pharmaceutical Statistics,
Norwegian Institute of Public Health, June 2019

Del 1

Part 1

1. Generelt om Reseptregisteret (NorPD) og legemiddelstatistikk

1.1 Reseptregisteret

Ny apoteklov som trådte i kraft 1. mars 2001 forpliktet alle apotek i Norge til å videresende reseptdata til en ny nasjonal legemiddeldatabase. Forskrift om innsamling og behandling av helseopplysninger i Reseptbasert legemiddelregister (Reseptregisteret), hjemlet i Helseregisterloven, ble vedtatt av kongen i Statsråd i oktober 2003 (1). Forskriften angir hvilke opplysninger som kan samles inn fra apotek og administrative registre. Opplysningene i Reseptregisteret kan bare anvendes til formål som er nevnt i § 1-3. Formålet med Reseptregisteret (jf. forskriftens § 1-3) er å samle inn og behandle data om legemiddelbruk hos mennesker og dyr for å:

1. kartlegge forbruket i landet og belyse endringer over tid
2. fremme og gi grunnlag for forskning og utredning for å kunne belyse positive og negative effekter av legemiddelbruk
3. gi myndighetene et statistisk grunnlag for kvalitetssikring av legemiddelbruk og overordnet tilsyn, styring og planlegging
4. gi legemiddelrevirenter et grunnlag for internkontroll og kvalitetsforbedring

1. General information about the Norwegian Prescription Database (NorPD) and drug statistics

1.1 About the NorPD

From March 1st 2001 the new legislation in the Norwegian pharmacy sector came into force. This legislation obliged all pharmacies in Norway to forward prescription data to a new national drug database. The regulation covering the «collection and handling of health information in the Norwegian Prescription Database (Reseptregisteret)», under the provision of the Personal Health Data Filing System Act, was approved in October 2003 (1). The regulation states which information the register can collect from the pharmacies and administrative registers. The objectives of the NorPD, as defined in authoritative regulations, are to collect and process data on drug use in individuals and animals in Norway to:

1. map usage trends and monitor trends over time
2. be a resource for research in order to see positive and negative effects of drug consumption
3. give health authorities a statistical management tool for quality control of drug use and for steering and planning
4. give prescribers a basis for internal control and quality improvement of their prescribing practices

Datainnsamling og variabler i Reseptregisteret

Folkehelseinstituttet har siden 1. januar 2004 mottatt opplysninger om hver enkelt ekspederte resept og rekvisisjon fra alle apotek i Norge (2). I apotekene er det tilrettelagt for automatisk innsending av rapport til Reseptregisteret til fast tidspunkt hver måned, slik at apotekene kan oppfylle sin rapporteringsplikt uten vesentlig ekstra arbeid.

Reseptregisteret inneholder informasjon om alle legemidler som er forskrevet og utlevert til enkelt-pasienter utenom sykehus og institusjoner. Legemidler forskrevet på godkjeningsfritak (legemidler uten markedsføringstillatelse) er også inkludert i registeret dersom varen er registrert i Vareregisteret (www.farmalogg.no/no/Om-Vareregisteret/). Legemidler som selges reseptfritt er ikke registrert i Reseptregisteret. Hvis reseptfrie legemidler er forskrevet på resept vil de imidlertid bli registrert i databasen.

De viktigste dataene i Reseptregisteret er basert på resepter forskrevet til enkeltpersoner, men også reseptekspederinger av legemidler fra veterinærer til dyr og legemidler utlevert til forskrivers egen praksis registreres i Reseptregisteret. Når det gjelder pasienter som er innlagt på sykehus eller sykehjem, samler registeret kun inn aggregerte data på institusjons- eller avdelingsnivå, basert på informasjon som apotekene registrerer når de leverer legemidler til institusjoner.

Reseptregisteret inneholder følgende variabler:

Pasient

Personidentifikasjon (kryptert), fødselsmåned/-år, døds måned/-år, kjønn og bosted (kommune og fylke)

Forskriver

Personidentifikasjon (kryptert), fødselsår, kjønn, profesjon og spesialitet

Legemiddel

Varenummer, handelsnavn, styrke, legemiddelform, pakningsstørrelse, ATC-kode, verdi og enhet for DDD, utleveringsgruppe og apotekets utsalgspris

Informasjon om den enkelte utlevering

Antall pakninger utlevert, antall definerte døgndoser (DDD), reseptkategori (se kap. 3.2), hjemmel, kode for refusjon (se under), utleveringsdato, pris for resepten og dyreart ved resept til dyr

Apotek

Apoteknavn, konsesjonsnummer, kommune og fylke

Data collection and variables in the NorPD

Since January 1st 2004, the Norwegian Institute of Public Health (NIPH) has received data on prescriptions and requisition from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy.

The NorPD contains information about all drugs prescribed and dispensed to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included if they are registered in «Vareregisteret» (the Norwegian Article Number Registry) (<https://www.farmalogg.no/en/The-Article-Number-Register/>). Drugs sold over-the-counter (OTC) are not recorded in the NorPD. However if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database.

The key data in the NorPD are based on prescriptions to individual humans, but dispensed prescriptions to animals from veterinarians and drugs delivered to a prescriber's own practice are also collected in the registry. For patients in nursing homes and hospitals, the register collects data on drug use at the level of the institution or the department, i.e. on an aggregate level.

The NorPD contains the following variables:

Patient

Person-identifier (encrypted), month/year of birth, month/year of death, gender and place of residence (municipality & county)

Prescriber

Person-identifier (encrypted), year of birth, gender, profession and speciality

Drug

Article number, brand name, strength, dosage form, package size, ATC code, DDD value and DDD unit, prescription category and pharmacy retail price

Information about each dispensed drug

Number of packages dispensed, number of Defined Daily Doses (DDD), prescription category (see chap. 3.2), prescription regulation, reimbursement code (see below), dispensing date, price per filled prescription and species of animal (if prescription from a veterinary)

Pharmacy

Name, license number, municipality and county



Figure 1.1. Data flow, the Norwegian Prescription Database (NorPD).

Varenummeret er en unik identifikasjon for hver pakning av et legemiddel og muliggjør kobling til andre registre som gir detaljert informasjon om legemidlene.

Reseptregisteret inneholder også informasjon om refusjonskoder registrert tilknyttet resepter refundert etter henholdsvis blåreseptforskriftens §§ 2 og 3 og forskrift om helseforetaksfinansierte reseptlegemidler, også kalt blåresepter og H-resepter. For blåresepter ble det tidligere registrert overordnede refusjonskoder etter egen liste definert i blåreseptforskriften, og refusjonskodene kunne da fungere som en grov diagnosekode for enkelte legemidler. Ny blåreseptforskrift trådte i kraft mars 2008, og ble fullstendig implementert fra mars 2009. I ny blåreseptforskrift er gyldige refusjonskoder angitt på en egen refusjonsliste. Refusjonskodene tar utgangspunkt i enten International Classification of Diseases versjon 10 (ICD-10) eller International Classification of Primary Care versjon 2 (ICPC-2). I tillegg har Legemiddelverket definert enkelte egne koder. For H-resepter ble krav om refusjonskoder innført i forbindelse med ikrafttredelse av forskriften 1. juli 2015. Det er ikke fastsatt noen refusjonsliste for H-resepter, så i utgangspunktet kan alle koder i International Classification of Diseases versjon 10 (ICD-10) eller International Classification of Primary Care versjon 2 (ICPC-2) benyttes. De første refusjonskodene tilknyttet H-resept ble registrert i august 2016, og i 2018 er det registrert refusjonskode for omtrent 60 % av H-reseptene i Reseptregisteret.

Datasikkerhet

Som illustrert i figur 1.1 blir registreringer av utleverte legemidler fra apotek overført automatisk (elektronisk) til Statistisk Sentralbyrå (SSB) før de kommer til FHI og inkluderes i Reseptregisteret. SSB

The article number is the key link to other registries providing detailed information about the drugs.

The NorPD also contains information on reimbursement codes registered associated with general reimbursement prescriptions (according to the “Blue prescription Regulation”) and Health Trust Financed Prescriptions (according to the “Regulation for Health Trust Financed medicinal products”). General reimbursement prescriptions were previously registered with general and wide reimbursement codes, which in some cases could act as a proxy of diagnosis for certain drugs. New reimbursement regulations came into force in March 2008 and was fully implemented from March 2009. Under the new reimbursement regulation, valid reimbursement codes are available on a separate reimbursement list. Reimbursement codes are based on either the International Classification of Diseases version 10 (ICD-10) or International Classification of Primary Care Version 2 (ICPC-2). In addition, NoMA assigns special codes for general reimbursement. For Health Trust Financed Prescriptions there are no list of pre-approved reimbursement codes. This means that all codes in the International Classification of Diseases version 10 (ICD-10) or International Classification of Primary Care version 2 (ICPC-2) can be used. The first reimbursement codes for Health Trust Financed Prescriptions were registered in the NorPD in August 2016. About 60 percent of all Health Trust Financed Prescriptions in 2018 were registered with a reimbursement code in the NorPD.

Data protection

As illustrated in figure 1.1 the pharmacy’s records of dispensed drugs are automatically transferred (electronically) through Statistics Norway before they arrive at NIPH and are included in the NorPD. Statistics Norway act as so-called “trusted third part” and is

fungerer som en såkalt tiltrodd tredjepart og er en del av datasikkerheten for å ivareta konfidensialitet og informasjonssikkerhet for all personlig informasjon. SSB har kun tilgang til pasientens fødselsnummer og forskrivers helsepersonellnummer og erstatter begge med et pseudonym. SSB kan ikke lese noen annen informasjon fra reseptene fordi denne informasjonen er kryptert før SSB mottar dataene. Når SSB sender data videre til Folkehelseinstituttet er fødselsnummer og forskrivers helsepersonellnummer erstattet av pseudonym, og FHI kan dekryptere helseopplysningene som fremgår av resepten igjen. Prinsippet for pseudonymisering er at ingen, heller ikke den som tildeler og forvalter pseudonymet, skal kunne ha samtidig tilgang til både pseudonym, helseopplysninger og personens identitet. Pseudonyme helseopplysninger er i reseptregisterforskriften definert som: «Helseopplysninger der identitet er kryptert eller skjult på annet vis, men likevel individualisert slik at det lar seg gjøre å følge hver person uten at identiteten røpes». Dette betyr at identiteten til pasienter og forskrivere har blitt kryptert i henhold til norsk lovgivning, men likevel er individuell, slik at det er mulig å følge enkeltpersoner over tid, og gjøre registerkoblingsstudier.

1.2 Nordiske reseptregistre

På slutten av 1980-tallet tok apotek i de nordiske landene gradvis i bruk elektroniske systemer ved ekspedering av resepter. Dette gjorde det mulig å samle inn reseptdata fra apotek på en enklere og mer effektiv måte. Selv om helsevesenet ikke er organisert likt i de nordiske landene, har alle fem land et helsevesen med universell dekning for helseutgifter. Alle borgere, uavhengig av sosioøkonomisk status, har tilgang til helsetjenester, inkludert delvis eller fullstendig refusjon av kjøpte legemidler. Nasjonale reseptdatabaser, som er basert på data fra ekspederte og utleverte legemidler fra apotek til individer utenfor sykehus/sykehjem, har vært tilgjengelig siden 1994 i Finland og Danmark, siden 2004 i Norge, siden 2005 i Sverige og siden 2006 på Island. Databasene dekker til sammen 26 millioner innbyggere (Danmark: 5,8 millioner, Finland: 5,5 millioner; Island: 0,3 millioner; Norge: 5,2 millioner og Sverige: 10 millioner). Det er mulig å koble disse dataene til ulike helseutfall og andre data basert på det unike fødselsnummeret/-koden som alle innbyggere i disse landene har. Databasene er en viktig ressurs for å kunne gjennomføre longitudinelle og registerkoblede studier med helseundersøkelser og andre

part of the data protection to ensure confidentiality of personal information. Statistics Norway only has access to the patients's Personal Identity Number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The principle of pseudonymisation is that no one, not even the trusted third part should have simultaneously access to pseudonym, health data and the person's identity. In the regulation of the NorPD, pseudonymous health data is defined as: «Health information where the identity is encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person without disclosing the identity». This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries.

1.2 Prescription statistics in the other Nordic countries

During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, independent of socioeconomic status, have access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 26 million inhabitants (Denmark: 5.8 million; Finland: 5.5 million; Iceland: 0.3 million; Norway: 5.2 million; and Sweden: 10 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also

registre. Databasene representerer også et godt kunnskapsgrunnlag for nasjonale beslutninger innen legemiddelbruk. En artikkel fra 2010 gir en oversikt over datainnsamlingsprosedyrer og innhold i de nordiske landenes reseptregistre (3).

1.3 Grossistbasert legemiddelstatistikk

Statistikk basert på totalt salg av legemidler fra grossist til apotek, sykehus/sykehjem har vært tilgjengelig i Norge siden 1970-tallet. Grossistbasert legemiddelstatistikk omfatter alt salg av legemidler fra grossist til apotek, sykehus/sykehjem, dagligvaredetaljister og andre med tillatelse til å omsette legemidler. Legemidler til dyr og mennesker, både reseptfrie og reseptbelagte, er inkludert i statistikken. Statistikken gir en oversikt over utviklingen på fylkesnivå. Statistikken inneholder imidlertid ikke opplysninger om den enkelte legemiddelbruker.

Legemiddelforbruket i Norge – årlig publikasjon
Årlig publiseres data fra den Grossistbaserte legemiddelstatistikken i publikasjonen *Legemiddelforbruket i Norge*. Hver utgave omfatter 5-årsoversikter over totalsalget av reseptfrie og reseptbelagte legemidler i Norge (4). Rapporten er tilgjengelig på nettsiden legemiddelforbruk.no. Nærmere informasjon vedrørende utlevering av data fra den grossistbaserte legemiddelstatistikken finnes på Folkehelseinstituttets nettside www.fhi.no.

1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifisering

Alle legemidler som er registrert i Norge er gruppert etter ATC-systemet. I ATC-systemet inndeles legemidlene i grupper på 5 nivåer: På 1. nivå fordeles legemidlene på 14 anatomiske hovedgrupper. Det neste nivået (2. nivå) er en terapeutisk eller farmakologisk undergruppe. 3. nivå og 4. nivå er terapeutiske, farmakologiske eller kjemiske undergrupper, mens 5. nivå representerer den kjemiske substansen.

ATC-koden

En fullstendig klassifisering av legemiddelsubstansen spironolakton (vanndrivende middel) med ATC-koden C03DA01 kan illustrere oppbyggingen av ATC-systemet:

C	Hjerte og kretsløp (1. nivå, anatomisk hovedgruppe)
C03	Diuretika (2. nivå, terapeutisk undergruppe)

offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription databases (3).

1.3 The Norwegian Drug Wholesales Statistics

Statistics based on total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user.

Drug Consumption in Norway – published annually
Data from the Norwegian Drug Wholesales Statistics Database have been published annually in *Drug Consumption in Norway* (4) since 1977. Each issue includes total sales data for 5 year periods for both prescription and non-prescription drugs in Norway. The report is available from the website drugconsumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no.

1.4 The Anatomical Therapeutic Chemical (ATC) classification system

In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/therapeutic sub-groups and the 5th level is the chemical substance.

The ATC code

A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:

C	Cardiovascular system (1st level, anatomical main group)
C03	Diuretics (2nd level, therapeutic sub-group).
C03D	Potassium-sparing agents (3rd level, pharmacological sub-group)

C03D Kaliumsparende midler (3. nivå, farmakologisk undergruppe)
C03DA Aldosteronantagonister (4. nivå, farmakologisk undergruppe)
C03DA01 Spironolakton (5. nivå, kjemisk substans)

Alle spironolakton preparater (Spirix® og Spironolactone®) gis i dette systemet koden C03DA01.

Ved hjelp av dette klassifikasjonssystemet kan man lage statistikker over legemiddelforbruk gruppert på fem ulike nivåer, fra tall som viser totalforbruket av alle preparater klassifisert f.eks. under hovedgruppe C – *Hjerte og kretsløp* (1. nivå), tall for de ulike undergruppene (2., 3. og 4. nivå) og ned til tall som viser forbruket av det enkelte virkestoff.

ATC-kode for hvert enkelt preparat er angitt i *apotekenes vareregister*, SPC på Legemiddelverkets hjemmeside og i preparatomtalene publisert i *Felleskatalogen*. Ved å bruke ATC-registeret på Felleskatalogens nettside (<http://felleskatalogen.no/medisin/atc-register>), vil man få en oversikt over hvilke produktnavn hver enkelt ATC-kode omfatter.

1.5 Definert Døgn dose (DDD)

I enkelte tabeller i del 3 i boken er volum av legemiddelbruk angitt i antall DDD. Ved å benytte definerte døgn doser (DDD) som måleenhet, får man bedre mulighet for sammenligninger mellom alternative legemidler uavhengig av prisdifferanser. Vurdering av volum av legemiddelforbruket gjennom lengre tidsperioder, nasjonalt og internasjonalt, blir enklere og bedre ved bruk av definerte døgn doser. Måleenheten DDD er definert som *den antatt gjennomsnittlige døgn dose brukt ved preparatets hovedindikasjon hos voksne*.

Døgn dosene fastsettes på bakgrunn av en vurdering av bruken internasjonalt, selv om de nasjonale terapitradisjonene kan variere fra et land til et annet (f.eks. bruksområde og doseringsanbefalinger). Den definerte døgn dose (DDD) bør derfor betraktes som en teknisk måleverdi.

Legemidler som benyttes ved forskjellige indikasjoner kan by på spesielle problemer som det må tas hensyn til ved vurdering av døgn dosestatistikk. Dosen ved hovedindikasjonen benyttes normalt ved fastsettelse av DDD. Med unntak av for noen få spesielle barnepreparater benyttes doseringer for voksne. Ofte vil DDD for ulike administrasjons-

C03DA Aldosterone antagonists (4th level, pharmacological sub-group)
C03DA01 Spironolactone (5th level, chemical substance)

All medicinal products containing plain spironolactone (Spirix® and Spironolactone®) are thus assigned the code C03DA01.

The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C – *Cardiovascular system* (1st level), figures for the various sub-groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient.

The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from *the pharmacy medicinal product register*, SPC at the Norwegian Medicines Agency's website and at the Felleskatalogens website (<http://felleskatalogen.no/medisin/atc-register>), lists all medicinal products belonging to each of the ATC 5th level codes.

1.5 The Defined Daily Dose (DDD)

In some tables in part 3 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as *the assumed average maintenance dose per day for a drug used on its main indication in adults*.

The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit.

Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their administration route will have more than one DDD, each of

former være like med unntak av der biotilgjengeligheten er svært forskjellig. For preparater der man benytter en støtdose og en vedlikeholdsdose, vil døgndosen være basert på vedlikeholdsdosen. Hvis mulig er DDD angitt i mengde aktiv substans. Er det umulig, som f.eks. ved kombinasjonspreparater og enkelte flytende preparater, angis DDD som antall enkeltdoser (antall tabletter, kapsler, milliliter osv.).

DDD representerer ikke nødvendigvis den mest forskrevne eller brukte dose, noe som må tas i betraktning når tallene vurderes. Det vil derfor ofte være vanskelig å beregne antall brukere ved kun å bruke DDD som måleenhet. Dette gjelder særlig der doseringsanbefalingene kan variere mye etter bruksområde.

1.6 WHO Collaborating Centre for Drug Statistics Methodology

ATC-/DDD-systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av Avdeling for legemiddelstatistikk ved Folkehelseinstituttet. Nærmere beskrivelse av systemet finnes i publikasjonen Guidelines for ATC classification and DDD assignment (5). ATC Index with DDDs, som inneholder en liste over alle fastsatte DDD, kan bestilles fra WHO-senteret (6). Begge publikasjonene finnes i engelsk og spansk versjon. Senterets webside har følgende adresse: www.whocc.no. Publikasjonene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology. ATC- og DDD-endringer som er vedtatt blir publisert årlig og gjort gjeldende ved årsskiftet. ATC-/DDD-versjon gjeldende fra januar 2018 er benyttet i rapporten.

them linked to a specific dosage form. For medications where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. When this is impossible, as is the case with combination preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.).

The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit.

1.6 WHO Collaborating Centre for Drug Statistics Methodology

The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Drug Statistics at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (5). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (6). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology. ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2018 has been used in this book.

Referanser/References:

1. Forskrift om innsamling og behandling av helseopplysninger i reseptbasert legemiddelregister (Reseptregisteret). 20-10-2003.
2. Strøm H. Reseptbasert legemiddelregister: et viktig verktøy for å oppnå detaljert legemiddelstatistikk. *Nor J Epidemiol.* 2004;14 (1):53-55.
3. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106(2):86-94.
4. Sakshaug S (Ed). Drug Consumption in Norway 2014–2018. [Legemiddelforbruket i Norge 2014–2018] Oslo: Norwegian Institute of Public Health, 2019.
5. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2019. Oslo, 2018.
6. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2018. Oslo, 2018

2. Reseptregisteret (NorPD) 2014–2018

2.1 Utvalgte nøkkeltall fra Reseptregisteret

Reseptregisteret inneholder opplysninger fra alle landets apotek om utlevering av legemidler på resept, til forskrivers egen praksis og til institusjoner. I 2018 ble rundt 97 % av legemidlene i Reseptregisteret (målt i DDD) utlevert til enkeltpersoner. Leveransene til institusjoner (sykehus og sykehjem) utgjorde 3 % av det totale antall DDD og ca. 0,4 % av totalt antall DDD ble utlevert til bruk i forskrivers egen praksis. Salg av reseptfrie legemidler er ikke inkludert i Reseptregisteret. Reseptfritt salg utgjorde i 2018 11 % av totalt salg av legemidler i Norge målt i DDD (Kilde: Grossistbasert legemiddelstatistikk, Folkehelseinstituttet).

2. The Norwegian Prescription Database (NorPD) 2014–2018

2.1 Selected key figures from the NorPD

The NorPD contains information from all Norwegian pharmacies of drugs dispensed to individuals, to a prescriber's own practice and to institutions. In 2018, about 97% of DDDs in the NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 3% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in the NorPD. OTC sales constitute 11% of total sales of pharmaceuticals in Norway in 2018, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health).

Table 2.1.a. Number of individuals and one-year prevalence (%) of the population who had at least one drug dispensed in Norway 2014–2018.

	Women n (%)	Men n (%)	Both genders n (%)
2014	1 939 431 (75.9)	1 605 342 (62.1)	3 544 773 (69.0)
2015	1 956 001 (75.9)	1 622 534 (62.1)	3 578 535 (69.0)
2016	1 981 012 (76.2)	1 649 902 (62.6)	3 630 914 (69.3)
2017	2 007 231 (76.7)	1 680 866 (63.2)	3 688 097 (69.9)
2018	2 022 967 (76.8)	1 701 415 (63.6)	3 724 382 (70.1)




Figure 2.1. One-year prevalence (%) of the population who had at least one drug dispensed in 2018 in Norway according to age and gender. The pink line shows the one-year prevalence (%) for women excluding contraceptives for topical use (ATC code G02B) and hormonal contraceptives for systemic use (ATC code G03A).

Reseptregisteret ble opprettet 1. januar 2004 og i perioden 2004–2018 har rundt 5,8 millioner individer blitt inkludert i registeret med minst ett legemiddel utlevert på resept fra apotek. Antall legemiddelutleveringer etter resept til pasienter i samme periode er rundt 620 millioner.

I 2018 fikk 70,1 % av den norske befolkningen utlevert minst ett legemiddel på resept, 76,8 % av kvinnene og 63,6 % av mennene (tabell 2.1.a). Krav om at pasientens fødselsnummer skal påføres resepten ble innført 1. oktober 2003. I 2004, det første driftsåret for Reseptregistret, var andelen av resepter med ugyldig eller manglende 11-sifret fødselsnummer 3,7 %. I årene 2005–2007 lå denne andelen på rundt 2 %, og i 2008 og 2009 har den ligget på i underkant av 1,4 %. I 2010–2018 var andelen uten gyldig fødselsnummer under 1 % (0,16 % i 2018).

Ettårsprevalensen for å få utlevert legemiddel etter resept i 2018 var lavest for kvinner i aldersgruppen 5–9 år og for menn i samme aldersgruppe (figur 2.1). Mellom 92 og 95 % av individene i aldersgruppene 70 år og eldre fikk utlevert medisiner etter resept. I aldersgruppene 15–29 år fikk mellom 74 og 82 % av kvinnene utlevert legemiddel etter resept i 2018. Dersom man ekskluderer kvinner som kun fikk utlevert hormonelle prevensjonsmidler (ATC-kode G02B og G03A) var andelen mellom 64 og 71 %. Andelen kvinnelige legemiddelbrukere over 15 år er høyere enn blant menn selv om de ekskluderes.

Since January 2004, approximately 5.8 million individuals have been included in NorPD with at least one prescribed drug dispensed from a pharmacy. The number of drugs dispensed to patients in the same period (2004–2018) is about 620 millions.

In 2018, 70.1% of the Norwegian population had at least one prescription dispensed, 76.8% of women and 63.6% of men (table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identity number was 3.7%. In the period 2005–2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identity number has declined further to just below 1.4% in 2008 and 2009. In 2010–2018 the proportion was less than 1% (0.16% in 2018).

The age-specific one year prevalence for being dispensed a drug in 2018 was lowest for women at about 5–9 years of age and for men at the same age (figure 2.1). Between 92 and 95% of individuals in the aged groups 70 years and older received prescribed drugs. In the age groups 15–29 years 74 to 82% of the women received prescribed drugs in 2018. If women who only received hormonal contraception (ATC code G02B and G03A) are excluded, the prevalence was 64 to 71%. The proportion of drug users among women over 15 years of age was still higher than in men.

Table 2.1.b. One-year prevalence (%) of the population who had at least one drug dispensed in Norway in 2018 according to the main ATC groups.

ATC	Women %	Men %	Both genders %
A Alimentary tract and metabolism	23.8	18.1	20.9
B Blood and blood forming organs	13.6	13.4	13.5
C Cardiovascular system	21.4	21.3	21.4
D Dermatologicals	16.1	13.0	14.5
G Genito urinary system and sex hormones	25.6	8.1	16.7
H Systemic hormonal preparations, excl. sex hormones and insulins	11.9	5.8	8.8
J Anti-infectives for systemic use	26.5	17.5	22.0
L Anti-neoplastic and immunomodulating agents	2.5	1.9	2.2
M Musculo-skeletal system	20.7	15.3	18.0
N Nervous system	32.9	22.7	27.7
P Anti-parasitic products, insecticides and repellents	2.2	1.4	1.8
R Respiratory system	29.7	22.9	26.3
S Sensory organs	14.6	10.8	12.7
V Various	0.7	0.7	0.7

Tabell 2.1.b viser ettårsprevalens for hele befolkningen som har fått utlevert minst ett legemiddel etter resept innen hver av de 14 ATC-hovedgruppene, totalt og fordelt på kvinner og menn. De tre legemiddelgruppene som er mest brukt blant begge kjønn er midler mot infeksjoner til systemisk bruk (ATC-gruppe J), legemidler med virkning på nervesystemet (ATC-gruppe N) og legemidler som brukes for sykdommer i luftveiene (ATC-gruppe R).

Tabell 2.1.c viser en oversikt over legemidler (definert som ATC 5.nivåer) med flest brukere i Norge i 2018. Paracetamol (smertestillende) har flest brukere, etterfulgt av fenoksymetylpenicillin (antibiotikum). Paracetamol selges også i reseptfrie pakninger. Denne bruken registreres ikke i Reseptregisteret.

Listen inneholder i hovedsak de samme legemidlene som tidligere år, men det er noen endringer i rekkefølgen. Doksosyklin (antibiotikum) er ikke lenger på listen over de 30 mest brukte legemidler.

Table 2.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one drug in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R).

Table 2.1.c shows an overview of medicines (defined as ATC 5th levels) with the highest number of users in Norway in 2018. Paracetamol (analgesic) is used by the highest numbers of individuals, followed by phenoxymethylpenicillin (antibiotic). Paracetamol is also sold OTC. This use is not covered by the NorPD.

The list contains essentially the same drugs as in previous years, but there are some changes in order. Doxycycline (antibiotic) is not longer represented on the list of the 30 most prescribed medicine.

Table 2.1.c. Drugs with the highest number of users in Norway in 2018.

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population
1	N02BE01	paracetamol ¹⁾	Analgesic	559 985	10.5
2	J01CE02	phenoxymethylpenicillin	Antibacterial	373 163	7.0
3	B01AC06	acetylsalicylic acid	Antithrombotic	359 317	6.8
4	N02AJ06	codeine and paracetamol	Analgesic	339 932	6.4
5	C10AA05	atorvastatin	Lipid modifying	329 576	6.2
6	M01AB05	diclofenac ¹⁾	NSAID/analgesic	307 370	5.8
7	C07AB02	metoprolol	Antihypertensive/cardiac disease	285 653	5.4
8	N05CF01	zopiclone	Hypnotic	283 705	5.3
9	R06AE07	cetirizine ¹⁾	Antiallergic	283 122	5.3
10	A02BC02	pantoprazole ¹⁾	Reflux oesofagitis (proton-pump inhibitor)	281 762	5.3
11	R03AC02	salbutamol	Asthma/COPD	274 663	5.2
12	R06AX27	desloratadine	Anti-allergic	267 221	5.0
13	R05DA01	ethylmorphine	Cough suppressant	262 514	4.9
14	N02AX02	tramadol	Analgesic	226 103	4.3
15	M01AE01	ibuprofen ¹⁾	NSAID/analgesic	221 288	4.2
16	H03AA01	levothyroxine sodium	Thyroxine supplement	212 354	4.0
17	J01CA08	pivmecillinam	Antibacterial	194 098	3.7
18	S01AA01	chloramphenicol	Antibacterial eye drops	193 278	3.6
19	C10AA01	simvastatin	Lipid modifying	192 106	3.6
20	H02AB06	prednisolone	Antiinflammatory/corticosteroid	191 453	3.6
21	A02BC05	esomeprazole	Reflux oesofagitis (proton-pump inhibitor)	181 114	3.4
22	R01AD09	mometasone ¹⁾	Corticosteroid nasal spray	176 300	3.3
23	C08CA01	amlodipine	Antihypertensive/cardiac disease	155 136	2.9
24	M01AE52	naproxen and esomeprazole	NSAID/analgesic with proton-pump inhibitor	154 154	2.9
25	A11CC05	colecalfiferol	Vitamin supplement	151 751	2.9
26	G03AA07	levonorgestrel and ethinylestradiol	Hormonal contraception	149 303	2.8
27	G03CA03	estradiol	Hormon replacement and postmenopausal osteoporosis	142 825	2.7
28	N05BA04	oxazepam	Anxiolytic	135 934	2.6
29	C09CA06	candesartan	Antihypertensive/cardiac disease	129 744	2.4
30	A10BA02	metformin	Antidiabetic	122 463	2.3

¹⁾The ATC-level comprises OTC-medicinal products. The number of individuals is registered for prescription sales only.

2.2 Reseptkategorier og refusjon av utgifter til legemidler

Reseptregisteret inneholder opplysninger om utlevering av legemidler fordelt på ulike reseptkategorier. Reseptkategoriene har følgende hovedinndeling:

- Hvit resept
- Blå resept (i henhold til Forskrift om stønad til dekning av utgifter til viktige legemidler mv. (Blåreseptforskriften) FOR-2007-06-28-814)
- Helseforetaksfinansiert resept (i henhold til Forskrift om helseforetaksfinansierte reseptlegemidler til bruk utenfor sykehus, FOR-2015-06-12-646)

Informasjon om følgende reseptkategorier er ikke inkludert i tabellene:

- Bidragsordningen (hjemlet i Lov om folketrygd (folketrygdloven) § 5-22)
- Støtte til legemidler for vernepliktige og ved yrkesskade (hjemlet i Lov om folketrygd § 5-25)
- Spesielle refusjonsordninger som f.eks. medlemskap i Jernbanepersonalets Helsefond

Se tabell 2.2 for fordeling mellom de ulike reseptkategoriene. For mer informasjon om reseptkategorier, se f. eks.:

<https://www.helsedirektoratet.no/tema/legemidler/legemiddelfinansiering/refusjon-av-legemidler>

<https://www.helsedirektoratet.no/tema/legemidler/legemiddelfinansiering/helseforetaksfinansierte-legemidler-brukt-utenfor-sykehus-h-reseptlegemidler>

2.2 Prescription categories and reimbursement of medicinal expenses

NorPD contains information about dispensed prescriptions based on the following prescription categories:

- Non-reimbursed prescriptions
- General reimbursement prescriptions (according to the "Blue Prescription Regulation" (FOR-2007-06-28-814))
- Health Trust financed prescription (according to the "Regulation for Health Trust Financed medicinal products", FOR 2015-06-12-646)

The following prescription categories are not included in the tables:

- Contribution to cover the cost of healthcare when expenses are not otherwise covered by other laws (according to the National Insurance Act § 5-22).
- Contribution to conscripted military and individuals with occupational injury (according to the National Insurance Act § 5-25)
- Special contribution, for instance membership in Jernbanepersonalets Helsefond (Railways Workers Health Fund)

See table 2.2 for the distribution of the different prescription categories. For more information regarding prescription categories, see e.g.

<https://www.helsedirektoratet.no/tema/legemidler/legemiddelfinansiering/refusjon-av-legemidler>

<https://www.helsedirektoratet.no/tema/legemidler/legemiddelfinansiering/helseforetaksfinansierte-legemidler-brukt-utenfor-sykehus-h-reseptlegemidler>

Table 2.2. Sales of drugs by prescription categories, overview 2018.

	Number of individuals	Proportion (%) of the population	Sales in 1000 NOK
Non-reimbursable prescriptions	3 152 088	59,3	3 265 269
Reimbursement prescriptions	2 534 644	47,7	11 921 850
Health trust financed prescriptions	57 871	1,1	4 852 110

2.3 Beskrivelse av hovedtabellene

Tabellene i del 2 i denne boken gir en oversikt over antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge. Alle som har hentet ut minst ett legemiddel er inkludert og opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. Selv om et individ har fått utlevert samme legemiddel flere ganger, telles vedkommende som bruker bare én gang. Det er kun utleveringer til individer med fullt fødselsnummer som er inkludert i tabellene i boken. I 2018 var 0,16 % av utleveringene registrert i reseptregisteret til individer hvor fullstendig fødselsnummer ikke var tilgjengelig.

Tabellene inneholder tall for perioden 2014–2018. I tillegg er følgende opplysninger for 2018 inkludert:

- Prevalens per 1 000 innbyggere
- Antall individer som har hentet ut minst ett legemiddel etter resept fordelt på følgende aldersgrupper: <15, 15–44, 45–69, ≥ 70. Dersom antall individer er lavere enn fem, angis < 5 i tabellene.
- Salg i 1 000 NOK fra apotek for utvalget i tabellen, dvs. til individer med fullt fødselsnummer. Kronebeløpet tilsvarer reell utsalgspris fra apotek.

Tabellene er sortert i henhold til ATC-systemet (se nærmere beskrivelse på s. 12). De aller fleste ATC-grupper med legemidler på det norske markedet er inkludert. Legemidler til pasienter i sykehus eller sykehjem er ikke tilgjengelig på individnivå i Reseptregisteret. Det totale antall legemiddelbrukere vil derfor være høyere enn det som fremgår av tabellene for en del legemidler, og spesielt for legemidler som brukes mye i sykehus. Vi har valgt å utelate noen ATC-grupper. Dette er legemidler som hovedsaklig brukes i sykehus eller institusjoner.

Følgende ATC-grupper er utelatt:

B05	Blodsubstitutter og infeksjonsløsninger
J06	Immunsera og immunglobuliner
J07	Vaksiner
L01	Antineoplastiske midler
M03A	Perifert virkende muskelrelakserende midler
N01	Anestetika
S01H	Lokalanestetika
S01J	Diagnostika
S01L	Midler ved okulær vaskulær sykdom
V	Varia (kun ATC-gruppe V01 Allergener og V03 Alle andre terapeutiske preparater er inkludert i tabellen)

2.3 Description of the main tables

The tables in section 2 of this book provide an overview of the number of individuals who have had drugs dispensed from pharmacies in Norway. Anyone who has had at least one drug dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same drug several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identity number are included in the tables. In NorPD the complete personal identity number is missing for 0.16% of the dispensed drugs to individuals in 2018.

The tables contain figures for the period 2014–2018. In addition, the following information for 2018 includes:

- Prevalence per 1 000 inhabitants
- The number of individuals who have had at least one drug dispensed in the following age groups: <15, 15–44, 45–69, ≥70. If the number of individuals is less than five, <5 is used in the tables.
- Sales in 1 000 Norwegian kroner (NOK), i.e. for prescriptions dispensed to individuals with a personal identity number. The amount in NOK corresponds to the actual retail price from the pharmacy.

The tables are arranged according to the ATC system (see further description in p. 12). The majority of ATC groups containing drugs on the Norwegian market are included. Drug use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of drug users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or other institutions.

The following ATC groups have been omitted:

B05	Blood substitutes and perfusion solutions
J06	Immune sera and immunoglobulins
J07	Vaccines
L01	Antineoplastic agents
M03A	Muscle relaxants, peripherally acting agents
N01	Anesthetics
S01H	Local anesthetics
S01J	Diagnostic agents
S01L	Ocular vascular disorder agents
V	Various (ATC group V01 Allergens and V03 All other therapeutic products are included in the table)

Figure 2.3. The report generator at www.norpd.no (Norwegian version at www.reseptregisteret.no)

Vær oppmerksom på at enkelte ATC-nivåer inneholder reseptfrie legemidler. Antall brukere er kun registrert for reseptbelagte salg.

Reseptfrie legemidler skrives i noen tilfeller også ut på resept, men i hovedsak vil salg av reseptfrie legemidler ikke være inkludert i reseptregisteret. Salg av reseptfrie legemidler, både i og utenom apotek, er med i den grossistbaserte legemiddelstatistikken, hvor tall blir publisert i publikasjonen *Legemiddelforbruket i Norge* (se også s. 13). I 2018 utgjorde reseptfrie legemidler en andel på 11 % av totalt antall solgte doser (DDD). Denne andelen har holdt seg relativt konstant over tid.

De fleste legemidler som forskrives på resept, har godkjent markedsføringstillatelse i Norge. Leger har imidlertid anledning til å forskrive legemidler uten markedsføringstillatelse. Det må da søkes om spesielt godkjeningsfritak fra Statens legemiddelverk. Det finnes også enkelte legemidler som inngår i en såkalt negativliste, og som bare kan utleveres etter spesiell tillatelse fra Legemiddelverket. Legemidler som er forskrevet på resept etter søknad om godkjeningsfritak eller etter spesiell tillatelse fra Legemiddelverket, er inkludert i tabellene i boken. Antall individer som behandles med disse legemidlene vil ofte være lavt.

Mange individer bruker flere legemidler. Vær derfor

Please note that some ATC levels comprises OTC products. The Number of individuals is registered for prescription sales only.

Non-prescription drugs are sometimes prescribed, but the majority of the OTC drug sales will not be included in the tables in the Norwegian Prescription Database. Sales of OTC drugs are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in «Drug Consumption in Norway» (see also p. 13). In 2018, OTC medicines had a share of 11% of total sales measured in DDDs. This share has remained almost unchanged over time.

Most prescribed drugs have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some drugs that are part of a so-called «negative list» which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these drugs is often low.

Many individuals use more than one drug. Please

oppmerksom på at man ikke kan summere antall brukere av ulike legemidler, eller legemiddelgrupper i tabellene, for å finne totalt antall brukere av to eller flere legemidler. Statistikk på aggregert nivå i tabellene vil imidlertid inneholde brukere av minst ett av legemidlene i undernivåene. For eksempel viser tallene at totalt antall brukere av sovemidler (ATC-gruppe N05C) er lavere enn summen av antall brukere av de enkelte legemidlene som er klassifisert i N05C. Det betyr at noen individer har fått utlevert mer enn en type sovemiddel i løpet av et år, enten ved bruk av flere sovemidler samtidig eller ved bytte fra ett middel til et annet.

Endringer i ATC-klassifisering

I ATC Index 2019 (gjeldende versjon i denne rapporten) er det gjort noen mindre ATC-endringer av betydning for statistikken. ATC koden for dimetylfumarat som brukes ved psoriasis og multippel sklerose er endret fra N07XX09 til L04AX07.

For mer informasjon om endringer i ATC-systemet og nye ATC-koder/DDD inkludert i 2019 Index, se oppdateringer på WHO senterets nettsider, www.whocc.no.

Historiske data er oppdatert i denne rapporten og i Reseptregisterets statistikkbank (reseptregisteret.no).

Reseptregisterets nettsider: www.reseptregisteret.no
Reseptregisteret har eget nettsted som kan brukes sammen med tabellene i denne rapporten for å få kompletterende informasjon. På søkesidene (figur 2.3) kan man selv lage rapporter over antall brukere av et bestemt legemiddel eller en legemiddelgruppe. Dette kan gjøres ved søk på forhåndsdefinerte legemiddelgrupper, via ATC-systemet eller ved søk på virkestoff eller produktnavn.

be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of hypnotics (ATC group N05C) is lower than the sum of the number of users of the individual drugs that are classified in N05C. This means that some individuals have been given more than one type of hypnotic during a year, either through the use of more than one simultaneously or by switching from one agent to another.

Changes in ATC classification

In ATC Index 2019 (current version of this report), ATC changes there are minor changes made of significance for statistics. The ATC code for dimethyl fumarate used in psoriasis and multiple sclerosis has been altered from N07XX09 to L04AX07.

For more information regarding alterations in the ATC system and new ATC codes / DDD included in the 2019 Index, see updates on the WHO Centre's website www.whocc.no.

Historical data has been updated in this report and the statistics bank (www.norpd.no).

The NorPD website: www.norpd.no

The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 2.3), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.

Følgende data om legemiddelbruk kan hentes ut fra nettstedet:

- Antall brukere, eventuelt fordelt på kjønn, 5 års aldersgrupper, fylke eller helseregion
- Antall brukere per 1 000 innbyggere (prevalens per 1 000)
- Omsetning i kroner
- Omsetning i doser (DDD – definerte døgndoser)
- Befolkningsgrunnlag i statistikken, eventuelt fordelt på kjønn, alder, fylke eller helseregion

Data er tilgjengelige fra 2004, og nettstedet oppdateres årlig med foregående års tall.

Tallene i denne rapporten kan avvike noe fra tallene som finnes på nettstedet. Årsaken er at individer uten kjent bostedsadresse er utelatt fra nettsiden, men inkludert i tabellene i denne rapporten. Rapporteringen av data fra apotek til Reseptregisteret er for en liten andel av reseptutleveringene forsinket. Forsinkelsen kan være på noen måneder, og dette innebærer at noen data fra foregående år blir rapportert på etterskudd. Nettstedet finnes også i engelsk versjon (www.norpd.no).

Utlevering av data fra Reseptregisteret

Det er mulig å søke om data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Søknadsskjema er tilgjengelige på nettstedet til FHI (www.fhi.no), og alle søknader om tilgang til data fra FHI skal sendes til datatilgang@fhi.no. Dataene er gratis, men kostnader i forbindelse med administrativ håndtering og filbehandling må påregnes.

Beregning av prevalens per 1000 innbyggere

Prevalens er ofte definert som antall individer som har fått utlevert ett legemiddel per 1000 innbyggere. Hvordan dette beregnes er vist i eksemplet nedenfor.

Antall individer som fikk minst ett hjerte-/karmiddel (ATC-gruppe C) i Norge i 2018: 1 134 322

Antall innbyggere i Norge per 1. juli 2018: 5 311 797

Beregning av prevalens (per 1000) for brukere av hjerte-/karmidler i Norge i 2018:

$$\frac{\text{Antall individer} \times 1000}{\text{Antall innbyggere}} = \frac{1\,134\,322 \times 1000}{5\,311\,797} = 213,6 \text{ individer per } 1000 \text{ innbyggere}$$

På s. 98 finnes tabeller over befolkningstallet i Norge for årene 2014–2018. Befolkningstallet for de fire aldersgruppene i tabellene er også angitt. Det brukes middelfolkemengden for hvert år, dvs. folketallet per 1. juli, beregnet ut fra Statistisk Sentralbyrås folketall 1.1 og 31.12. Alder er definert som den alder individet har ved slutten av året (utleveringsår minus fødselsår).

The following data on drug use can be extracted from the website:

- Number of users, split by gender, 5-year age groups, county or health region
- Number of users per 1 000 population (prevalence per 1 000)
- Turnover in NOK (pharmacy retail price)
- Turnover in doses (DDD – defined daily doses)
- Population base for the statistics, split by gender, age, county or health region

Data are available from 2004 with an annual update for the preceding year.

The figures in this book may differ slightly from the numbers found on the website. This is because individuals without known address are included in the tables in this book but not on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year.

Access to data from NorPD

It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required.

Calculation of prevalence per 1000 inhabitants

Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one drug dispensed in a pharmacy during a specific time period. Please read the following example for the calculation:

The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2018: 1 134 322

The number of inhabitants in Norway as of 1st July 2018: 5 311 797

Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2018:

$$\frac{\text{The number of individuals} \times 1000}{\text{The number of inhabitants}} = \frac{1\,134\,322 \times 1000}{5\,311\,797} = 213.6 \text{ individuals per } 1000 \text{ inhabitants}$$

The population in Norway for the years 2014–2018 is shown on p. 98. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).

2.4 ATC main groups

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A	ALIMENTARY TRACT AND METABOLISM	884 462	942 979	1 010 908	1 081 423	1 112 220	209.4	47 344	269 901	465 420	329 555	2 558 844
B	BLOOD AND BLOOD FORMING ORGANS	640 857	658 268	678 638	699 782	714 990	134.6	5 359	82 587	280 709	346 335	1 989 763
C	CARDIOVASCULAR SYSTEM	1 060 387	1 076 292	1 100 496	1 117 715	1 134 322	213.6	10 137	100 336	553 243	470 606	1 852 329
D	DERMATOLOGICALS	674 324	686 931	713 156	747 278	772 456	145.4	113 072	282 360	245 067	131 957	441 597
G	GENITO URINARY SYSTEM AND SEX HORMONES	814 987	835 159	859 381	876 623	889 096	167.4	4 102	443 058	285 681	156 255	1 147 178
H	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	437 511	445 610	452 531	463 794	469 293	88.4	18 156	112 666	198 712	139 759	548 811
J	ANTIINFECTIVES FOR SYSTEMIC USE	1 252 912	1 239 430	1 209 403	1 177 724	1 167 183	219.7	117 077	451 075	380 772	218 259	1 284 841
L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	95 704	100 442	105 983	112 500	116 797	22.0	1 602	26 431	53 640	35 124	4 277 921
M	MUSCULO-SKELETAL SYSTEM	928 438	942 110	946 467	963 353	954 846	179.8	15 248	318 251	441 641	179 706	495 981
N	NERVOUS SYSTEM	1 353 896	1 380 464	1 411 698	1 450 416	1 473 116	277.3	33 128	465 180	625 750	349 058	3 168 219
P	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	97 581	94 700	93 310	93 329	94 332	17.8	4 509	41 622	35 657	12 544	30 006
R	RESPIRATORY SYSTEM	1 259 843	1 296 996	1 330 147	1 374 981	1 397 861	263.2	159 019	507 225	508 602	223 015	1 779 464
S	SENSORY ORGANS	653 581	643 475	646 492	668 750	674 467	127.0	104 833	192 838	215 644	161 152	427 356
V	VARIOUS	27 786	30 050	32 694	35 372	37 093	7.0	5 420	12 581	11 428	7 664	187 635

2.5 ATC group A – Alimentary tract and metabolism

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
A	ALIMENTARY TRACT AND METABOLISM	884 462	942 979	1 010 908	1 081 423	1 112 220	209.4	47 344	269 901	465 420	329 555	2 558 844
A01	STOMATOLOGICAL PREPARATIONS	23 893	30 613	37 008	43 992	49 505	9.3	968	18 163	16 472	13 902	12 595
A01A	STOMATOLOGICAL PREPARATIONS	23 893	30 613	37 008	43 992	49 505	9.3	968	18 163	16 472	13 902	12 595
A01AA	Caries prophylactic agents	18 919	25 107	31 112	37 554	42 580	8.0	287	15 156	14 320	12 817	10 661
A01AA01	sodium fluoride	18 919	25 107	31 112	37 554	42 580	8.0	287	15 156	14 320	12 817	10 661
A01AB	Antiinfectives and antiseptics for local oral treatment	2 870	3 345	3 577	3 937	3 850	0.7	240	1 825	1 136	649	569
A01AB03	chlorhexidine	2 808	3 271	3 523	3 861	3 781	0.7	238	1 809	1 107	627	506
A01AB04	amphotericin B	29	28	24	30	25	0.0	0	5	10	10	22
A01AB09	miconazole	7	15	8	14	11	0.0	<5	<5	<5	<5	13
A01AB11	various	27	32	26	33	35	0.0	<5	9	15	10	28
A01AC	Corticosteroids for local oral treatment	1 705	1 735	1 893	2 244	2 676	0.5	404	858	949	465	1 037
A01AC01	triamcinolone	1 651	1 677	1 772	2 098	2 458	0.5	401	824	829	404	603
A01AC03	hydrocortisone	<5	5	<5	<5	0	0.0	0	0	0	0	0
A01AD	Other agents for local oral treatment	534	593	629	563	689	0.1	42	402	164	81	328
A01AD01	epinephrine	10	15	8	6	9	0.0	0	<5	8	0	13
A01AD02	benzylamine	500	552	592	528	666	0.1	34	399	153	80	313
A01AD11	various	24	26	29	29	14	0.0	8	<5	<5	<5	2
A02	DRUGS FOR ACID RELATED DISORDERS	441 259	467 788	493 407	521 160	541 858	102.0	11 042	112 457	247 505	170 854	322 498
A02A	ANTACIDS	5 498	6 151	6 361	6 351	6 488	1.2	125	1 183	2 135	3 045	12 432
A02AA	Magnesium compounds	26	30	69	84	99	0.0	0	12	34	53	37
A02AA04	magnesium hydroxide	26	30	69	84	99	0.0	0	12	34	53	37
A02AC	Calcium compounds	810	724	600	600	497	0.1	15	107	173	202	288
A02AC01	calcium carbonate	810	724	600	600	497	0.1	15	107	173	202	288
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	1 612	1 823	1 771	1 489	1 488	0.3	31	722	451	284	239
A02AD01	ordinary salt combinations	1 612	1 823	1 771	1 489	1 488	0.3	31	722	451	284	239
A02AH	Antacids with sodium bicarbonate	3 258	3 707	3 996	4 249	4 444	0.8	38	337	1 511	2 558	11 238
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	438 777	465 040	490 594	518 289	538 917	101.5	10 948	111 965	246 609	169 395	310 065
A02BA	H₂-receptor antagonists	53 151	49 972	45 877	45 543	47 143	8.9	1 668	12 822	20 631	12 022	16 477

ATC group A

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
A02BA01 cimetidine	29	20	19	18	18	0.0	<5	<5	8	6	24
A02BA02 ranitidine	52 116	49 572	45 523	45 163	46 860	8.8	1 661	12 737	20 528	11 934	16 249
A02BA03 famotidine	1 103	630	434	441	303	0.1	7	93	111	92	204
A02BB Prostaglandins	358	264	371	476	512	0.1	<5	406	68	37	161
A02BB01 misoprostol	358	264	371	476	512	0.1	<5	406	68	37	161
A02BC Proton pump inhibitors	402 262	433 695	461 724	490 510	510 637	96.1	9 697	103 858	235 067	162 015	291 856
A02BC01 omeprazole	44 226	43 649	42 405	41 463	39 402	7.4	3 446	8 225	15 670	12 061	35 894
A02BC02 pantoprazole	193 342	217 250	239 547	263 785	281 762	53.0	1 136	59 941	127 773	92 912	115 981
A02BC03 lansoprazole	40 451	38 478	36 516	34 983	33 068	6.2	340	4 649	16 240	11 839	22 616
A02BC05 esomeprazole	148 765	159 849	168 378	176 064	181 114	34.1	5 479	37 741	86 232	51 662	117 364
A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	3 210	3 788	4 273	5 367	5 382	1.0	398	1 887	1 884	1 213	1 571
A02BX02 sucralfate	488	471	461	509	510	0.1	7	113	216	174	435
A02BX12 bismuth subnitrate	36	34	37	58	11	0.0	0	6	<5	<5	22
A02BX13 alginic acid	2 705	3 300	3 788	4 824	4 894	0.9	391	1 777	1 676	1 050	1 114
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	67 041	66 795	68 127	70 684	72 780	13.7	969	24 734	27 069	20 008	15 765
A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	4 619	4 775	5 059	5 738	5 628	1.1	222	1 108	1 776	2 522	2 465
A03AA Synthetic anticholinergics, esters with tertiary amino group	35	41	36	56	77	0.0	<5	30	38	8	92
A03AA04 mebeverine	34	40	33	53	76	0.0	<5	29	38	8	72
A03AA05 trimebutine	0	0	<5	<5	<5	-	0	<5	0	0	16
A03AA07 dicycloverine	<5	<5	<5	<5	<5	-	0	<5	0	0	4
A03AB Synthetic anticholinergics, quaternary ammonium compounds	680	938	1 155	1 382	1 411	0.3	7	39	366	999	368
A03AB02 glycopyrronium bromide	676	932	1 148	1 373	1 401	0.3	7	33	363	998	344
A03AB05 propantheline	<5	6	5	6	6	0.0	0	<5	<5	<5	15
A03AB07 methantheline	0	0	<5	<5	<5	-	0	<5	0	0	9
A03AD Papaverine and derivatives	49	37	42	45	28	0.0	0	6	13	9	33
A03AD01 papaverine	49	37	42	45	28	0.0	0	6	13	9	33
A03AX Other drugs for functional gastrointestinal disorders	3 872	3 776	3 848	4 284	4 134	0.8	214	1 035	1 369	1 516	1 973
A03AX13 silicones	3 872	3 776	3 848	4 284	4 134	0.8	214	1 035	1 369	1 516	1 973
A03B BELLADONNA AND DERIVATIVES, PLAIN	2 517	2 603	2 680	3 108	3 398	0.6	18	1 458	1 368	554	1 536
A03BA Belladonna alkaloids, tertiary amines	1 857	1 879	1 850	1 919	2 096	0.4	10	923	806	357	848

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A03BA01	atropine	28	21	21	8	13	0.0	0	<5	10	0	4
A03BA03	hyoscyamine	1 829	1 858	1 830	1 911	2 083	0.4	10	920	796	357	843
A03BB	Belladonna alkaloids, semisynthetic, quaternary ammonium compounds	672	738	842	1 202	1 318	0.3	8	543	566	201	688
A03BB01	butylscopolamine	659	725	842	1 202	1 318	0.3	8	543	566	201	688
A03BB03	methylscopolamine	14	14	0	0	0	0.0	0	0	0	0	0
A03C	ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	17	14	19	22	19	0.0	0	<5	7	8	26
A03CA	Synthetic anticholinergic agents in combination with psycholeptics	17	14	19	22	19	0.0	0	<5	7	8	26
A03CA02	clidinium and psycholeptics	17	14	19	22	19	0.0	0	<5	7	8	26
A03F	PROPULSIVES	61 033	60 678	61 727	63 378	65 341	12.3	739	22 491	24 512	17 599	11 738
A03FA	Propulsives	61 033	60 678	61 727	63 378	65 341	12.3	739	22 491	24 512	17 599	11 738
A03FA01	metoclopramide	60 932	60 583	61 627	63 262	65 211	12.3	719	22 459	24 469	17 564	11 471
A03FA02	cisapride	14	0	0	0	0	0.0	0	0	0	0	0
A03FA03	domperidone	96	97	110	133	141	0.0	21	39	46	35	254
A03FA05	alizapride	13	9	6	<5	5	0.0	0	<5	<5	<5	13
A04	ANTIEMETICS AND ANTINAUSEANTS	17 291	18 971	19 680	20 854	22 099	4.2	682	5 206	9 776	6 435	47 416
A04A	ANTIEMETICS AND ANTINAUSEANTS	17 291	18 971	19 680	20 854	22 099	4.2	682	5 206	9 776	6 435	47 416
A04AA	Serotonin (5HT3) antagonists	14 013	15 454	16 470	18 169	19 412	3.7	594	4 210	8 629	5 979	44 840
A04AA01	ondansetron	13 992	15 366	15 859	15 811	16 482	3.1	589	3 860	6 816	5 217	29 174
A04AA02	granisetron	13	62	80	85	113	0.0	25	<5	42	43	1 045
A04AA03	tropisetron	<5	<5	0	0	0	0.0	0	0	0	0	0
A04AA05	palonosetron	51	107	83	52	16	0.0	0	<5	5	10	95
A04AA55	palonosetron, combinations	0	0	983	3 760	4 678	0.9	0	595	2 938	1 145	14 526
A04AD	Other antiemetics	6 100	6 483	5 953	3 785	3 257	0.6	100	1 075	1 478	604	2 576
A04AD01	scopolamine	2 393	2 487	2 355	2 572	2 710	0.5	90	998	1 146	476	1 053
A04AD10	dronabinol	0	0	0	0	<5	-	0	0	0	<5	36
A04AD12	aprepitant	3 724	4 008	3 605	1 223	551	0.1	11	78	334	128	1 486
A05	BILE AND LIVER THERAPY	2 890	3 013	3 210	3 373	3 599	0.7	102	1 064	1 592	841	13 268
A05A	BILE THERAPY	2 890	3 013	3 210	3 373	3 599	0.7	102	1 064	1 592	841	13 268
A05AA	Bile acids and derivatives	2 890	3 013	3 210	3 373	3 599	0.7	102	1 064	1 592	841	13 268
A05AA01	chenodeoxycholic acid	0	0	<5	<5	0	0.0	0	0	0	0	0
A05AA02	ursodeoxycholic acid	2 890	3 013	3 209	3 373	3 595	0.7	102	1 064	1 590	839	8 273
A05AA04	obeticholic acid	0	0	0	7	30	0.0	0	<5	26	<5	4 979

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A06	DRUGS FOR CONSTIPATION	65 798	73 418	83 960	94 189	102 443	19.3	21 525	16 770	28 629	35 519	79 041
A06A	DRUGS FOR CONSTIPATION	65 798	73 418	83 960	94 189	102 443	19.3	21 525	16 770	28 629	35 519	79 041
A06AA	Softeners, emollients	1 056	1 112	1 295	1 344	1 521	0.3	149	182	424	766	1 183
A06AA01	liquid paraffin	1 056	1 112	1 295	1 344	1 521	0.3	149	182	424	766	1 183
A06AB	Contact laxatives	27 607	28 650	30 656	30 836	30 018	5.7	592	3 550	12 030	13 846	9 799
A06AB02	bisacodyl	5 701	5 586	5 667	5 533	5 642	1.1	129	759	1 907	2 847	1 923
A06AB06	senna glycosides	1 760	1 475	1 462	1 329	1 270	0.2	11	124	351	784	786
A06AB08	sodium picosulfate	14 083	15 122	16 038	16 766	17 244	3.3	381	2 108	5 960	8 795	4 614
A06AB20	contact laxatives in combination	27	22	21	16	0	0.0	0	0	0	0	0
A06AB56	senna glycosides, combinations	38	59	<5	0	0	0.0	0	0	0	0	0
A06AB58	sodium picosulfate, combinations	7 639	7 990	9 198	8 889	7 628	1.4	92	722	4 465	2 349	2 476
A06AC	Bulk-forming laxatives	2 512	3 049	3 643	4 717	6 120	1.2	93	1 745	2 331	1 951	2 630
A06AC01	ispaghula (psylla seeds)	2 511	3 049	3 643	4 717	6 120	1.2	93	1 745	2 331	1 951	2 630
A06AC51	ispaghula, combinations	<5	0	0	0	0	0.0	0	0	0	0	0
A06AD	Osmotically acting laxatives	39 680	46 213	54 417	64 136	72 531	13.7	21 040	11 316	16 327	23 848	37 315
A06AD11	lactulose	16 269	16 713	17 324	18 482	18 532	3.5	911	2 556	6 199	8 866	5 730
A06AD12	lactitol	34	37	36	23	19	0.0	12	6	<5	0	22
A06AD15	macrogol	239	212	33	28	17	0.0	13	<5	0	0	78
A06AD17	sodium phosphate	1 687	1 055	671	801	729	0.1	0	189	361	179	151
A06AD65	macrogol, combinations	23 193	30 255	38 581	47 418	56 190	10.6	20 362	8 893	10 757	16 178	31 333
A06AG	Enemas	6 203	6 105	6 254	6 790	6 748	1.3	772	1 497	2 083	2 396	14 391
A06AG02	bisacodyl	1 808	1 674	1 556	1 452	1 263	0.2	32	316	539	376	733
A06AG04	glycerol	939	905	819	1 024	1 069	0.2	194	310	268	297	7 926
A06AG06	oil	59	64	129	114	106	0.0	14	24	30	38	289
A06AG10	docusate sodium, incl. combinations	1 626	1 578	1 709	1 900	2 023	0.4	128	483	610	802	2 522
A06AG11	sodium lauryl sulfoacetate, incl. combinations	2 197	2 276	2 470	2 779	2 773	0.5	436	472	797	1 068	2 922
A06AH	Peripheral opioid receptor antagonists	173	194	637	801	903	0.2	<5	113	412	377	4 776
A06AH01	methylnaltrexone bromide	173	138	153	132	82	0.0	0	7	38	37	1 565
A06AH03	naloxegol	0	59	498	693	836	0.2	<5	109	381	345	3 210
A06AX	Other drugs for constipation	1 174	1 811	2 478	2 676	2 984	0.6	26	1 066	1 353	539	8 948
A06AX01	glycerol	0	40	137	134	128	0.0	14	<5	48	62	45
A06AX04	linaclotide	769	1 362	1 927	2 160	2 478	0.5	11	942	1 138	387	7 241
A06AX05	prucalopride	452	475	504	480	464	0.1	<5	159	204	100	1 662

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
A07	ANTIDIARRHEALS, INTESTINAL ANTI-INFLAMMATORY/ ANTIINFECTIVE AGENTS	81 037	83 057	85 501	88 869	92 403	17.4	9 227	23 539	36 219	23 418	204 594
A07A	INTESTINAL ANTIINFECTIVES	35 631	35 536	36 202	36 965	37 503	7.1	8 722	8 553	11 790	8 438	20 116
A07AA	Antibiotics	35 631	35 536	36 202	36 965	37 503	7.1	8 722	8 553	11 790	8 438	20 116
A07AA01	neomycin	28	<5	0	<5	0	0.0	0	0	0	0	0
A07AA02	nystatin	35 091	35 051	35 641	36 290	36 737	6.9	8 711	8 402	11 401	8 223	11 994
A07AA06	paromomycin	343	174	77	42	76	0.0	<5	42	26	<5	56
A07AA09	vancomycin	239	265	277	391	370	0.1	<5	71	146	152	1 258
A07AA11	rifaximin	174	197	276	303	403	0.1	7	62	258	76	6 762
A07AA12	fidaxomicin	6	8	5	11	<5	-	0	0	<5	<5	47
A07B	INTESTINAL ADSORBENTS	127	176	173	196	261	0.1	6	109	104	42	60
A07BA	Charcoal preparations	87	94	94	65	95	0.0	6	21	40	28	25
A07BA01	medicinal charcoal	87	94	94	65	95	0.0	6	21	40	28	25
A07BB	Bismuth preparations	40	82	79	131	166	0.0	0	88	64	14	36
A07C	ELECTROLYTES WITH CARBOHYDRATES	490	451	444	445	444	0.1	188	122	82	52	1 902
A07CA	Oral rehydration salt formulations	482	441	427	426	420	0.1	166	121	82	51	369
A07D	ANTIPROPULSIVES	19 771	20 595	21 467	23 288	25 560	4.8	111	4 766	10 963	9 720	14 756
A07DA	Antipropulsives	19 771	20 595	21 467	23 288	25 560	4.8	111	4 766	10 963	9 720	14 756
A07DA01	diphenoxylate	<5	<5	<5	0	0	0.0	0	0	0	0	0
A07DA02	opium	224	223	268	306	400	0.1	0	20	206	174	1 704
A07DA03	loperamide	19 567	20 232	21 098	22 778	24 846	4.7	111	4 476	10 693	9 566	11 090
A07DA06	eluxadoline	0	0	0	119	432	0.1	<5	253	132	45	1 810
A07DA53	loperamide, combinations	197	362	400	437	423	0.1	0	137	170	116	151
A07E	INTESTINAL ANTI-INFLAMMATORY AGENTS	26 754	28 209	29 560	30 654	31 533	5.9	215	10 468	14 701	6 149	166 878
A07EA	Corticosteroids acting locally	5 811	6 043	6 834	7 507	7 712	1.5	55	2 373	3 361	1 923	26 296
A07EA01	prednisolone	1 122	69	0	10	17	0.0	0	6	5	6	40
A07EA02	hydrocortisone	324	339	390	322	198	0.0	<5	49	112	35	338
A07EA06	budesonide	4 476	5 720	6 500	7 230	7 543	1.4	53	2 335	3 267	1 888	25 918
A07EB	Antiallergic agents, excl. corticosteroids	43	46	42	47	53	0.0	6	15	26	6	1 428
A07EB01	cromoglicic acid	43	46	42	47	53	0.0	6	15	26	6	1 428
A07EC	Aminosalicylic acid and similar agents	23 005	24 112	25 111	25 797	26 488	5.0	186	9 315	12 404	4 583	139 154
A07EC01	sulfasalazine	5 737	5 771	5 683	5 457	5 410	1.0	7	1 226	2 901	1 276	6 653
A07EC02	mesalazine	16 912	18 010	19 121	20 045	20 861	3.9	179	8 060	9 390	3 232	130 035

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A07EC03	olsalazine	346	343	281	273	254	0.1	<5	45	150	57	908
A07EC04	balsalazide	555	528	479	471	388	0.1	0	91	210	87	1 558
A07F	ANTIDIARRHEAL MICROORGANISMS	1 334	1 185	725	559	422	0.1	8	163	190	61	746
A07FA	Antidiarrheal microorganisms	1 334	1 185	725	559	422	0.1	8	163	190	61	746
A07FA01	lactic acid producing organisms	882	742	370	294	215	0.0	7	96	96	16	616
A07FA02	saccharomyces boulardii	556	528	377	287	217	0.0	<5	71	99	45	110
A07FA51	lactic acid producing organisms, combinations	13	20	53	<5	<5	-	0	<5	0	<5	12
A07X	OTHER ANTIDIARRHEALS	29	67	7	<5	0	0.0	0	0	0	0	0
A07XA	Other antidiarrheals	29	67	7	<5	0	0.0	0	0	0	0	0
A07XA04	racecadotril	18	57	<5	0	0	0.0	0	0	0	0	0
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	6 716	6 361	6 293	6 256	8 051	1.5	<5	2 786	4 528	736	18 829
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	6 716	6 361	6 293	6 256	8 051	1.5	<5	2 786	4 528	736	18 829
A08AA	Centrally acting antiobesity products	0	0	0	265	3 072	0.6	0	1 314	1 663	95	8 153
A08AA62	bupropion and naltrexone	0	0	0	265	3 072	0.6	0	1 314	1 663	95	8 153
A08AB	Peripherally acting antiobesity products	6 716	6 361	6 293	6 019	5 186	1.0	<5	1 558	2 977	650	10 676
A08AB01	orlistat	6 716	6 361	6 293	6 019	5 186	1.0	<5	1 558	2 977	650	10 676
A09	DIGESTIVES, INCL. ENZYMES	5 758	5 925	6 091	6 597	6 919	1.3	113	899	3 066	2 841	21 256
A09A	DIGESTIVES, INCL. ENZYMES	5 758	5 925	6 091	6 597	6 919	1.3	113	899	3 066	2 841	21 256
A09AA	Enzyme preparations	5 683	5 849	6 022	6 364	6 657	1.3	110	800	2 942	2 805	20 937
A09AA02	multienzymes (lipase, protease etc.)	5 676	5 839	6 012	6 359	6 648	1.3	110	797	2 936	2 805	20 918
A09AB	Acid preparations	64	50	64	65	63	0.0	<5	14	25	23	66
A09AB01	glutamic acid hydrochloride	35	36	53	51	53	0.0	0	12	19	22	53
A09AB02	betaine hydrochloride	22	10	9	9	10	0.0	<5	<5	6	<5	13
A09AB03	hydrochloric acid	7	<5	<5	5	0	0.0	0	0	0	0	0
A09AC	Enzyme and acid preparations, combinations	23	31	31	195	217	0.0	<5	92	104	19	254
A09AC01	pepsin and acid preparations	0	5	28	194	217	0.0	<5	92	104	19	254
A09AC02	multienzymes and acid preparations	23	26	<5	<5	0	0.0	0	0	0	0	0
A10	DRUGS USED IN DIABETES	170 495	176 615	183 452	192 542	199 563	37.6	2 106	26 643	99 204	71 610	1 080 419
A10A	INSULINS AND ANALOGUES	59 804	61 559	63 529	65 733	68 136	12.8	2 081	15 460	29 349	21 246	474 171

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
A10AB	Insulins and analogues for injection, fast-acting	39 557	40 730	42 145	43 534	45 172	8.5	2 078	13 898	18 971	10 225	171 970
A10AB01	insulin (human)	1 024	911	825	742	640	0.1	<5	47	326	266	1 476
A10AB04	insulin lispro	9 804	10 214	10 717	11 202	10 699	2.0	553	3 470	4 726	1 950	39 467
A10AB05	insulin aspart	29 231	30 073	31 059	32 700	35 590	6.7	1 742	11 111	14 595	8 142	129 764
A10AB06	insulin glulisine	419	430	456	459	385	0.1	<5	115	194	73	1 263
A10AC	Insulins and analogues for injection, intermediate-acting	33 082	33 618	34 174	33 804	32 246	6.1	282	3 913	14 141	13 910	98 851
A10AC01	insulin (human)	33 082	33 618	34 174	33 804	32 246	6.1	282	3 913	14 141	13 910	98 851
A10AD	Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting	6 561	5 938	5 323	4 678	4 081	0.8	<5	207	1 487	2 384	19 789
A10AD03	insulin (pork)	<5	0	0	0	0	0.0	0	0	0	0	0
A10AD04	insulin lispro	616	541	481	405	342	0.1	<5	39	145	156	1 488
A10AD05	insulin aspart	5 957	5 404	4 853	4 278	3 741	0.7	<5	168	1 343	2 229	18 301
A10AE	Insulins and analogues for injection, long-acting	18 621	19 708	21 381	25 315	29 213	5.5	1 055	8 897	13 432	5 829	183 561
A10AE02	insulin (beef)	<5	0	<5	0	0	0.0	0	0	0	0	0
A10AE04	insulin glargine	12 570	13 617	15 044	16 352	16 677	3.1	455	5 350	7 507	3 365	74 025
A10AE05	insulin detemir	6 261	6 284	6 126	5 721	4 957	0.9	542	1 703	1 875	837	25 713
A10AE06	insulin degludec	5	127	1 087	3 386	5 938	1.1	103	2 232	2 706	897	34 966
A10AE54	insulin glargine and lixisenatide	0	0	0	0	32	0.0	0	<5	17	12	85
A10AE56	insulin degludec and liraglutide	0	0	46	1 642	3 459	0.7	0	276	2 184	999	48 771
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	133 286	139 072	145 510	154 588	160 950	30.3	32	13 169	84 997	62 752	606 248
A10BA	Biguanides	108 031	110 646	113 917	120 061	122 463	23.1	23	11 124	65 846	45 470	62 587
A10BA02	metformin	108 031	110 646	113 917	120 061	122 463	23.1	23	11 124	65 846	45 470	62 587
A10BB	Sulfonylureas	36 011	34 201	32 265	29 721	26 538	5.0	8	951	13 003	12 576	12 203
A10BB01	glibenclamide	981	813	677	615	530	0.1	5	26	218	281	285
A10BB07	glipizide	3 057	2 790	2 466	2 109	1 785	0.3	0	36	704	1 045	1 085
A10BB12	glimepiride	32 089	30 775	29 212	27 064	24 274	4.6	<5	889	12 105	11 277	10 834
A10BD	Combinations of oral blood glucose lowering drugs	18 377	20 716	23 050	26 294	28 781	5.4	0	1 568	17 413	9 800	128 160
A10BD05	metformin and pioglitazone	34	36	27	23	27	0.0	0	<5	16	7	115
A10BD07	metformin and sitagliptin	7 749	9 169	10 815	13 391	15 199	2.9	0	834	9 195	5 170	63 303
A10BD08	metformin and vildagliptin	10 113	10 629	10 786	10 655	10 162	1.9	0	453	5 974	3 735	46 667
A10BD10	metformin and saxagliptin	81	109	117	110	112	0.0	0	7	70	35	504
A10BD11	metformin and linagliptin	369	533	632	669	726	0.1	0	35	436	255	3 148

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A10BD15	metformin and dapagliflozin	165	436	588	852	1 166	0.2	0	108	789	269	5 484
A10BD19	linagliptin and empagliflozin	0	0	0	0	122	0.0	0	6	75	41	637
A10BD20	metformin and empagliflozin	0	<5	331	881	1 527	0.3	0	130	1 041	356	6 800
A10BD21	saxagliptin and dapagliflozin	0	0	0	91	201	0.0	0	18	115	68	1 449
A10BD23	metformin and ertugliflozin	0	0	0	0	<5	-	0	0	<5	<5	4
A10BD24	sitagliptin and ertugliflozin	0	0	0	0	17	0.0	0	0	12	5	49
A10BF	Alpha glucosidase inhibitors	519	495	463	442	416	0.1	0	40	202	174	550
A10BF01	acarbose	519	495	463	442	416	0.1	0	40	202	174	550
A10BG	Thiazolidinediones	1 552	1 500	1 492	1 415	1 373	0.3	0	48	748	577	2 962
A10BG03	pioglitazone	1 552	1 500	1 492	1 415	1 373	0.3	0	48	748	577	2 962
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors	16 324	19 048	21 861	25 212	27 093	5.1	0	1 032	12 599	13 462	109 728
A10BH01	sitagliptin	8 852	10 158	12 060	14 903	16 770	3.2	0	762	8 460	7 548	65 886
A10BH02	vildagliptin	2 519	2 540	2 500	2 374	2 163	0.4	0	70	940	1 153	7 774
A10BH03	saxagliptin	1 547	1 438	1 351	1 233	1 087	0.2	0	31	589	467	5 017
A10BH05	linagliptin	3 716	5 225	6 268	7 066	7 333	1.4	0	174	2 691	4 468	31 051
A10BJ	Glucagon-like peptide-1 (GLP-1) analogues	8 101	9 715	11 074	12 861	14 626	2.8	<5	1 300	9 662	3 663	178 641
A10BJ01	exenatide	1 067	1 317	1 324	1 251	1 112	0.2	0	59	750	303	10 552
A10BJ02	liraglutide	6 715	7 488	7 980	9 083	10 119	1.9	<5	958	6 677	2 483	131 580
A10BJ03	lixisenatide	488	940	725	525	398	0.1	0	29	277	92	3 216
A10BJ05	dulaglutide	0	335	1 432	2 314	3 277	0.6	0	265	2 159	853	33 245
A10BJ06	semaglutide	0	0	0	0	18	0.0	0	8	9	<5	49
A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors	5 713	9 442	14 041	20 330	25 613	4.8	0	1 700	16 949	6 964	111 161
A10BK01	dapagliflozin	5 713	8 475	9 437	10 588	11 297	2.1	0	725	7 619	2 953	47 184
A10BK03	empagliflozin	0	1 102	4 910	10 105	14 625	2.8	0	987	9 553	4 085	63 881
A10BK04	ertugliflozin	0	0	0	0	49	0.0	0	<5	34	11	96
A10BX	Other blood glucose lowering drugs, excl. insulins	208	184	172	163	156	0.0	<5	<5	76	77	257
A10BX02	repaglinide	208	184	172	163	156	0.0	<5	<5	76	77	257
A11	VITAMINS	156 279	186 916	226 346	265 039	261 391	49.2	4 932	85 410	96 204	74 845	156 920
A11A	MULTIVITAMINS, COMBINATIONS	162	175	183	223	227	0.0	108	103	16	0	1 099
A11AA	Multivitamins with minerals	162	175	183	223	227	0.0	108	103	16	0	1 099
A11AA03	multivitamins and other minerals, incl. combinations	162	175	183	223	227	0.0	108	103	16	0	1 099
A11B	MULTIVITAMINS, PLAIN	52	55	43	71	113	0.0	104	8	<5	0	55
A11BA	Multivitamins, plain	52	55	43	71	113	0.0	104	8	<5	0	55

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A11C	VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO	59 145	86 076	116 905	155 272	159 187	30.0	4 248	68 619	57 651	28 669	78 592
A11CA	Vitamin A, plain	77	76	94	96	105	0.0	6	29	62	8	128
A11CA01	retinol (vit A)	58	64	79	85	96	0.0	6	25	58	7	78
A11CA02	betacarotene	19	12	15	11	9	0.0	0	<5	<5	<5	49
A11CC	Vitamin D and analogues	59 091	86 035	116 856	155 234	159 147	30.0	4 243	68 610	57 631	28 663	78 464
A11CC01	ergocalciferol	26	44	35	115	239	0.0	6	113	101	19	128
A11CC03	alfacalcidol	4 733	4 850	4 880	4 960	4 911	0.9	105	588	1 816	2 402	7 483
A11CC04	calcitriol	2 972	3 119	3 265	3 267	3 101	0.6	6	379	1 237	1 479	3 865
A11CC05	colecalfiferol	51 659	78 532	109 295	147 685	151 751	28.6	4 132	67 680	54 858	25 081	66 989
A11D	VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12	930	1 033	984	1 140	1 146	0.2	20	214	588	324	1 255
A11DA	Vitamin B1, plain	920	1 024	976	1 131	1 143	0.2	20	214	586	323	1 253
A11DA01	thiamine (vit B1)	920	1 024	976	1 131	1 143	0.2	20	214	586	323	1 253
A11DB	Vitamin B1 in combination with vitamin B6 and/or vitamin B12	10	9	8	9	<5	-	0	0	<5	<5	3
A11E	VITAMIN B-COMPLEX, INCL. COMBINATIONS	100 038	107 798	120 911	126 088	118 406	22.3	433	21 657	45 040	51 276	72 934
A11EA	Vitamin B-complex, plain	98 596	106 245	119 520	124 436	116 701	22.0	387	21 333	44 374	50 607	71 473
A11EB	Vitamin B-complex with vitamin C	593	713	597	807	872	0.2	11	226	369	266	332
A11EX	Vitamin B-complex, other combinations	961	944	897	976	974	0.2	35	111	361	467	1 129
A11G	ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS	3 425	3 033	2 933	2 702	2 258	0.4	15	301	558	1 384	742
A11GA	Ascorbic acid (vitamin C), plain	3 425	3 033	2 933	2 702	2 258	0.4	15	301	558	1 384	742
A11GA01	ascorbic acid (vit C)	3 425	3 033	2 933	2 702	2 258	0.4	15	301	558	1 384	742
A11H	OTHER PLAIN VITAMIN PREPARATIONS	1 808	1 513	1 472	1 577	1 558	0.3	180	917	339	122	1 905
A11HA	Other plain vitamin preparations	1 808	1 513	1 472	1 577	1 558	0.3	180	917	339	122	1 905
A11HA01	nicotinamide	20	29	35	35	33	0.0	<5	11	12	9	22
A11HA02	pyridoxine (vit B6)	1 459	1 176	1 168	1 296	1 274	0.2	93	841	256	84	711
A11HA03	tocopherol (vit E)	266	257	222	195	194	0.0	64	45	59	26	626
A11HA04	riboflavin (vit B2)	20	18	18	15	27	0.0	5	11	8	<5	15
A11HA05	biotin	8	13	19	27	26	0.0	14	8	<5	0	428
A11HA06	pyridoxal phosphate	35	21	5	<5	<5	-	<5	<5	0	<5	28
A11HA08	tocofersolan	<5	5	8	7	<5	-	<5	0	0	0	74

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A11J	OTHER VITAMIN PRODUCTS, COMBINATIONS	70	74	71	70	70	0.0	53	13	<5	<5	328
A11JA	Combinations of vitamins	63	71	71	70	70	0.0	53	13	<5	<5	328
A11JB	Vitamins with minerals	7	<5	0	0	0	0.0	0	0	0	0	0
A12	MINERAL SUPPLEMENTS	141 418	149 619	159 592	169 017	175 598	33.1	448	11 617	69 569	93 964	147 090
A12A	CALCIUM	120 026	128 588	138 349	147 490	153 648	28.9	221	10 155	62 404	80 868	117 706
A12AA	Calcium	1 088	1 183	1 193	1 233	1 017	0.2	57	181	395	384	1 334
A12AA02	calcium glubionate	<5	0	<5	0	0	0.0	0	0	0	0	0
A12AA03	calcium gluconate	0	<5	8	5	6	0.0	6	0	0	0	6
A12AA06	calcium lactate gluconate	1 083	1 175	1 184	1 228	1 012	0.2	52	181	395	384	1 328
A12AX	Calcium, combinations with vitamin D and/or other drugs	119 209	127 683	137 414	146 576	152 946	28.8	167	10 025	62 135	80 619	116 372
A12B	POTASSIUM	21 269	20 554	20 684	20 365	20 526	3.9	127	1 177	6 472	12 750	17 916
A12BA	Potassium	21 269	20 554	20 684	20 365	20 526	3.9	127	1 177	6 472	12 750	17 916
A12BA01	potassium chloride	19 263	18 469	18 437	18 209	18 118	3.4	22	936	5 653	11 507	12 025
A12BA02	potassium citrate	2 358	3 048	2 705	2 647	2 898	0.6	115	301	954	1 528	5 850
A12BA30	potassium (different salts in combination)	<5	6	<5	5	6	0.0	0	<5	<5	0	40
A12C	OTHER MINERAL SUPPLEMENTS	6 770	7 483	8 088	8 996	9 500	1.8	142	619	2 953	5 786	11 468
A12CA	Sodium	1 443	1 851	2 277	2 554	3 114	0.6	6	131	826	2 151	4 021
A12CA01	sodium chloride	1 443	1 851	2 277	2 554	3 114	0.6	6	131	826	2 151	4 021
A12CB	Zinc	712	621	607	566	456	0.1	38	89	184	145	312
A12CB01	zinc sulfate	712	621	607	566	456	0.1	38	89	184	145	312
A12CC	Magnesium	4 747	5 148	5 385	6 063	6 184	1.2	100	402	2 017	3 665	6 926
A12CC01	magnesium chloride	0	<5	0	0	0	0.0	0	0	0	0	0
A12CC04	magnesium citrate	0	18	27	53	80	0.0	15	7	32	26	162
A12CC10	magnesium oxide	158	189	222	289	399	0.1	14	37	121	227	445
A12CC30	magnesium (different salts in combination)	4 615	4 942	5 139	5 750	5 803	1.1	46	366	1 891	3 500	5 543
A12CX	Other mineral products	7	10	16	17	15	0.0	<5	<5	<5	6	209
A13	TONICS	0	<5	<5	<5	0	0.0	0	0	0	0	0
A14	ANABOLIC AGENTS FOR SYSTEMIC USE	1 239	1 279	1 067	1 017	998	0.2	0	300	621	77	885
A14A	ANABOLIC STEROIDS	1 239	1 279	1 067	1 017	998	0.2	0	300	621	77	885
A14AA	Androstan derivatives	1 198	1 230	1 030	974	951	0.2	0	280	596	75	713
A14AA07	prasterone	1 198	1 228	1 028	973	951	0.2	0	280	596	75	713
A14AA08	oxandrolone	0	<5	<5	<5	0	0.0	0	0	0	0	0
A14AB	Estren derivatives	29	28	21	20	11	0.0	0	5	6	0	35
A14AB01	nandrolone	29	28	21	20	11	0.0	0	5	6	0	35

ATC group A

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	419	407	410	462	466	0.1	153	168	117	28	438 068
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	394	405	409	462	466	0.1	153	168	117	28	438 068
A16AA	Amino acids and derivatives	186	200	208	229	205	0.0	107	65	24	9	27 046
A16AA01	levocarnitine	129	147	168	186	169	0.0	101	45	14	9	3 098
A16AA03	glutamine	14	16	7	5	<5	-	0	<5	<5	0	5
A16AA04	mercaptamine	9	9	10	10	10	0.0	<5	7	0	0	19 251
A16AA05	carglumic acid	0	0	<5	5	<5	-	<5	0	0	0	3 441
A16AA06	betaine	23	25	23	24	24	0.0	<5	14	6	0	1 250
A16AB	Enzymes	69	80	82	86	90	0.0	12	37	37	<5	228 671
A16AB02	imiglucerase	8	9	8	8	9	0.0	0	<5	<5	<5	23 235
A16AB03	agalsidase alfa	22	20	17	16	16	0.0	0	6	7	<5	28 762
A16AB04	agalsidase beta	30	39	40	41	43	0.0	0	20	23	0	70 082
A16AB05	laronidase	<5	0	0	0	0	0.0	0	0	0	0	0
A16AB07	alglucosidase alfa	<5	<5	<5	<5	<5	-	0	0	<5	0	3 830
A16AB08	galsulfase	<5	<5	<5	<5	<5	-	<5	0	0	0	10 700
A16AB09	idursulfase	<5	<5	<5	<5	<5	-	<5	<5	0	0	10 783
A16AB10	velaglucerase alfa	<5	<5	<5	<5	<5	-	0	<5	<5	0	6 961
A16AB12	elosulfase alfa	0	<5	6	10	12	0.0	6	5	<5	0	74 319
A16AX	Various alimentary tract and metabolism products	146	131	122	155	179	0.0	40	67	57	15	182 350
A16AX01	thioctic acid	82	64	41	42	35	0.0	0	8	20	7	46
A16AX03	sodium phenylbutyrate	<5	<5	<5	<5	<5	-	<5	<5	0	0	277
A16AX04	nitisinone	17	16	15	16	17	0.0	9	8	0	0	15 415
A16AX05	zinc acetate	16	13	14	14	15	0.0	<5	8	<5	0	164
A16AX06	miglustat	5	6	6	8	10	0.0	5	<5	<5	0	8 417
A16AX07	sapropterin	23	21	22	33	36	0.0	10	23	<5	0	27 630
A16AX08	teduglutide	0	<5	10	26	45	0.0	11	9	17	8	79 812
A16AX10	eliglustat	0	<5	<5	<5	<5	-	0	<5	<5	0	4 032
A16AX12	trientine	<5	8	12	14	14	0.0	0	7	7	0	38 500
A16AX14		0	0	0	<5	5	0.0	0	<5	<5	0	8 027
A16AX15	telotristat	0	0	0	0	<5	-	0	0	<5	0	30

2.6 ATC group B – Blood and bloodforming organs

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
B	BLOOD AND BLOOD FORMING ORGANS	640 857	658 268	678 638	699 782	714 990	134.6	5 359	82 587	280 709	346 335	1 989 763
B01	ANTITHROMBOTIC AGENTS	525 381	533 688	542 849	551 056	557 207	104.9	502	25 039	213 505	318 161	1 332 301
B01A	ANTITHROMBOTIC AGENTS	525 381	533 688	542 849	551 056	557 207	104.9	502	25 039	213 505	318 161	1 332 301
B01AA	Vitamin K antagonists	77 831	69 357	60 605	51 304	42 737	8.1	44	1 582	11 065	30 046	42 020
B01AA01	dicoumarol	63	51	47	39	33	0.0	0	5	11	17	199
B01AA02	phenindione	<5	0	0	0	0	0.0	0	0	0	0	0
B01AA03	warfarin	77 769	69 306	60 561	51 268	42 704	8.0	44	1 577	11 054	30 029	41 821
B01AB	Heparin group	50 696	54 116	56 268	56 928	56 295	10.6	198	13 026	24 340	18 731	142 604
B01AB01	heparin	1 209	1 180	1 184	1 327	1 230	0.2	119	175	573	363	1 609
B01AB04	dalteparin	27 592	31 785	34 748	36 168	36 792	6.9	39	7 251	16 547	12 955	90 904
B01AB05	enoxaparin	22 732	21 964	21 078	20 307	19 037	3.6	42	5 716	7 604	5 675	50 090
B01AB10	tinzaparin	<5	0	0	0	0	0.0	0	0	0	0	0
B01AC	Platelet aggregation inhibitors excl. heparin	397 622	396 119	395 053	393 102	390 695	73.6	276	9 353	160 669	220 397	291 555
B01AC04	clopidogrel	25 588	26 629	27 618	30 764	34 742	6.5	<5	683	13 231	20 827	35 297
B01AC05	ticlopidine	180	132	108	104	81	0.0	0	<5	20	59	250
B01AC06	acetylsalicylic acid	373 995	370 946	368 557	364 426	359 317	67.7	275	8 817	149 113	201 112	98 922
B01AC07	dipyridamole	19 568	19 030	18 752	17 789	16 485	3.1	0	152	5 525	10 808	20 480
B01AC09	epoprostenol	<5	<5	<5	<5	<5	-	0	0	<5	0	1 434
B01AC11	iloprost	8	<5	5	<5	<5	-	0	0	<5	0	169
B01AC21	treprostinil	16	17	20	24	18	0.0	<5	6	8	<5	36 758
B01AC22	prasugrel	1 747	1 745	1 627	1 625	1 645	0.3	0	74	1 249	322	6 800
B01AC24	ticagrelor	8 738	9 022	9 476	9 588	9 654	1.8	0	313	6 169	3 172	52 676
B01AC27	selexipag	0	0	9	13	15	0.0	0	<5	9	<5	11 080
B01AC30	combinations	15 573	16 239	16 805	16 809	16 207	3.1	0	222	5 983	10 002	27 688
B01AD	Enzymes	<5	<5	<5	<5	<5	-	<5	0	0	0	160
B01AD02	alteplase	<5	<5	<5	<5	<5	-	<5	0	0	0	160
B01AE	Direct thrombin inhibitors	15 365	13 846	13 331	13 118	12 918	2.4	0	116	3 015	9 787	98 984
B01AE07	dabigatran etexilate	15 365	13 846	13 331	13 118	12 918	2.4	0	116	3 015	9 787	98 984
B01AF	Direct factor Xa inhibitors	28 940	45 988	65 036	83 783	101 146	19.0	0	2 736	27 968	70 442	756 888
B01AF01	rivaroxaban	20 804	25 492	28 935	30 795	31 822	6.0	0	1 312	10 165	20 345	248 212
B01AF02	apixaban	8 651	21 514	37 297	54 002	69 381	13.1	0	1 443	17 773	50 165	499 658
B01AF03	edoxaban	0	0	15	448	1 479	0.3	0	18	458	1 003	9 018
B01AX	Other antithrombotic agents	12	12	18	21	34	0.0	0	5	15	14	90
B01AX05	fondaparinux	12	12	18	21	34	0.0	0	5	15	14	90
B02	ANTIHEMORRHAGICS	13 825	13 700	13 711	14 447	14 723	2.8	365	7 406	6 154	798	346 797
B02A	ANTIFIBRINOLYTICS	13 321	13 162	13 112	13 819	14 074	2.7	233	7 168	6 002	671	6 243

ATC group B

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
B02AA	Amino acids	13 319	13 160	13 110	13 817	14 073	2.7	233	7 168	6 001	671	5 205
B02AA02	tranexamic acid	13 319	13 160	13 110	13 817	14 073	2.7	233	7 168	6 001	671	5 205
B02AB	Proteinase inhibitors	<5	<5	<5	<5	<5	-	0	0	<5	0	1 038
B02AB02	alfa1 antitrypsin	<5	<5	<5	<5	<5	-	0	0	<5	0	1 038
B02B	VITAMIN K AND OTHER HEMOSTATICS	590	627	697	740	771	0.2	162	274	192	143	340 553
B02BA	Vitamin K	259	260	280	269	283	0.1	70	105	48	60	140
B02BA01	phytomenadione	259	260	280	269	283	0.1	70	105	48	60	140
B02BB	Fibrinogen	<5	<5	<5	<5	<5	-	0	0	<5	<5	278
B02BB01	fibrinogen, human	<5	<5	<5	<5	<5	-	0	0	<5	<5	278
B02BC	Local hemostatics	<5	<5	0	0	0	0.0	0	0	0	0	0
B02BC30	combinations	<5	<5	0	0	0	0.0	0	0	0	0	0
B02BD	Blood coagulation factors	256	274	280	287	295	0.1	89	132	69	5	290 956
B02BD01	coagulation factor IX, II, VII and X in combination	<5	<5	<5	<5	<5	-	<5	0	<5	0	290
B02BD02	coagulation factor VIII	182	189	191	198	200	0.0	70	84	44	<5	214 090
B02BD03	factor VIII inhibitor bypassing activity	9	9	11	8	6	0.0	0	<5	<5	0	17 057
B02BD04	coagulation factor IX	38	47	49	51	58	0.0	14	30	12	<5	34 826
B02BD06	von Willebrand factor and coagulation factor VIII in combination	15	16	12	14	12	0.0	<5	5	<5	<5	5 786
B02BD07	coagulation factor XIII	<5	<5	<5	<5	<5	-	0	0	<5	0	187
B02BD08	coagulation factor VIIa	11	10	17	15	19	0.0	7	8	<5	0	12 518
B02BD10	von Willebrand factor	<5	<5	<5	<5	<5	-	0	<5	0	0	6 201
B02BX	Other systemic hemostatics	72	91	137	182	192	0.0	<5	37	74	77	49 178
B02BX04	romiplostim	17	23	30	41	45	0.0	0	7	22	16	18 465
B02BX05	eltrombopag	59	72	113	150	154	0.0	<5	31	56	63	30 713
B03	ANTIANEMIC PREPARATIONS	153 378	164 552	180 060	196 585	209 315	39.4	4 129	53 721	80 175	71 290	171 804
B03A	IRON PREPARATIONS	30 391	33 866	38 027	41 525	44 374	8.4	2 457	15 981	9 554	16 382	17 822
B03AA	Iron bivalent, oral preparations	28 833	32 306	36 331	39 712	42 478	8.0	2 456	15 021	8 921	16 080	15 416
B03AA01	ferrous glycine sulfate	8 744	9 522	11 113	10 275	12 755	2.4	877	5 002	2 734	4 142	6 328
B03AA02	ferrous fumarate	1 685	1 623	1 822	1 959	1 380	0.3	1 062	121	62	135	316
B03AA07	ferrous sulfate	18 758	21 566	23 850	28 907	29 018	5.5	599	10 073	6 232	12 114	8 772
B03AB	Iron trivalent, oral preparations	0	0	0	0	10	0.0	0	5	<5	<5	9
B03AB10	ferric maltol	0	0	0	0	10	0.0	0	5	<5	<5	9
B03AC	Iron, parenteral preparations	1 667	1 702	1 853	1 968	2 065	0.4	<5	1 036	668	358	2 397

ATC group B

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
B03B	VITAMIN B12 AND FOLIC ACID	126 704	134 438	146 564	160 606	171 521	32.3	1 871	40 414	72 170	57 066	102 596
B03BA	Vitamin B12 (cyanocobalamin and analogues)	86 847	97 519	102 261	104 146	111 351	21.0	524	25 928	46 840	38 059	69 034
B03BA01	cyanocobalamin	12 834	15 171	14 032	20 180	39 217	7.4	279	11 277	16 511	11 150	17 952
B03BA02	cyanocobalamin tannin complex	9 833	0	<5	<5	0	0.0	0	0	0	0	0
B03BA03	hydroxocobalamin	68 907	85 109	91 031	87 855	76 289	14.4	254	15 809	32 201	28 025	51 014
B03BA05	mecobalamin	253	257	173	179	64	0.0	0	24	37	<5	66
B03BB	Folic acid and derivatives	44 351	40 763	49 263	62 657	67 279	12.7	1 373	15 890	27 957	22 059	33 562
B03BB01	folic acid	44 351	40 717	49 204	62 614	67 205	12.7	1 372	15 863	27 921	22 049	33 506
B03X	OTHER ANTIANEMIC PREPARATIONS	3 389	3 491	3 591	3 653	3 758	0.7	30	308	1 211	2 209	51 386
B03XA	Other antianemic preparations	3 389	3 491	3 591	3 653	3 758	0.7	30	308	1 211	2 209	51 386
B03XA01	erythropoietin	267	284	259	237	254	0.1	<5	16	67	168	4 787
B03XA02	darbepoetin alfa	2 895	2 985	3 190	3 336	3 277	0.6	28	271	1 078	1 900	44 372
B03XA03	methoxy polyethylene glycol-epoetin beta	261	244	205	109	372	0.1	0	34	118	220	2 227
B06	OTHER HEMATOLOGICAL AGENTS	95	110	117	135	141	0.0	12	63	57	9	103 612
B06A	OTHER HEMATOLOGICAL AGENTS	95	110	117	135	141	0.0	12	63	57	9	103 612
B06AA	Enzymes	10	10	5	8	10	0.0	0	<5	5	<5	24
B06AA03	hyaluronidase	10	10	5	8	10	0.0	0	<5	5	<5	24
B06AB	Other hem products	0	0	<5	<5	<5	-	0	0	<5	0	332
B06AC	Drugs used in hereditary angioedema	85	100	111	126	130	0.0	12	59	51	8	103 256
B06AC01	c1-inhibitor, plasma derived	58	63	72	88	90	0.0	10	43	32	5	75 551
B06AC02	icatibant	58	65	73	87	90	0.0	10	37	38	5	27 705
B06AC04	conestat alfa	<5	0	0	0	0	0.0	0	0	0	0	0

2.7 ATC group C – Cardiovascular system

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
C	CARDIOVASCULAR SYSTEM	1 060 387	1 076 292	1 100 496	1 117 715	1 134 322	213.6	10 137	100 336	553 243	470 606	1 852 329
C01	CARDIAC THERAPY	113 053	108 891	110 225	109 551	109 087	20.5	7 618	10 967	35 464	55 038	111 572
C01A	CARDIAC GLYCOSIDES	14 063	12 900	11 878	11 153	10 482	2.0	14	63	1 549	8 856	5 274
C01AA	Digitalis glycosides	14 063	12 900	11 878	11 153	10 482	2.0	14	63	1 549	8 856	5 274
C01AA04	digitoxin	935	657	525	398	322	0.1	0	0	40	282	116
C01AA05	digoxin	13 215	12 279	11 377	10 769	10 167	1.9	14	63	1 510	8 580	5 158
C01B	ANTIARRHYTHMICS, CLASS I AND III	14 593	15 234	16 006	16 810	17 401	3.3	92	619	7 470	9 220	44 196
C01BA	Antiarrhythmics, class Ia	103	91	100	100	99	0.0	<5	7	35	55	236
C01BA01	quinidine	<5	<5	<5	<5	5	0.0	<5	<5	0	<5	32
C01BA03	disopyramide	101	89	96	96	94	0.0	0	6	35	53	204
C01BB	Antiarrhythmics, class Ib	26	33	37	39	45	0.0	0	12	21	12	1 046
C01BB02	mexiletine	26	33	37	39	45	0.0	0	12	21	12	1 046
C01BC	Antiarrhythmics, class Ic	7 600	7 755	7 890	8 152	8 194	1.5	88	452	4 194	3 460	16 132
C01BC03	propafenone	6	5	5	7	5	0.0	0	<5	<5	<5	17
C01BC04	flecainide	7 594	7 750	7 885	8 145	8 190	1.5	88	451	4 192	3 459	16 115
C01BD	Antiarrhythmics, class III	7 167	7 717	8 315	8 871	9 391	1.8	<5	164	3 404	5 820	26 781
C01BD01	amiodarone	5 784	5 978	6 232	6 551	6 813	1.3	<5	121	2 287	4 402	5 474
C01BD07	dronedarone	1 526	1 924	2 253	2 520	2 792	0.5	0	47	1 231	1 514	21 307
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	22 904	21 929	25 873	27 585	29 479	5.6	7 506	9 538	9 441	2 994	31 504
C01CA	Adrenergic and dopaminergic agents	22 904	21 929	25 873	27 585	29 479	5.6	7 506	9 538	9 441	2 994	31 504
C01CA01	etilefrine	116	80	66	59	58	0.0	<5	18	23	16	125
C01CA03	norepinephrine	0	0	<5	0	0	0.0	0	0	0	0	0
C01CA06	phenylephrine	<5	0	0	<5	0	0.0	0	0	0	0	0
C01CA17	midodrine	29	44	54	69	72	0.0	0	21	15	36	568
C01CA24	epinephrine	22 754	21 811	25 751	27 454	29 347	5.5	7 505	9 499	9 401	2 942	29 794
C01CA26	ephedrine	8	<5	<5	5	5	0.0	0	0	5	0	2
C01CA27	droxidopa	0	0	0	<5	<5	-	0	0	<5	0	1 014
C01D	VASODILATORS USED IN CARDIAC DISEASES	65 806	62 794	60 017	57 317	54 876	10.3	0	738	17 673	36 465	29 487
C01DA	Organic nitrates	65 805	62 794	60 017	57 316	54 875	10.3	0	738	17 673	36 464	29 485
C01DA02	glyceryl trinitrate	50 736	48 662	46 507	44 297	42 413	8.0	0	701	15 286	26 426	9 186
C01DA08	isosorbide dinitrate	1 153	933	722	231	0	0.0	0	0	0	0	0
C01DA14	isosorbide mononitrate	27 093	25 701	24 237	23 752	22 774	4.3	0	96	4 755	17 923	20 298
C01DX	Other vasodilators used in cardiac diseases	<5	<5	<5	<5	<5	-	0	0	<5	<5	2
C01DX12	molsidomine	<5	<5	<5	<5	<5	-	0	0	<5	<5	2

ATC group C

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
C01E	OTHER CARDIAC PREPARATIONS	62	84	172	286	289	0.1	6	63	165	55	1 111
C01EB	Other cardiac preparations	62	84	172	286	289	0.1	6	63	165	55	1 111
C01EB09	ubidecarenone	0	0	0	0	10	0.0	5	<5	<5	<5	104
C01EB15	trimetazidine	5	5	6	10	7	0.0	0	0	7	0	12
C01EB17	ivabradine	42	59	141	249	241	0.1	<5	60	140	40	617
C01EB18	ranolazine	15	20	25	28	32	0.0	0	0	18	14	378
C02	ANTIHYPERTENSIVES	16 939	16 820	17 147	17 723	17 686	3.3	357	1 001	7 285	9 043	109 415
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	6 485	6 468	6 644	7 025	7 169	1.4	348	462	3 170	3 189	10 897
C02AB	Methyldopa	65	58	57	46	40	0.0	0	21	12	7	119
C02AB01	methyldopa (levorotatory)	65	58	57	46	40	0.0	0	21	12	7	119
C02AC	Imidazoline receptor agonists	6 430	6 419	6 592	6 982	7 132	1.3	348	441	3 160	3 183	10 779
C02AC01	clonidine	107	100	125	200	282	0.1	8	122	142	10	474
C02AC02	guanfacine	0	0	96	417	477	0.1	340	126	11	0	4 656
C02AC05	moxonidine	6 324	6 320	6 373	6 367	6 377	1.2	0	196	3 008	3 173	5 649
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING	10 638	10 486	10 610	10 818	10 630	2.0	<5	484	4 202	5 943	14 150
C02CA	Alpha-adrenoreceptor antagonists	10 638	10 486	10 610	10 818	10 630	2.0	<5	484	4 202	5 943	14 150
C02CA01	prazosin	64	79	95	140	145	0.0	0	106	39	0	263
C02CA04	doxazosin	10 574	10 410	10 517	10 681	10 488	2.0	<5	379	4 165	5 943	13 888
C02D	ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON	337	360	383	383	411	0.1	<5	25	142	243	605
C02DB	Hydrazinophthalazine derivatives	306	312	330	322	363	0.1	<5	15	113	234	306
C02DB02	hydralazine	306	312	330	322	363	0.1	<5	15	113	234	306
C02DC	Pyrimidine derivatives	31	48	56	62	50	0.0	0	10	31	9	299
C02DC01	minoxidil	31	48	56	62	50	0.0	0	10	31	9	299
C02K	OTHER ANTIHYPERTENSIVES	230	268	304	326	337	0.1	8	76	169	84	83 763
C02KD	Serotonin antagonists	12	11	11	10	10	0.0	0	<5	5	<5	378
C02KD01	ketanserin	12	11	11	10	10	0.0	0	<5	5	<5	378
C02KX	Antihypertensives for pulmonary arterial hypertension	219	258	294	317	328	0.1	8	74	165	81	83 384
C02KX01	bosentan	133	117	111	106	103	0.0	8	31	45	19	18 898
C02KX02	ambrisentan	56	55	55	58	47	0.0	0	14	24	9	13 480
C02KX04	macitentan	38	87	114	144	155	0.0	<5	28	85	41	43 446
C02KX05	riociguat	7	11	19	21	28	0.0	0	<5	12	14	7 560
C03	DIURETICS	187 618	180 739	175 921	170 540	169 410	31.9	233	6 372	56 909	105 896	119 631

ATC group C

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
C03A	LOW-CEILING DIURETICS, THIAZIDES	40 871	37 627	35 304	32 893	31 977	6.0	17	982	14 225	16 753	15 209
C03AA	Thiazides, plain	13 434	12 993	12 857	12 495	13 253	2.5	12	530	6 054	6 657	3 806
C03AA01	benzoflumeziumthiazide	0	0	0	<5	<5	-	<5	0	<5	<5	2
C03AA03	hydrochlorothiazide	13 434	12 993	12 857	12 492	13 250	2.5	11	530	6 053	6 656	3 804
C03AB	Thiazides and potassium in combination	27 546	24 716	22 519	20 465	18 795	3.5	5	459	8 201	10 130	11 403
C03AB01	benzoflumeziumthiazide and potassium	27 546	24 716	22 519	20 465	18 795	3.5	5	459	8 201	10 130	11 403
C03B	LOW-CEILING DIURETICS, EXCL. THIAZIDES	17	14	11	7	8	0.0	0	<5	<5	5	25
C03BA	Sulfonamides, plain	17	14	11	7	8	0.0	0	<5	<5	5	25
C03BA04	chlortalidone	10	7	8	6	6	0.0	0	0	<5	<5	5
C03BA08	metolazone	7	7	<5	<5	<5	-	0	<5	0	<5	20
C03C	HIGH-CEILING DIURETICS	122 417	119 815	118 174	115 668	116 446	21.9	198	4 086	33 504	78 658	58 135
C03CA	Sulfonamides, plain	122 417	119 815	118 174	115 668	116 446	21.9	198	4 086	33 504	78 658	58 135
C03CA01	furosemide	86 842	82 939	79 694	75 970	74 596	14.0	197	3 161	23 508	47 730	19 599
C03CA02	bumetanide	40 285	41 465	42 921	44 130	46 219	8.7	<5	1 017	10 883	34 318	38 536
C03CA04	torasemide	<5	<5	0	0	0	0.0	0	0	0	0	0
C03D	POTASSIUM-SPARING AGENTS	19 299	20 004	21 421	22 492	24 209	4.6	44	1 416	8 991	13 758	15 680
C03DA	Aldosterone antagonists	19 280	19 982	21 406	22 476	24 196	4.6	44	1 414	8 983	13 755	15 606
C03DA01	spironolactone	18 221	18 795	20 091	20 980	22 160	4.2	44	1 316	7 927	12 873	8 710
C03DA02	potassium canrenoate	0	<5	0	0	0	0.0	0	0	0	0	0
C03DA04	eplerenone	1 208	1 339	1 489	1 671	2 236	0.4	0	110	1 146	980	6 896
C03DB	Other potassium-sparing agents	21	23	16	18	16	0.0	0	<5	10	<5	74
C03DB01	amiloride	21	23	16	18	16	0.0	0	<5	10	<5	74
C03E	DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	20 874	18 854	16 977	15 279	13 339	2.5	10	192	5 162	7 975	2 816
C03EA	Low-ceiling diuretics and potassium-sparing agents	20 874	18 854	16 977	15 279	13 339	2.5	10	192	5 162	7 975	2 816
C03EA01	hydrochlorothiazide and potassium-sparing agents	20 874	18 854	16 977	15 279	13 339	2.5	10	192	5 162	7 975	2 816
C03X	OTHER DIURETICS	61	55	78	160	187	0.0	0	43	87	57	27 766
C03XA	Vasopressin antagonists	61	55	78	160	187	0.0	0	43	87	57	27 766
C03XA01	tolvaptan	61	55	78	160	187	0.0	0	43	87	57	27 766
C04	PERIPHERAL VASODILATORS	739	655	634	567	508	0.1	0	27	147	334	643
C04A	PERIPHERAL VASODILATORS	739	655	634	567	508	0.1	0	27	147	334	643
C04AD	Purine derivatives	737	654	631	565	507	0.1	0	27	146	334	581
C04AD03	pentoxifylline	737	654	631	565	507	0.1	0	27	146	334	581

ATC group C

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
C04AX	Other peripheral vasodilators	<5	<5	<5	<5	<5	-	0	0	<5	0	62
C04AX02	phenoxylbenzamine	<5	<5	<5	<5	<5	-	0	0	<5	0	62
C05	VASOPROTECTIVES	72 133	71 938	69 823	55 313	49 437	9.3	581	20 710	18 891	9 255	13 664
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	65 990	65 841	63 639	48 839	43 259	8.1	540	19 553	16 393	6 773	12 593
C05AA	Corticosteroids	63 521	63 231	60 591	45 308	39 122	7.4	484	17 474	14 783	6 381	8 542
C05AA01	hydrocortisone	4 107	3 214	3 254	2 993	2 060	0.4	34	752	919	355	345
C05AA04	prednisolone	60 659	60 926	58 216	42 937	37 446	7.1	450	16 869	14 037	6 090	8 198
C05AE	Muscle relaxants	4 037	4 287	4 826	4 896	5 320	1.0	47	2 723	2 080	470	3 933
C05AE01	glyceryl trinitrate	4 037	4 287	4 826	4 896	5 320	1.0	47	2 723	2 080	470	3 933
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use	160	62	76	86	432	0.1	18	199	150	65	117
C05AX03	other preparations, combinations	148	49	68	69	408	0.1	17	190	137	64	68
C05B	ANTIVARICOSE THERAPY	6 393	6 338	6 407	6 680	6 366	1.2	41	1 205	2 569	2 551	1 050
C05BA	Heparins or heparinoids for topical use	6 382	6 328	6 397	6 668	6 359	1.2	41	1 203	2 564	2 551	1 041
C05BA01	organo-heparinoid	6 382	6 328	6 397	6 668	6 359	1.2	41	1 203	2 564	2 551	1 041
C05BB	Sclerosing agents for local injection	11	10	10	12	7	0.0	0	<5	5	0	8
C05BB02	polidocanol	11	10	10	12	7	0.0	0	<5	5	0	8
C05C	CAPILLARY STABILIZING AGENTS	7	7	12	8	10	0.0	0	<5	<5	5	22
C05CA	Bioflavonoids	7	7	12	8	10	0.0	0	<5	<5	5	22
C05CA01	rutoside	7	7	12	8	10	0.0	0	<5	<5	5	22
C07	BETA BLOCKING AGENTS	372 668	373 078	375 425	378 400	379 605	71.5	715	24 258	148 450	206 182	219 851
C07A	BETA BLOCKING AGENTS	369 031	369 672	372 172	375 321	376 704	70.9	715	24 172	146 918	204 899	217 805
C07AA	Beta blocking agents, non-selective	23 139	21 003	20 165	20 491	21 170	4.0	350	5 438	8 474	6 908	19 715
C07AA03	pindolol	11	12	13	11	7	0.0	0	<5	5	<5	14
C07AA05	propranolol	17 453	15 740	15 274	15 992	17 116	3.2	315	5 220	7 277	4 304	13 618
C07AA06	timolol	13	11	8	13	11	0.0	0	0	8	<5	137
C07AA07	sotalol	5 608	5 228	4 768	4 346	3 872	0.7	<5	119	1 142	2 607	2 697
C07AA12	nadolol	109	122	139	163	189	0.0	32	105	50	<5	3 249
C07AB	Beta blocking agents, selective	328 613	330 834	333 820	336 587	337 155	63.5	372	16 348	131 117	189 318	181 648
C07AB02	metoprolol	274 751	277 459	280 496	283 411	285 653	53.8	333	14 182	112 127	159 011	152 857
C07AB03	atenolol	27 982	26 316	24 654	23 277	21 435	4.0	37	1 197	7 618	12 583	5 978

ATC group C

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
C07AB07	bisoprolol	29 022	30 299	31 582	33 069	34 311	6.5	<5	1 144	12 784	20 381	22 761
C07AB12	nebivolol	36	22	41	79	98	0.0	0	23	59	16	52
C07AG	Alpha and beta blocking agents	22 109	21 960	21 956	22 064	22 019	4.2	16	2 796	8 691	10 516	16 442
C07AG01	labetalol	2 469	2 671	2 789	2 819	2 963	0.6	<5	2 137	526	297	2 206
C07AG02	carvedilol	19 658	19 314	19 189	19 267	19 077	3.6	13	665	8 172	10 227	14 236
C07B	BETA BLOCKING AGENTS AND THIAZIDES	4 030	3 729	3 563	3 342	3 113	0.6	0	90	1 625	1 398	2 047
C07BB	Beta blocking agents, selective, and thiazides	4 030	3 729	3 563	3 342	3 113	0.6	0	90	1 625	1 398	2 047
C07BB07	bisoprolol and thiazides	4 028	3 725	3 556	3 336	3 105	0.6	0	87	1 622	1 396	2 037
C07BB12	nebivolol and thiazides	<5	<5	7	6	8	0.0	0	<5	<5	<5	10
C08	CALCIUM CHANNEL BLOCKERS	237 478	241 894	249 493	256 070	260 260	49.0	156	9 965	113 737	136 402	148 850
C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	221 504	226 742	234 822	241 764	246 300	46.4	149	9 219	108 857	128 075	134 232
C08CA	Dihydropyridine derivatives	221 504	226 742	234 822	241 764	246 300	46.4	149	9 219	108 857	128 075	134 232
C08CA01	amlodipine	129 550	131 318	134 703	137 090	155 136	29.2	133	5 312	68 949	80 742	52 017
C08CA02	felodipine	14 310	13 945	13 522	12 982	14 561	2.7	<5	295	5 588	8 677	9 296
C08CA03	isradipine	458	446	422	351	275	0.1	<5	<5	100	170	371
C08CA05	nifedipine	38 829	42 101	46 124	50 280	47 653	9.0	17	3 123	21 242	23 271	47 893
C08CA06	nimodipine	38	41	31	45	35	0.0	<5	10	19	5	26
C08CA13	lercanidipine	41 539	42 239	43 626	44 738	51 137	9.6	0	1 390	22 503	27 244	24 630
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	17 062	16 236	15 746	15 374	15 121	2.9	7	807	5 321	8 986	14 617
C08DA	Phenylalkylamine derivatives	13 057	12 401	11 965	11 662	11 357	2.1	7	715	3 978	6 657	7 865
C08DA01	verapamil	13 057	12 401	11 965	11 662	11 357	2.1	7	715	3 978	6 657	7 865
C08DB	Benzothiazepine derivatives	4 050	3 941	3 850	3 763	3 820	0.7	0	98	1 361	2 361	6 752
C08DB01	diltiazem	4 050	3 941	3 850	3 763	3 820	0.7	0	98	1 361	2 361	6 752
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	565 340	577 002	592 066	607 098	620 693	116.9	571	30 101	312 754	277 267	545 401
C09A	ACE INHIBITORS, PLAIN	134 833	134 856	135 955	137 321	138 648	26.1	398	6 526	61 846	69 878	67 563
C09AA	ACE inhibitors, plain	134 833	134 856	135 955	137 321	138 648	26.1	398	6 526	61 846	69 878	67 563
C09AA01	captopril	1 718	1 535	1 381	1 339	1 205	0.2	169	66	391	579	3 354
C09AA02	enalapril	45 946	45 640	46 041	46 333	46 453	8.8	233	2 820	21 949	21 451	19 462
C09AA03	lisinopril	23 394	22 235	21 466	20 709	20 334	3.8	<5	939	9 256	10 137	9 254
C09AA04	perindopril	14	24	39	52	60	0.0	0	13	36	11	36
C09AA05	ramipril	64 292	65 938	67 562	69 406	71 098	13.4	<5	2 712	30 403	37 979	35 454
C09AA10	trandolapril	62	41	0	0	0	0.0	0	0	0	0	0

ATC group C

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
C09AA15	zofenopril	<5	<5	0	<5	<5	-	0	<5	0	<5	3
C09B	ACE INHIBITORS, COMBINATIONS	32 710	31 299	30 217	29 243	28 185	5.3	0	715	12 922	14 548	21 936
C09BA	ACE inhibitors and diuretics	31 140	29 646	28 485	27 337	26 093	4.9	0	620	11 816	13 657	19 446
C09BA02	enalapril and diuretics	18 916	18 210	17 658	17 149	16 553	3.1	0	443	7 745	8 365	13 104
C09BA03	lisinopril and diuretics	12 243	11 448	10 836	10 189	9 561	1.8	0	177	4 083	5 301	6 337
C09BA06	quinapril and diuretics	0	<5	<5	<5	<5	-	0	0	0	<5	4
C09BA15	zofenopril and diuretics	0	<5	0	<5	<5	-	0	0	<5	0	1
C09BB	ACE inhibitors and calcium channel blockers	1 593	1 669	1 755	1 930	2 125	0.4	0	98	1 117	910	2 490
C09BB02	enalapril and lercanidipine	1 593	1 669	1 755	1 930	2 125	0.4	0	98	1 117	910	2 490
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN	215 131	225 379	236 972	248 444	261 041	49.1	187	17 490	136 694	106 670	172 050
C09CA	Angiotensin II receptor blockers (ARBs), plain	215 131	225 379	236 972	248 444	261 041	49.1	187	17 490	136 694	106 670	172 050
C09CA01	losartan	64 088	65 539	66 606	67 344	69 440	13.1	35	3 262	35 469	30 674	33 707
C09CA02	eprosartan	1 285	1 183	1 105	988	902	0.2	0	8	321	573	1 775
C09CA03	valsartan	30 018	32 325	35 101	38 060	40 080	7.6	<5	2 008	21 277	16 794	45 176
C09CA04	irbesartan	18 711	18 445	18 209	17 853	17 579	3.3	0	509	8 315	8 755	16 791
C09CA06	candesartan	95 249	102 232	110 321	118 609	129 744	24.4	152	11 662	69 572	48 358	65 049
C09CA07	telmisartan	5 699	5 657	5 705	5 680	5 794	1.1	0	220	2 980	2 594	6 479
C09CA08	olmesartan medoxomil	1 600	1 555	1 542	1 538	1 644	0.3	0	79	884	681	3 073
C09D	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS	221 086	222 462	226 709	230 147	232 332	43.7	0	7 105	120 529	104 698	283 774
C09DA	Angiotensin II receptor blockers (ARBs) and diuretics	181 504	178 645	178 238	176 742	173 718	32.7	0	4 396	87 135	82 187	133 697
C09DA01	losartan and diuretics	66 303	64 608	64 474	63 337	61 870	11.7	0	1 461	30 060	30 349	33 414
C09DA02	eprosartan and diuretics	1 394	1 267	1 201	1 113	1 024	0.2	0	21	457	546	2 212
C09DA03	valsartan and diuretics	26 794	26 698	26 633	26 833	26 530	5.0	0	678	13 473	12 379	30 160
C09DA04	irbesartan and diuretics	26 036	24 757	23 578	22 301	21 177	4.0	0	305	9 621	11 251	22 558
C09DA06	candesartan and diuretics	56 924	57 400	58 597	59 488	60 366	11.4	0	1 896	32 164	26 306	38 902
C09DA07	telmisartan and diuretics	3 689	3 548	3 414	3 266	3 131	0.6	0	75	1 545	1 511	4 419
C09DA08	olmesartan medoxomil and diuretics	1 087	1 020	992	972	973	0.2	0	14	497	462	2 031
C09DB	Angiotensin II receptor blockers (ARBs) and calcium channel blockers	25 205	26 972	29 272	31 687	34 464	6.5	0	1 728	19 511	13 225	60 689
C09DB01	valsartan and amlodipine	24 907	26 659	28 939	31 375	34 097	6.4	0	1 712	19 297	13 088	59 802
C09DB02	olmesartan medoxomil and amlodipine	304	315	336	321	372	0.1	0	16	216	140	887

ATC group C

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
C09DX Angiotensin II receptor blockers (ARBs), other combinations	19 311	21 561	24 276	26 922	29 700	5.6	0	1 240	16 872	11 588	89 388
C09DX01 valsartan, amlodipine and hydrochlorothiazide	19 311	21 559	23 861	26 003	28 023	5.3	0	1 185	16 110	10 728	64 860
C09DX03 olmesartan medoxomil, amlodipine and hydrochlorothiazide	0	<5	0	0	<5	-	0	0	<5	<5	2
C09DX04 valsartan and sacubitril	0	0	417	921	1 682	0.3	0	55	762	865	24 527
C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	53	40	35	32	10	0.0	0	0	5	5	77
C09XA Renin-inhibitors	53	40	35	32	10	0.0	0	0	5	5	77
C09XA02 aliskiren	53	40	35	32	10	0.0	0	0	5	5	77
C10 LIPID MODIFYING AGENTS	518 485	530 298	546 563	567 610	582 167	109.6	280	20 928	287 981	272 978	583 268
C10A LIPID MODIFYING AGENTS, PLAIN	514 628	524 937	536 005	553 452	573 452	108.0	280	20 546	283 011	269 615	505 471
C10AA HMG CoA reductase inhibitors	506 319	515 553	524 774	540 449	558 729	105.2	260	19 362	275 484	263 623	276 906
C10AA01 simvastatin	271 504	252 759	232 429	212 312	192 106	36.2	17	4 168	79 216	108 705	61 418
C10AA02 lovastatin	825	770	705	719	742	0.1	0	14	269	459	1 141
C10AA03 pravastatin	19 189	18 617	18 317	17 903	17 497	3.3	17	426	7 256	9 798	12 519
C10AA04 fluvastatin	7 432	7 590	7 731	7 469	5 152	1.0	0	396	2 696	2 060	9 626
C10AA05 atorvastatin	211 717	237 283	264 578	295 715	329 576	62.1	181	13 257	177 262	138 876	150 155
C10AA07 rosuvastatin	12 552	15 939	20 448	25 959	30 921	5.8	49	1 710	18 187	10 975	40 356
C10AA08 pitavastatin	24	32	49	48	30	0.0	0	<5	19	10	1 690
C10AB Fibrates	315	311	301	316	329	0.1	<5	42	232	54	1 615
C10AB02 bezafibrate	44	42	36	36	39	0.0	0	<5	27	11	158
C10AB04 gemfibrozil	90	74	68	67	61	0.0	0	9	40	12	567
C10AB05 fenofibrate	182	195	197	215	230	0.0	<5	32	166	31	889
C10AC Bile acid sequestrants	2 556	2 754	3 011	3 277	3 412	0.6	13	751	1 794	854	10 222
C10AC01 colestyramine	1 866	2 049	2 328	2 610	2 763	0.5	13	674	1 427	649	3 038
C10AC02 colestipol	268	256	242	216	196	0.0	0	20	83	93	536
C10AC04 colesevelam	454	471	464	478	478	0.1	0	63	296	119	6 647
C10AD Nicotinic acid and derivatives	25	20	15	13	10	0.0	0	<5	6	<5	346
C10AD02 nicotinic acid	18	14	11	10	7	0.0	0	<5	<5	<5	316
C10AD06 acipimox	7	6	<5	<5	<5	-	0	0	<5	0	31
C10AX Other lipid modifying agents	26 228	29 683	33 353	38 964	53 420	10.1	18	2 513	31 258	19 631	216 382
C10AX02 probucol	0	0	0	0	<5	-	0	0	<5	0	22
C10AX06 omega-3-triglycerides incl. other esters and acids	4 233	4 400	4 480	4 725	4 813	0.9	<5	535	3 275	999	38 009

ATC group C

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
C10AX09 ezetimibe	22 561	25 884	29 420	34 729	49 074	9.2	14	1 978	28 342	18 740	123 539
C10AX12 lomitapide	0	0	<5	<5	<5	-	0	<5	0	0	6 891
C10AX13 evolocumab	0	45	217	317	484	0.1	<5	45	350	88	25 557
C10AX14 alirocumab	0	10	185	280	474	0.1	0	36	338	100	22 364
C10B LIPID MODIFYING AGENTS, COMBINATIONS	3 664	8 136	14 974	20 260	21 745	4.1	9	1 005	13 122	7 609	72 448
C10BA HMG CoA reductase inhibi- tors in combination with other lipid modifying agents	3 664	8 136	14 974	20 260	21 745	4.1	9	1 005	13 122	7 609	72 448
C10BA02 simvastatin and ezetimibe	3 664	4 127	4 251	4 555	4 629	0.9	0	131	2 487	2 011	20 602
C10BA05 atorvastatin and ezetimibe	0	4 136	10 871	15 847	17 293	3.3	9	882	10 746	5 656	51 846

2.8 ATC group D – Dermatologicals

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
D	DERMATOLOGICALS	674 324	686 931	713 156	747 278	772 456	145.4	113 072	282 360	245 067	131 957	441 597
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	138 096	141 400	145 187	150 144	153 601	28.9	14 255	55 982	54 885	28 479	40 761
D01A	ANTIFUNGALS FOR TOPICAL USE	120 842	124 070	127 061	132 033	134 332	25.3	13 966	49 261	45 189	25 916	22 352
D01AA	Antibiotics	43	32	13	27	41	0.0	7	19	5	10	11
D01AA01	nystatin	43	32	13	27	41	0.0	7	19	5	10	11
D01AC	Imidazole and triazole derivatives	95 521	99 330	102 356	107 077	109 065	20.5	11 855	39 745	35 689	21 776	15 540
D01AC01	clotrimazole	9 356	9 703	10 096	10 505	10 533	2.0	1 600	3 808	2 587	2 538	1 842
D01AC02	miconazole	2 421	2 313	2 321	2 309	2 381	0.5	410	801	716	454	434
D01AC03	econazole	839	949	975	1 016	1 035	0.2	37	178	370	450	160
D01AC08	ketoconazole	18 365	18 825	19 256	20 378	21 874	4.1	1 490	10 556	6 950	2 878	4 331
D01AC20	imidazoles/triazoles in combination with corticosteroids	69 350	72 618	74 981	78 325	78 596	14.8	8 801	26 435	26 740	16 620	8 773
D01AE	Other antifungals for topical use	28 894	28 407	28 410	28 823	29 125	5.5	2 477	10 948	10 806	4 894	6 801
D01AE02	methylrosaniline	878	908	812	873	586	0.1	155	116	163	152	85
D01AE14	ciclopirox	2 763	3 824	4 645	4 773	4 976	0.9	119	1 412	2 507	938	1 836
D01AE15	terbinafine	19 949	19 116	19 117	19 520	19 822	3.7	2 104	8 424	6 277	3 017	3 904
D01AE16	amorolfine	5 820	5 032	4 335	4 152	4 212	0.8	116	1 162	2 069	865	976
D01B	ANTIFUNGALS FOR SYSTEMIC USE	21 538	21 816	22 551	22 760	24 057	4.5	488	8 650	11 755	3 164	18 409
D01BA	Antifungals for systemic use	21 538	21 816	22 551	22 760	24 057	4.5	488	8 650	11 755	3 164	18 409
D01BA01	griseofulvin	30	22	19	33	23	0.0	17	5	0	<5	21
D01BA02	terbinafine	21 513	21 799	22 533	22 733	24 038	4.5	474	8 646	11 755	3 163	18 388
D02	EMOLLIENTS AND PROTECTIVES	3 153	3 500	28 189	75 655	111 674	21.0	50 883	29 398	19 887	11 506	104 314
D02A	EMOLLIENTS AND PROTECTIVES	3 153	3 500	28 180	75 646	111 662	21.0	50 882	29 394	19 881	11 505	104 295
D02AB	Zinc products	9	5	10	11	7	0.0	<5	<5	<5	<5	2
D02AC	Soft paraffin and fat products	0	0	0	7	16	0.0	<5	6	<5	5	8
D02AE	Carbamide products	1 423	1 665	26 158	73 598	109 617	20.6	50 431	28 935	19 192	11 059	103 525
D02AE01	carbamide	1 423	1 665	26 158	73 598	109 617	20.6	50 431	28 935	19 192	11 059	103 525
D02AF	Salicylic acid preparations	1 398	1 422	1 611	1 651	1 709	0.3	163	434	692	420	406
D02AX	Other emollients and protectives	353	463	641	881	966	0.2	643	132	98	93	354
D02B	PROTECTIVES AGAINST UV-RADIATION	0	0	10	9	13	0.0	<5	<5	7	<5	19
D02BA	Protectives against UV-radiation for topical use	0	0	10	9	13	0.0	<5	<5	7	<5	19

ATC group D

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
D03	PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	71	63	47	67	147	0.0	5	46	54	42	40
D03A	CICATRIZANTS	71	63	47	67	147	0.0	5	46	54	42	40
D03AX	Other cicatrizants	71	63	47	67	147	0.0	5	46	54	42	40
D03AX03	dexpantenol	71	63	47	67	147	0.0	5	46	54	42	40
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	8 038	8 386	8 560	8 761	8 573	1.6	920	3 453	2 341	1 859	1 665
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	8 038	8 386	8 560	8 761	8 573	1.6	920	3 453	2 341	1 859	1 665
D04AA	Antihistamines for topical use	<5	15	17	6	5	0.0	0	<5	<5	<5	2
D04AA13	dimetindene	<5	15	17	6	5	0.0	0	<5	<5	<5	2
D04AB	Anesthetics for topical use	6 538	6 757	6 809	6 949	6 599	1.2	563	2 893	1 883	1 260	1 333
D04AB01	lidocaine	6 538	6 757	6 809	6 949	6 599	1.2	563	2 893	1 883	1 260	1 333
D04AX	Other antipruritics	1 522	1 644	1 765	1 838	2 000	0.4	360	568	465	607	330
D05	ANTIPSORIATICS	29 403	30 301	30 801	31 250	30 297	5.7	531	8 329	15 220	6 217	47 794
D05A	ANTIPSORIATICS FOR TOPICAL USE	27 839	28 530	28 920	29 303	28 441	5.4	519	8 033	14 054	5 835	40 163
D05AA	Tars	1 102	1 299	1 550	1 917	1 940	0.4	167	619	612	542	507
D05AC	Antracen derivatives	11	10	<5	7	7	0.0	0	5	<5	<5	8
D05AC01	dithranol	11	10	<5	7	7	0.0	0	5	<5	<5	8
D05AD	Psoralens for topical use	0	0	0	<5	<5	-	0	<5	<5	0	1
D05AD02	methoxsalen	0	0	0	<5	<5	-	0	<5	<5	0	1
D05AX	Other antipsoriatics for topical use	26 883	27 416	27 610	27 683	26 768	5.0	363	7 511	13 553	5 341	39 648
D05AX02	calcipotriol	902	20	116	369	471	0.1	6	138	229	98	291
D05AX03	calcitriol	1 439	1 406	1 284	1 162	1 022	0.2	11	235	550	226	715
D05AX52	calcipotriol, combinations	25 685	26 546	26 701	26 676	25 818	4.9	350	7 280	13 053	5 135	38 642
D05B	ANTIPSORIATICS FOR SYSTEMIC USE	2 117	2 360	2 446	2 519	2 463	0.5	13	425	1 538	487	7 630
D05BA	Psoralens for systemic use	14	17	11	16	15	0.0	0	<5	6	8	11
D05BA02	methoxsalen	14	17	11	16	15	0.0	0	<5	6	8	11
D05BB	Retinoids for treatment of psoriasis	2 047	2 277	2 361	2 442	2 412	0.5	13	414	1 507	478	6 163
D05BB02	acitretin	2 047	2 277	2 361	2 442	2 412	0.5	13	414	1 507	478	6 163
D05BX	Other antipsoriatics for systemic use	60	71	78	66	38	0.0	0	10	25	<5	1 457
D05BX51	fumaric acid derivatives, combinations	60	71	78	66	38	0.0	0	10	25	<5	1 457

ATC group D

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	114 774	114 332	111 663	108 688	106 031	20.0	10 942	38 991	34 547	21 551	32 634
D06A	ANTIBIOTICS FOR TOPICAL USE	58 416	57 378	56 016	54 255	53 256	10.0	9 319	16 699	16 514	10 724	5 202
D06AA	Tetracycline and derivatives	3 258	3 340	3 230	3 226	3 276	0.6	358	945	1 218	755	573
D06AA02	chlortetracycline	25	26	16	29	28	0.0	<5	6	14	7	10
D06AA03	oxytetracycline	3 235	3 315	3 214	3 198	3 248	0.6	357	939	1 204	748	563
D06AX	Other antibiotics for topical use	55 337	54 247	52 966	51 217	50 163	9.4	8 977	15 805	15 360	10 021	4 629
D06AX01	fusidic acid	51 972	50 693	48 979	47 857	47 490	8.9	8 256	14 914	14 769	9 551	4 249
D06AX05	bacitracin	2 121	2 138	2 357	2 893	2 805	0.5	753	929	628	495	357
D06AX07	gentamicin	0	0	<5	<5	<5	-	0	<5	0	<5	1
D06AX09	mupirocin	97	98	47	43	39	0.0	12	16	8	<5	22
D06AX13	retapamulin	1 387	1 552	1 813	640	0	0.0	0	0	0	0	0
D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE	58 373	58 986	57 534	56 248	54 554	10.3	1 713	22 868	18 648	11 325	27 432
D06BA	Sulfonamides	3 577	3 313	3 124	2 866	2 893	0.5	428	978	927	560	394
D06BA01	silver sulfadiazine	3 577	3 313	3 124	2 866	2 893	0.5	428	978	927	560	394
D06BB	Antivirals	38 267	36 191	35 673	35 270	34 585	6.5	1 046	16 826	10 564	6 149	17 722
D06BB03	aciclovir	16 329	15 254	14 818	15 101	15 302	2.9	841	6 384	5 996	2 081	2 752
D06BB04	podophyllotoxin	13 286	12 623	12 096	10 834	10 353	2.0	72	8 704	1 486	91	2 910
D06BB06	penciclovir	1 385	1 087	958	871	691	0.1	25	252	300	114	150
D06BB10	imiquimod	8 079	7 993	8 494	9 299	8 973	1.7	108	2 074	2 897	3 894	11 902
D06BB12	sinecatechins	102	169	75	0	0	0.0	0	0	0	0	0
D06BB53	aciclovir, combinations	0	0	0	0	32	0.0	<5	13	13	<5	8
D06BX	Other chemotherapeutics	17 174	20 174	19 386	18 720	17 664	3.3	240	5 193	7 371	4 860	9 316
D06BX01	metronidazole	14 089	14 666	14 082	13 311	12 426	2.3	239	5 094	5 133	1 960	2 540
D06BX02	ingenol mebutate	3 132	5 571	5 363	5 459	5 275	1.0	<5	101	2 254	2 919	6 776
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	383 757	390 663	406 760	420 091	424 136	79.9	66 068	129 203	145 312	83 553	100 254
D07A	CORTICOSTEROIDS, PLAIN	326 739	336 817	349 112	360 719	361 928	68.1	59 969	109 243	122 439	70 277	76 866
D07AA	Corticosteroids, weak (group I)	31 278	32 883	34 121	36 466	36 146	6.8	17 768	9 168	5 863	3 347	4 354
D07AA02	hydrocortisone	31 278	32 883	34 121	36 466	36 146	6.8	17 768	9 168	5 863	3 347	4 354
D07AB	Corticosteroids, moderately potent (group II)	108 829	114 463	117 426	124 714	125 571	23.6	33 077	37 421	34 107	20 966	18 189
D07AB02	hydrocortisone butyrate	86 711	90 268	92 705	98 183	99 175	18.7	27 056	29 854	26 094	16 171	14 292
D07AB08	desonide	23 447	25 654	26 249	28 161	27 855	5.2	6 549	7 925	8 332	5 049	3 897
D07AC	Corticosteroids, potent (group III)	169 282	169 883	176 406	176 748	173 574	32.7	17 944	56 299	62 508	36 823	37 564

ATC group D

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D07AC01	betamethasone	61 411	50 585	58 525	55 767	54 129	10.2	3 550	17 357	20 768	12 454	8 201
D07AC03	desoximetasone	11 620	14 876	12 571	11 848	10 660	2.0	421	2 668	4 568	3 003	4 534
D07AC04	fluocinolone acetonide	5 246	7 312	5 773	5 634	5 132	1.0	161	1 039	2 229	1 703	903
D07AC08	fluocinonide	498	477	446	376	362	0.1	<5	60	176	122	70
D07AC13	mometasone	86 651	100 745	98 164	102 116	102 281	19.3	13 080	34 714	34 657	19 830	21 765
D07AC17	fluticasone	11 447	5 704	8 791	8 661	7 759	1.5	1 297	2 542	2 520	1 400	2 090
D07AD	Corticosteroids, very potent (group IV)	64 294	69 390	71 624	74 810	76 790	14.5	2 646	21 934	34 795	17 415	16 759
D07AD01	clobetasol	64 294	69 390	71 624	74 810	76 790	14.5	2 646	21 934	34 795	17 415	16 759
D07B	CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS	32 142	26 806	32 087	32 979	37 187	7.0	5 248	10 823	12 746	8 370	5 754
D07BB	Corticosteroids, moderately potent, combinations with antiseptics	6 059	10 013	9 621	4 673	6 995	1.3	2 111	1 739	1 866	1 279	1 108
D07BB02	desonide and antiseptics	6 059	10 013	9 621	4 673	6 995	1.3	2 111	1 739	1 866	1 279	1 108
D07BC	Corticosteroids, potent, combinations with antiseptics	26 519	17 796	23 369	28 949	30 910	5.8	3 404	9 266	11 040	7 200	4 646
D07BC01	betamethasone and antiseptics	23 822	12 283	19 354	26 980	28 898	5.4	3 258	8 755	10 203	6 682	4 421
D07BC02	fluocinolone acetonide and antiseptics	3 030	6 371	4 786	2 260	2 135	0.4	156	536	887	556	225
D07C	CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS	25 863	26 063	26 192	26 831	25 974	4.9	4 531	7 731	8 558	5 154	3 596
D07CA	Corticosteroids, weak, combinations with antibiotics	25 856	25 992	25 707	26 181	25 437	4.8	4 437	7 545	8 409	5 046	3 481
D07CA01	hydrocortisone and antibiotics	25 856	25 992	25 707	26 181	25 437	4.8	4 437	7 545	8 409	5 046	3 481
D07CB	Corticosteroids, moderately potent, combinations with antibiotics	<5	<5	0	0	0	0.0	0	0	0	0	0
D07CB01	triamcinolone and antibiotics	<5	<5	0	0	0	0.0	0	0	0	0	0
D07CC	Corticosteroids, potent, combinations with antibiotics	6	77	514	687	563	0.1	102	198	154	109	115
D07CC01	betamethasone and antibiotics	5	76	513	684	562	0.1	102	197	154	109	114
D07CC05	fluocinonide and antibiotics	<5	<5	<5	<5	<5	-	0	<5	0	0	1
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS	28 040	29 011	30 276	31 931	32 026	6.0	990	11 310	13 097	6 629	14 039
D07XA	Corticosteroids, weak, other combinations	12	10	5	11	<5	-	<5	0	<5	0	3
D07XA01	hydrocortisone	12	10	5	11	<5	-	<5	0	<5	0	3
D07XC	Corticosteroids, potent, other combinations	28 028	29 001	30 271	31 920	32 022	6.0	988	11 310	13 095	6 629	14 036

ATC group D

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
D07XC01	betamethasone	28 028	29 001	30 271	31 920	32 022	6.0	988	11 310	13 095	6 629	14 036
D08	ANTISEPTICS AND DISINFECTANTS	20 798	20 487	20 934	22 159	22 094	4.2	3 802	8 321	6 570	3 401	4 639
D08A	ANTISEPTICS AND DISINFECTANTS	20 798	20 487	20 934	22 159	22 094	4.2	3 802	8 321	6 570	3 401	4 639
D08AB	Aluminium agents	462	526	570	753	794	0.2	224	248	209	113	118
D08AC	Biguanides and amidines	17 537	17 157	17 667	18 699	18 749	3.5	2 908	7 405	5 719	2 717	3 930
D08AC01	dibrompropamide	6 341	6 356	6 234	6 662	6 837	1.3	2 263	2 070	1 390	1 114	1 284
D08AC02	chlorhexidine	11 595	11 223	11 815	12 426	12 332	2.3	779	5 471	4 430	1 652	2 646
D08AG	Iodine products	111	118	93	111	138	0.0	13	32	38	55	39
D08AG02	povidone-iodine	78	76	66	83	109	0.0	6	21	33	49	34
D08AG03	iodine	33	42	27	28	29	0.0	7	11	5	6	5
D08AJ	Quaternary ammonium compounds	156	139	180	198	165	0.0	21	45	54	45	36
D08AJ03	cetylpyridinium	156	139	180	198	165	0.0	21	45	54	45	36
D08AL	Silver compounds	26	22	16	12	13	0.0	0	<5	7	<5	16
D08AL01	silver nitrate	26	22	16	12	13	0.0	0	<5	7	<5	16
D08AX	Other antiseptics and disinfectants	2 683	2 686	2 570	2 596	2 436	0.5	700	641	594	501	501
D08AX01	hydrogen peroxide	1 442	1 453	1 188	1 166	1 114	0.2	295	308	276	235	142
D08AX06	potassium permanganate	1 260	1 239	1 391	1 436	1 320	0.3	408	335	318	259	342
D09	MEDICATED DRESSINGS	1 670	1 427	1 330	1 144	1 129	0.2	84	224	374	447	308
D09A	MEDICATED DRESSINGS	1 670	1 427	1 330	1 144	1 129	0.2	84	224	374	447	308
D09AA	Medicated dressings with antiinfectives	1 539	1 324	1 238	1 067	1 060	0.2	83	216	356	405	145
D09AA02	fusidic acid	1 539	1 324	1 238	1 067	1 060	0.2	83	216	356	405	145
D09AB	Zinc bandages	135	103	92	77	69	0.0	<5	8	18	42	163
D09AB01	zinc bandage without supplements	135	103	92	77	69	0.0	<5	8	18	42	163
D10	ANTI-ACNE PREPARATIONS	73 127	75 653	78 061	82 095	83 202	15.7	5 234	64 069	11 214	2 685	70 052
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE	66 073	67 313	68 595	71 573	70 960	13.4	4 977	52 999	10 371	2 613	26 461
D10AD	Retinoids for topical use in acne	38 278	40 391	43 437	46 115	47 702	9.0	3 980	39 326	3 467	929	20 078
D10AD01	tretinoin	2 728	3 113	3 253	3 483	3 608	0.7	23	1 554	1 551	480	1 192
D10AD03	adapalene	8 037	7 719	7 161	6 883	6 789	1.3	477	5 235	741	336	1 451
D10AD51	tretinoin, combinations	741	4 942	9 127	10 042	10 111	1.9	902	8 680	477	52	2 969
D10AD53	adapalene, combinations	27 931	26 587	26 519	28 445	29 909	5.6	2 866	26 202	772	69	14 466
D10AE	Peroxides	2 886	2 736	2 630	3 390	3 939	0.7	476	3 294	149	20	934
D10AE01	benzoyl peroxide	2 886	2 736	2 630	3 390	3 939	0.7	476	3 294	149	20	934

ATC group D

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
D10AF	Antiinfectives for treatment of acne	17 315	16 533	15 651	14 791	11 270	2.1	679	7 445	2 644	502	2 109
D10AF01	clindamycin	17 279	16 503	15 619	14 758	11 245	2.1	676	7 430	2 638	501	2 096
D10AF02	erythromycin	38	31	33	35	26	0.0	<5	15	7	<5	13
D10AX	Other anti-acne preparations for topical use	16 600	15 938	14 338	14 562	15 006	2.8	539	8 719	4 534	1 214	3 340
D10AX03	azelaic acid	16 593	15 934	14 334	14 554	15 003	2.8	539	8 718	4 533	1 213	3 339
D10AX30	various combinations	7	<5	<5	8	<5	-	0	<5	<5	<5	1
D10B	ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE	10 676	12 523	14 285	15 925	17 959	3.4	529	16 287	1 055	88	43 592
D10BA	Retinoids for treatment of acne	10 676	12 523	14 285	15 925	17 959	3.4	529	16 287	1 055	88	43 592
D10BA01	isotretinoin	10 676	12 523	14 285	15 925	17 959	3.4	529	16 287	1 055	88	43 592
D11	OTHER DERMATOLOGICAL PREPARATIONS	23 400	27 571	32 631	38 672	41 048	7.7	3 982	18 294	14 491	4 281	39 067
D11A	OTHER DERMATOLOGICAL PREPARATIONS	23 400	27 571	32 631	38 672	41 048	7.7	3 982	18 294	14 491	4 281	39 067
D11AC	Medicated shampoos	1 721	1 809	2 134	2 237	1 921	0.4	160	1 206	444	111	251
D11AC03	selenium compounds	1 721	1 809	2 134	2 237	1 921	0.4	160	1 206	444	111	251
D11AF	Wart and anti-corn preparations	2 701	2 857	2 884	3 214	3 010	0.6	1 301	1 116	454	139	762
D11AH	Agents for dermatitis, excluding corticosteroids	14 358	16 458	17 758	19 667	20 505	3.9	2 489	9 444	6 635	1 937	27 566
D11AH01	tacrolimus	9 659	10 394	10 859	11 229	11 511	2.2	1 401	5 175	3 775	1 160	5 169
D11AH02	pimecrolimus	4 571	5 747	6 543	8 054	8 630	1.6	1 169	4 255	2 479	727	3 956
D11AH04	alitretinoin	364	733	853	967	973	0.2	0	326	559	88	17 836
D11AH05	dupilumab	0	0	0	0	6	0.0	0	<5	5	0	605
D11AX	Other dermatologicals	4 777	6 705	10 323	14 238	16 363	3.1	46	6 898	7 268	2 151	10 489
D11AX01	minoxidil	325	358	397	469	597	0.1	6	349	169	73	302
D11AX10	finasteride	582	541	515	519	511	0.1	0	358	149	<5	2 720
D11AX16	eflornithine	560	685	790	934	1 019	0.2	6	595	329	89	770
D11AX18	diclofenac	339	249	368	406	304	0.1	0	8	107	189	332
D11AX21	brimonidine	1 572	2 489	1 954	1 805	1 405	0.3	<5	604	627	172	980
D11AX22	ivermectin	0	840	4 655	8 311	10 395	2.0	23	3 755	5 179	1 438	4 285
D11AX24	deoxycholic acid	0	0	0	<5	0	0.0	0	0	0	0	0

2.9 ATC group G – Genito urinary system and sex hormones

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
G	GENITO URINARY SYSTEM AND SEX HORMONES	814 987	835 159	859 381	876 623	889 096	167.4	4 102	443 058	285 681	156 255	1 147 178
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	37 665	38 586	40 070	42 519	41 124	7.7	124	29 880	9 283	1 837	9 921
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	37 665	38 586	40 070	42 519	41 124	7.7	124	29 880	9 283	1 837	9 921
G01AA	Antibiotics	22 764	23 983	24 308	23 450	22 820	4.3	67	16 771	5 174	808	5 661
G01AA10	clindamycin	22 764	23 983	24 308	23 450	22 820	4.3	67	16 771	5 174	808	5 661
G01AC	Quinoline derivatives	0	11	1 928	6 558	7 965	1.5	6	5 877	1 878	204	1 897
G01AC05	dequalinium	0	11	1 928	6 558	7 965	1.5	6	5 877	1 878	204	1 897
G01AD	Organic acids	11	16	12	10	11	0.0	<5	<5	<5	5	17
G01AD02	acetic acid	11	16	12	10	11	0.0	<5	<5	<5	5	17
G01AF	Imidazole derivatives	16 475	16 267	15 785	15 115	13 005	2.5	53	9 323	2 739	890	2 334
G01AF01	metronidazole	7 559	7 378	6 968	6 303	6 261	1.2	10	4 519	1 473	259	867
G01AF02	clotrimazole	7 953	8 021	7 976	7 989	5 936	1.1	36	4 244	1 094	562	1 267
G01AF05	econazole	1 268	1 168	1 127	1 127	1 034	0.2	7	734	209	84	200
G01AX	Other antiinfectives and antiseptics	8	9	10	8	7	0.0	0	<5	<5	<5	11
G01AX03	poliuresulen	8	9	10	8	7	0.0	0	<5	<5	<5	11
G02	OTHER GYNECOLOGICALS	48 836	49 301	50 823	52 144	55 340	10.4	9	47 541	7 523	267	64 548
G02A	UTEROTONICS	9	10	7	11	<5	-	0	<5	0	0	0
G02AB	Ergot alkaloids	9	10	7	11	<5	-	0	<5	0	0	0
G02AB01	methylergometrine	9	10	7	11	<5	-	0	<5	0	0	0
G02B	CONTRACEPTIVES FOR TOPICAL USE	46 545	46 915	48 551	49 912	53 116	10.0	8	46 322	6 773	13	61 600
G02BA	Intrauterine contraceptives	27 849	28 972	31 358	34 139	38 443	7.2	6	32 310	6 115	12	47 696
G02BA03	plastic IUD with progestogen	27 849	28 972	31 358	34 139	38 443	7.2	6	32 310	6 115	12	47 696
G02BB	Intravaginal contraceptives	19 002	18 259	17 547	16 170	15 083	2.8	<5	14 407	673	<5	13 904
G02BB01	vaginal ring with progestogen and estrogen	19 002	18 259	17 547	16 170	15 083	2.8	<5	14 407	673	<5	13 904
G02C	OTHER GYNECOLOGICALS	2 374	2 444	2 331	2 296	2 295	0.4	<5	1 282	758	254	2 947
G02CB	Prolactine inhibitors	2 310	2 279	2 315	2 293	2 295	0.4	<5	1 282	758	254	2 947
G02CB01	bromocriptine	936	797	728	654	595	0.1	<5	396	135	63	427
G02CB03	cabergoline	1 196	1 320	1 424	1 503	1 579	0.3	0	856	545	178	1 903
G02CB04	quinagolide	215	200	206	175	162	0.0	0	60	87	15	618
G02CX	Other gynecologicals	64	165	16	<5	0	0.0	0	0	0	0	0
G02CX04	Cimicifugae rhizoma	64	165	16	<5	0	0.0	0	0	0	0	0

ATC group G

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	575 031	583 927	593 953	594 870	594 129	111.9	3 160	369 058	166 423	55 488	530 391
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	344 874	350 607	353 941	351 197	345 926	65.1	1 834	324 013	20 063	16	185 421
G03AA	Progestogens and estrogens, fixed combinations	237 366	238 577	236 034	230 419	222 612	41.9	1 354	214 635	6 617	6	111 167
G03AA07	levonorgestrel and ethinylestradiol	138 553	145 951	150 143	152 705	149 303	28.1	1 078	145 102	3 119	<5	53 260
G03AA09	desogestrel and ethinylestradiol	45 974	41 679	37 097	31 982	28 788	5.4	114	27 355	1 318	<5	12 906
G03AA12	drospirenone and ethinylestradiol	51 713	48 906	46 233	43 520	41 128	7.7	199	39 161	1 768	0	37 996
G03AA13	norelgestromin and ethinylestradiol	9 061	8 751	8 394	7 926	7 630	1.4	12	7 262	356	0	5 867
G03AA14	nomegestrol and estradiol	1 140	1 152	1 095	1 068	1 080	0.2	<5	984	93	<5	1 095
G03AA16	dienogest and ethinylestradiol	0	0	0	0	102	0.0	0	98	<5	0	42
G03AB	Progestogens and estrogens, sequential preparations	12 601	11 539	10 426	9 293	8 116	1.5	28	7 145	942	<5	3 942
G03AB04	norethisterone and ethinylestradiol	10 762	9 765	8 750	7 727	6 684	1.3	19	5 891	773	<5	2 344
G03AB08	dienogest and estradiol	1 860	1 796	1 694	1 577	1 441	0.3	9	1 263	169	0	1 598
G03AC	Progestogens	112 335	119 628	128 200	132 116	134 848	25.4	572	121 502	12 763	11	70 280
G03AC01	norethisterone	5 326	4 909	4 625	4 256	3 823	0.7	<5	3 072	746	<5	977
G03AC06	medroxyprogesterone	18 607	18 083	17 296	16 340	15 329	2.9	36	11 243	4 047	<5	4 381
G03AC08	etonogestrel	8 044	12 689	19 677	23 778	27 216	5.1	146	26 644	421	5	31 352
G03AC09	desogestrel	83 077	87 457	90 935	92 421	92 912	17.5	410	84 849	7 649	<5	33 570
G03AD	Emergency contraceptives	1 091	285	151	141	115	0.0	<5	104	9	0	33
G03AD01	levonorgestrel	131	71	64	56	56	0.0	<5	52	<5	0	14
G03AD02	ulipristal	962	216	88	85	60	0.0	<5	53	6	0	19
G03B	ANDROGENS	10 714	12 268	14 554	15 427	15 997	3.0	31	4 047	9 477	2 442	61 939
G03BA	3-oxoandrogen (4) derivatives	10 706	12 264	14 550	15 422	15 997	3.0	31	4 047	9 477	2 442	61 900
G03BA03	testosterone	10 706	12 264	14 550	15 422	15 997	3.0	31	4 047	9 477	2 442	61 900
G03BB	5-androstanon (3) derivatives	11	5	8	9	6	0.0	0	5	<5	0	39
G03BB01	mesterolone	11	5	8	9	6	0.0	0	5	<5	0	39
G03C	ESTROGENS	134 122	138 256	144 129	150 015	156 072	29.4	164	7 540	99 292	49 076	117 603
G03CA	Natural and semisynthetic estrogens, plain	127 204	131 613	137 669	143 976	150 342	28.3	164	7 434	94 622	48 122	109 052
G03CA01	ethinylestradiol	35	22	13	17	12	0.0	<5	5	<5	<5	349
G03CA03	estradiol	118 044	123 120	129 932	136 672	142 825	26.9	31	7 132	91 978	43 684	104 947

ATC group G

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
G03CA04	estriol	10 657	9 956	9 242	8 853	9 411	1.8	131	339	3 674	5 267	3 754
G03CA57	conjugated estrogens	6	5	<5	5	<5	-	0	0	<5	<5	2
G03CX	Other estrogens	7 896	7 504	7 301	6 897	6 528	1.2	0	139	5 327	1 062	8 551
G03CX01	tibolone	7 896	7 504	7 301	6 897	6 528	1.2	0	139	5 327	1 062	8 551
G03D	PROGESTOGENS	40 263	38 822	38 079	39 183	39 586	7.5	1 130	28 178	10 083	195	26 725
G03DA	Pregnen (4) derivatives	15 007	15 507	15 875	16 568	17 737	3.3	41	12 275	5 236	185	23 894
G03DA02	medroxyprogesterone	6 557	6 510	6 469	6 869	7 303	1.4	41	3 867	3 283	112	1 415
G03DA04	progesterone	8 612	9 174	9 584	9 934	10 675	2.0	0	8 586	2 015	74	22 479
G03DB	Pregnadien derivatives	169	172	191	241	388	0.1	0	354	34	0	690
G03DB01	dydrogesterone	0	0	0	64	221	0.0	0	217	<5	0	202
G03DB06	chlormadinone	0	<5	<5	0	0	0.0	0	0	0	0	0
G03DB08	dienogest	169	171	190	177	167	0.0	0	137	30	0	488
G03DC	Estren derivatives	25 847	23 943	22 767	23 274	22 376	4.2	1 094	16 328	4 943	11	2 140
G03DC02	norethisterone	25 847	23 943	22 767	23 274	22 376	4.2	1 094	16 328	4 943	11	2 140
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION	43 978	42 974	42 769	41 514	42 210	8.0	<5	2 720	35 416	4 073	36 063
G03FA	Progestogens and estrogens, fixed combinations	34 657	33 672	33 661	32 749	33 086	6.2	0	748	28 412	3 926	29 756
G03FA01	norethisterone and estrogen	33 829	32 779	32 742	31 823	32 146	6.1	0	686	27 617	3 843	28 631
G03FA12	medroxyprogesterone and estrogen	954	997	1 014	1 027	1 053	0.2	0	65	904	84	1 126
G03FB	Progestogens and estrogens, sequential preparations	10 426	10 359	10 196	9 801	10 129	1.9	<5	2 052	7 922	154	6 307
G03FB05	norethisterone and estrogen	10 426	10 359	10 196	9 801	10 129	1.9	<5	2 052	7 922	154	6 307
G03G	GONADOTROPINS AND OTHER OVULATION STIMULANTS	10 411	10 672	10 733	9 047	8 573	1.6	0	8 307	257	9	90 918
G03GA	Gonadotropins	6 475	6 932	7 143	7 587	7 743	1.5	0	7 609	132	<5	89 821
G03GA01	chorionic gonadotrophin	990	655	639	736	91	0.0	0	58	31	<5	446
G03GA02	human menopausal gonadotrophin	2 220	2 494	2 832	2 849	2 782	0.5	0	2 745	37	0	26 889
G03GA04	urofollitropin	461	81	5	<5	225	0.0	0	222	<5	0	1 374
G03GA05	follitropin alfa	2 004	2 627	2 812	3 532	4 000	0.8	0	3 960	40	0	39 712
G03GA06	follitropin beta	2 039	2 000	2 086	1 324	851	0.2	0	844	7	0	7 141
G03GA07	lutropin alfa	8	<5	0	0	0	0.0	0	0	0	0	0
G03GA08	choriogonadotropin alfa	5 308	6 005	6 240	6 467	7 067	1.3	0	6 979	88	0	4 565
G03GA09	corifollitropin alfa	289	313	352	486	469	0.1	0	457	12	0	3 671
G03GA10	follitropin delta	0	0	0	98	220	0.0	0	220	0	0	2 598
G03GA30	combinations	28	69	34	96	215	0.0	0	214	<5	0	3 425

ATC group G

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
G03GB Ovulation stimulants, synthetic	4 883	4 732	4 489	1 935	1 031	0.2	0	891	133	7	1 097
G03GB02 clomifene	4 883	4 732	4 489	1 935	1 031	0.2	0	891	133	7	1 097
G03H ANTIANDROGENS	15 961	15 321	14 968	14 553	13 982	2.6	117	13 342	456	67	6 471
G03HA Antiandrogens, plain	160	199	221	255	312	0.1	0	198	47	67	721
G03HA01 cyproterone	160	199	221	255	312	0.1	0	198	47	67	721
G03HB Antiandrogens and estrogens	15 802	15 127	14 749	14 301	13 672	2.6	117	13 146	409	0	5 750
G03HB01 cyproterone and estrogen	15 802	15 127	14 749	14 301	13 672	2.6	117	13 146	409	0	5 750
G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	838	1 346	1 903	2 062	1 155	0.2	<5	316	660	178	5 250
G03XA Antigonadotropins and similar agents	57	42	46	46	44	0.0	<5	12	23	8	196
G03XA01 danazol	57	42	46	46	44	0.0	<5	12	23	8	196
G03XB Progesterone receptor modulators	255	965	1 559	1 766	894	0.2	0	304	589	<5	4 425
G03XB01 mifepristone	0	<5	<5	<5	<5	-	0	<5	0	0	1
G03XB02 ulipristal	255	961	1 557	1 765	893	0.2	0	303	589	<5	4 424
G03XC Selective estrogen receptor modulators	526	339	298	250	217	0.0	0	0	48	169	629
G03XC01 raloxifene	526	339	298	250	217	0.0	0	0	48	169	629
G04 UROLOGICALS	198 315	210 612	224 538	239 882	253 063	47.6	834	26 771	117 667	107 791	542 318
G04B UROLOGICALS	136 908	144 609	154 301	165 551	174 799	32.9	831	23 151	91 688	59 129	421 642
G04BA Acidifiers	<5	<5	<5	5	<5	-	<5	<5	0	0	92
G04BD Drugs for urinary frequency and incontinence	56 111	59 257	62 109	65 824	69 472	13.1	789	6 621	26 122	35 940	224 116
G04BD04 oxybutynin	1 624	1 882	2 364	2 839	3 499	0.7	158	1 995	895	451	15 126
G04BD07 tolterodine	9 815	8 622	7 939	7 389	6 550	1.2	362	338	2 061	3 789	16 409
G04BD08 solifenacin	18 606	17 576	17 047	16 400	16 145	3.0	279	1 121	6 127	8 618	41 729
G04BD10 darifenacin	2 862	2 454	2 187	2 011	1 803	0.3	0	80	627	1 096	5 423
G04BD11 fesoterodine	11 256	10 029	9 437	8 942	8 483	1.6	7	516	3 349	4 611	27 273
G04BD12 mirabegron	17 823	24 299	28 867	34 219	39 629	7.5	37	3 080	15 614	20 898	118 155
G04BE Drugs used in erectile dysfunction	82 779	87 401	94 327	101 982	107 704	20.3	38	16 466	66 818	24 382	192 458
G04BE01 alprostadil	3 165	3 134	3 169	3 091	3 280	0.6	0	143	1 817	1 320	5 985
G04BE03 sildenafil	36 589	39 750	44 279	49 803	54 309	10.2	37	8 317	33 301	12 654	68 882
G04BE04 yohimbine	11	<5	0	0	0	0.0	0	0	0	0	0
G04BE08 tadalafil	43 262	45 287	48 390	50 838	53 660	10.1	<5	8 612	34 101	10 946	104 090
G04BE09 vardenafil	8 321	8 096	8 256	8 188	6 931	1.3	<5	769	4 431	1 730	10 708
G04BE10 avanafil	0	0	0	286	1 224	0.2	0	191	770	263	845

ATC group G

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
G04BE30	combinations	326	335	403	636	727	0.1	0	34	461	232	1 948
G04BX	Other urologicals	74	113	229	378	491	0.1	<5	294	160	34	4 977
G04BX01	magnesium hydroxide	20	14	23	17	20	0.0	<5	6	<5	9	27
G04BX13	dimethyl sulfoxide	0	<5	<5	<5	0	0.0	0	0	0	0	0
G04BX14	dapoxetine	13	37	139	294	394	0.1	0	272	119	<5	231
G04BX15	pentosan polysulfate sodium	37	58	60	61	72	0.0	0	14	37	21	4 678
G04BX16	tiopronin	<5	<5	<5	5	5	0.0	<5	<5	0	<5	41
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	72 725	78 579	83 917	89 368	94 665	17.8	<5	3 966	32 619	58 077	120 676
G04CA	Alpha-adrenoreceptor antagonists	60 216	66 025	71 252	76 632	81 729	15.4	<5	2 031	30 057	49 638	102 120
G04CA01	alfuzosin	16	27	28	23	18	0.0	0	<5	<5	13	52
G04CA02	tamsulosin	47 791	50 322	52 615	55 027	57 370	10.8	<5	1 933	23 060	32 374	43 035
G04CA03	terazosin	547	502	509	421	395	0.1	0	45	159	191	373
G04CA52	tamsulosin and dutasteride	14 946	18 364	21 617	24 463	27 008	5.1	0	44	7 869	19 095	55 584
G04CA53	tamsulosin and solifenacin	0	25	348	703	1 134	0.2	0	22	521	591	3 076
G04CB	Testosterone-5-alpha reductase inhibitors	17 815	17 549	17 492	17 414	17 467	3.3	0	1 945	3 613	11 909	18 556
G04CB01	finasteride	16 774	16 641	16 687	16 763	16 869	3.2	0	1 900	3 517	11 452	16 863
G04CB02	dutasteride	1 098	962	846	686	637	0.1	0	59	102	476	1 692

2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
H	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	437 511	445 610	452 531	463 794	469 293	88.4	18 156	112 666	198 712	139 759	548 811
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	26 356	26 947	26 687	27 881	27 529	5.2	9 836	14 090	2 007	1 596	293 191
H01A	ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES	2 027	2 079	2 091	2 133	2 178	0.4	1 179	634	303	62	93 267
H01AA	ACTH	0	<5	<5	<5	<5	-	<5	0	0	0	23
H01AA02	tetracosactide	0	<5	<5	<5	<5	-	<5	0	0	0	23
H01AB	Thyrotropin	0	0	<5	0	0	0.0	0	0	0	0	0
H01AB01	thyrotropin alfa	0	0	<5	0	0	0.0	0	0	0	0	0
H01AC	Somatropin and somatropin agonists	1 995	2 042	2 048	2 087	2 133	0.4	1 175	625	281	52	80 626
H01AC01	somatropin	1 995	2 042	2 046	2 083	2 130	0.4	1 175	622	281	52	80 500
H01AC03	mecasermin	0	0	<5	6	5	0.0	0	5	0	0	126
H01AX	Other anterior pituitary lobe hormones and analogues	32	35	40	42	41	0.0	0	9	22	10	12 617
H01AX01	pegvisomant	32	35	40	42	41	0.0	0	9	22	10	12 617
H01B	POSTERIOR PITUITARY LOBE HORMONES	18 980	18 930	18 399	19 303	18 602	3.5	8 695	7 564	1 220	1 123	48 236
H01BA	Vasopressin and analogues	11 736	11 854	11 662	11 983	11 997	2.3	8 635	1 089	1 153	1 120	46 260
H01BA02	desmopressin	11 736	11 854	11 662	11 982	11 996	2.3	8 635	1 089	1 153	1 119	46 241
H01BA04	terlipressin	0	0	0	<5	<5	-	0	0	0	<5	19
H01BB	Oxytocin and analogues	7 249	7 078	6 737	7 320	6 607	1.2	60	6 477	67	<5	1 976
H01BB02	oxytocin	7 249	7 078	6 737	7 320	6 607	1.2	60	6 477	67	<5	1 976
H01C	HYPOTHALAMIC HORMONES	5 608	6 196	6 487	6 745	7 042	1.3	10	6 049	558	425	151 688
H01CA	Gonadotropin-releasing hormones	2 833	3 031	2 954	2 632	2 483	0.5	<5	2 466	15	<5	5 774
H01CA02	nafarelin	2 833	3 031	2 954	2 632	2 483	0.5	<5	2 466	15	<5	5 774
H01CB	Somatostatin and analogues	830	895	927	944	987	0.2	9	63	491	424	132 796
H01CB02	octreotide	603	638	616	617	607	0.1	0	43	301	263	71 724
H01CB03	lanreotide	248	291	329	351	397	0.1	9	17	198	173	57 286
H01CB05	pasireotide	<5	5	5	11	11	0.0	0	<5	6	<5	3 786
H01CC	Anti-gonadotropin-releasing hormones	2 304	2 685	3 082	3 650	4 053	0.8	0	3 999	54	0	13 117
H01CC01	ganirelix	2 075	2 607	3 011	3 071	3 495	0.7	0	3 449	46	0	11 073
H01CC02	cetrotorelix	286	109	143	753	640	0.1	0	632	8	0	2 044
H02	CORTICOSTEROIDS FOR SYSTEMIC USE	227 420	231 293	233 848	240 224	242 825	45.7	6 043	60 390	101 961	74 431	84 138

ATC group H

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	227 187	231 055	233 616	240 195	242 824	45.7	6 043	60 390	101 961	74 430	84 137
H02AA	Mineralocorticoids	1 403	1 442	1 490	1 546	1 563	0.3	88	462	652	361	497
H02AA02	fludrocortisone	1 403	1 442	1 490	1 546	1 563	0.3	88	462	652	361	497
H02AB	Glucocorticoids	227 005	230 866	233 414	239 986	242 602	45.7	6 038	60 347	101 908	74 309	83 640
H02AB01	betamethasone	2 307	2 669	2 982	3 476	3 984	0.8	2 487	518	746	233	875
H02AB02	dexamethasone	5 508	7 268	8 837	10 446	11 688	2.2	439	1 088	5 748	4 413	16 647
H02AB04	methylprednisolone	10 306	9 769	9 093	7 919	6 941	1.3	33	1 444	3 307	2 157	2 625
H02AB06	prednisolone	174 044	177 416	181 260	187 335	191 453	36.0	2 699	41 808	80 621	66 325	34 389
H02AB07	prednisone	330	303	294	268	114	0.0	0	15	42	57	643
H02AB08	triamcinolone	38 537	37 521	35 086	34 710	32 421	6.1	282	16 055	13 367	2 717	5 274
H02AB09	hydrocortisone	683	700	827	948	989	0.2	84	342	473	90	16 030
H02AB10	cortisone	2 905	3 006	3 130	3 254	3 351	0.6	103	827	1 538	883	6 795
H02AB13	deflazacort	36	45	51	55	59	0.0	30	20	6	<5	361
H02B	CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS	416	418	402	107	<5	-	0	0	<5	<5	1
H02BX	Corticosteroids for systemic use, combinations	416	418	402	107	<5	-	0	0	<5	<5	1
H02BX01	methylprednisolone, combinations	416	418	402	107	<5	-	0	0	<5	<5	1
H03	THYROID THERAPY	202 576	207 068	212 089	216 620	220 398	41.5	1 417	40 676	104 204	74 101	103 541
H03A	THYROID PREPARATIONS	197 828	202 215	207 170	211 335	214 677	40.4	1 374	39 006	101 789	72 508	95 349
H03AA	Thyroid hormones	197 828	202 215	207 170	211 335	214 677	40.4	1 374	39 006	101 789	72 508	95 349
H03AA01	levothyroxine sodium	196 793	200 938	205 630	209 382	212 354	40.0	1 369	38 320	100 325	72 340	67 846
H03AA02	liothyronine sodium	5 361	6 206	7 273	8 412	9 883	1.9	18	2 840	5 960	1 065	7 030
H03AA03	combinations of levothyroxine and liothyronine	<5	<5	<5	<5	<5	-	<5	<5	<5	0	5
H03AA04	tiratricol	0	0	0	0	<5	-	0	<5	0	0	1
H03AA05	thyroid gland preparations	1 828	2 662	3 407	4 144	4 885	0.9	6	1 488	3 078	313	20 466
H03B	ANTITHYROID PREPARATIONS	6 713	6 924	7 103	7 525	8 175	1.5	59	2 654	3 548	1 914	8 188
H03BA	Thiouracils	733	629	557	559	552	0.1	<5	278	208	64	807
H03BA02	propylthiouracil	733	629	557	559	552	0.1	<5	278	208	64	807
H03BB	Sulfur-containing imidazole derivatives	6 239	6 484	6 729	7 157	7 814	1.5	57	2 497	3 393	1 867	7 381
H03BB01	carbimazole	6 239	6 484	6 729	7 157	7 814	1.5	57	2 497	3 393	1 867	7 381
H03C	IODINE THERAPY	6	12	7	<5	5	0.0	0	<5	<5	0	4
H03CA	Iodine therapy	6	12	7	<5	5	0.0	0	<5	<5	0	4
H04	PANCREATIC HORMONES	5 495	5 398	5 588	5 427	5 353	1.0	1 169	2 282	1 460	442	2 180

ATC group H

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
H04A	GLYCOGENOLYTIC HORMONES	5 495	5 398	5 588	5 427	5 353	1.0	1 169	2 282	1 460	442	2 180
H04AA	Glycogenolytic hormones	5 495	5 398	5 588	5 427	5 353	1.0	1 169	2 282	1 460	442	2 180
H04AA01	glucagon	5 495	5 398	5 588	5 427	5 353	1.0	1 169	2 282	1 460	442	2 180
H05	CALCIUM HOMEOSTASIS	1 375	1 559	1 827	2 096	2 139	0.4	0	146	988	1 005	65 757
H05A	PARATHYROID HORMONES AND ANALOGUES	608	720	931	1 151	1 133	0.2	0	65	597	471	52 003
H05AA	Parathyroid hormones and analogues	608	720	931	1 151	1 133	0.2	0	65	597	471	52 003
H05AA02	teriparatide	608	720	931	1 151	1 123	0.2	0	61	592	470	35 199
H05AA03	parathyroid hormone	0	0	0	<5	22	0.0	0	7	14	<5	16 804
H05B	ANTI-PARATHYROID AGENTS	767	839	896	945	1 006	0.2	0	81	391	534	13 755
H05BA	Calcitonin preparations	16	8	7	8	6	0.0	0	<5	0	<5	57
H05BA01	calcitonin (salmon synthetic)	16	8	7	8	6	0.0	0	<5	0	<5	57
H05BX	Other anti-parathyroid agents	751	831	889	937	1 001	0.2	0	78	391	532	13 698
H05BX01	cinacalcet	520	569	615	674	734	0.1	0	43	264	427	9 333
H05BX02	paricalcitol	289	309	341	333	336	0.1	0	42	160	134	4 364

2.11 ATC group J – Antiinfectives for systemic use

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
J	ANTIINFECTIVES FOR SYSTEMIC USE	1 252 912	1 239 430	1 209 403	1 177 724	1 167 183	219.7	117 077	451 075	380 772	218 259	1 284 841
J01	ANTIBACTERIALS FOR SYSTEMIC USE	1 172 061	1 151 008	1 109 722	1 063 315	1 026 325	193.2	109 935	390 234	331 479	194 677	297 864
J01A	TETRACYCLINES	179 821	181 380	168 809	159 385	152 173	28.7	2 433	79 325	47 780	22 635	31 310
J01AA	Tetracyclines	179 821	181 380	168 809	159 385	152 173	28.7	2 433	79 325	47 780	22 635	31 310
J01AA02	doxycycline	138 206	141 617	131 272	122 266	115 433	21.7	1 035	52 799	40 408	21 191	18 899
J01AA04	lymecycline	24 963	24 561	23 337	24 396	24 801	4.7	1 037	18 642	4 354	768	8 973
J01AA06	oxytetracycline	32	21	30	26	29	0.0	0	13	11	5	9
J01AA07	tetracycline	19 709	18 062	16 804	15 267	14 239	2.7	400	9 510	3 530	799	3 398
J01AA08	minocycline	95	56	35	28	23	0.0	0	9	8	6	32
J01AA12	tigecycline	<5	<5	<5	0	0	0.0	0	0	0	0	0
J01B	AMPHENICOLS	0	0	<5	0	0	0.0	0	0	0	0	0
J01BA	Amphenicols	0	0	<5	0	0	0.0	0	0	0	0	0
J01BA01	chloramphenicol	0	0	<5	0	0	0.0	0	0	0	0	0
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS	774 578	769 281	750 891	730 187	713 965	134.4	83 728	263 956	226 979	139 302	134 101
J01CA	Penicillins with extended spectrum	323 045	319 429	311 008	298 397	299 130	56.3	22 217	93 443	100 035	83 435	57 574
J01CA01	ampicillin	46	50	62	54	66	0.0	0	5	14	47	203
J01CA04	amoxicillin	133 023	132 447	125 992	119 990	117 650	22.2	18 346	26 852	40 800	31 652	18 008
J01CA08	pivmecillinam	203 727	200 847	198 004	190 781	194 098	36.5	4 088	69 117	63 416	57 477	39 355
J01CA11	mecillinam	11	10	16	18	6	0.0	0	<5	<5	<5	8
J01CE	Beta-lactamase sensitive penicillins	421 779	417 025	404 417	394 483	373 320	70.3	61 531	149 233	111 417	51 139	51 761
J01CE01	benzylpenicillin	127	120	149	166	209	0.0	<5	24	69	114	281
J01CE02	phenoxymethylpenicillin	421 648	416 879	404 289	394 344	373 163	70.3	61 529	149 188	111 371	51 075	51 161
J01CE08	benzathine benzylpenicillin	82	87	60	57	51	0.0	0	30	17	<5	319
J01CF	Beta-lactamase resistant penicillins	104 462	105 990	105 128	103 589	105 680	19.9	5 274	42 485	36 399	21 522	22 904
J01CF01	dicloxacillin	101 196	104 241	103 820	103 272	105 556	19.9	5 211	42 473	36 377	21 495	22 454
J01CF02	cloxacillin	3 964	2 211	1 624	379	105	0.0	0	15	40	50	195
J01CF05	flucloxacillin	22	29	47	66	78	0.0	69	8	0	<5	256
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	652	770	1 017	1 652	2 829	0.5	891	386	729	823	1 862
J01CR02	amoxicillin and beta-lactamase inhibitor	599	695	916	1 588	2 762	0.5	889	379	703	791	1 452
J01CR05	piperacillin and beta-lactamase inhibitor	53	79	104	66	70	0.0	<5	8	26	34	410

ATC group J

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
J01D	OTHER BETA-LACTAM ANTIBACTERIALS	19 475	17 366	14 827	13 449	12 545	2.4	1 838	4 598	4 031	2 078	6 028
J01DB	First-generation cephalosporins	18 026	16 071	13 968	12 546	11 728	2.2	1 791	4 284	3 795	1 858	1 887
J01DB01	cefalexin	18 012	16 055	13 951	12 529	11 708	2.2	1 791	4 282	3 784	1 851	1 853
J01DB03	cefalotin	15	16	19	17	22	0.0	<5	<5	12	7	33
J01DC	Second-generation cephalosporins	78	93	97	72	75	0.0	0	9	19	47	96
J01DC02	cefuroxime	78	93	97	72	75	0.0	0	9	19	47	96
J01DD	Third-generation cephalosporins	1 373	1 171	740	785	717	0.1	47	304	202	164	1 663
J01DD01	cefotaxime	1 054	789	363	305	169	0.0	<5	23	65	77	276
J01DD02	ceftazidime	77	69	68	75	55	0.0	<5	23	15	15	238
J01DD04	ceftriaxone	244	313	312	412	494	0.1	41	258	124	71	1 148
J01DD08	cefixime	0	0	0	0	<5	-	0	0	0	<5	1
J01DF	Monobactams	13	14	13	16	18	0.0	<5	8	<5	<5	819
J01DF01	aztreonam	13	14	13	16	18	0.0	<5	8	<5	<5	819
J01DH	Carbapenems	65	86	73	86	71	0.0	<5	16	29	24	1 446
J01DH02	meropenem	49	49	58	63	53	0.0	<5	12	22	17	1 021
J01DH03	ertapenem	16	32	10	21	18	0.0	0	<5	7	8	415
J01DH51	imipenem and cilastatin	<5	9	8	<5	<5	-	0	<5	0	0	11
J01DI	Other cephalosporins and penems	0	0	0	<5	<5	-	0	<5	0	0	117
J01DI54	ceftolozane and beta-lactamase inhibitor	0	0	0	<5	<5	-	0	<5	0	0	117
J01E	SULFONAMIDES AND TRIMETHOPRIM	121 251	121 066	121 722	121 434	125 601	23.7	12 478	30 893	42 652	39 578	15 421
J01EA	Trimethoprim and derivatives	76 472	72 140	69 823	68 123	66 833	12.6	7 374	17 586	21 008	20 865	6 188
J01EA01	trimethoprim	76 472	72 140	69 823	68 123	66 833	12.6	7 374	17 586	21 008	20 865	6 188
J01EC	Intermediate-acting sulfonamides	0	0	<5	9	<5	-	0	0	<5	0	2
J01EC02	sulfadiazine	0	0	<5	9	<5	-	0	0	<5	0	2
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives	49 930	54 153	57 183	58 807	64 637	12.2	5 529	14 307	23 514	21 287	9 231
J01EE01	sulfamethoxazole and trimethoprim	49 930	54 153	57 183	58 807	64 637	12.2	5 529	14 307	23 514	21 287	9 231
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	267 602	242 351	217 006	187 736	163 664	30.8	21 286	67 258	55 173	19 947	29 571
J01FA	Macrolides	212 200	190 236	168 977	145 999	123 066	23.2	17 734	51 656	40 262	13 414	20 242
J01FA01	erythromycin	110 826	101 160	92 247	82 929	67 900	12.8	14 576	24 098	21 296	7 930	10 417

ATC group J

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
J01FA02	spiramycin	1 863	1 652	1 307	1 065	884	0.2	13	292	443	136	139
J01FA06	roxithromycin	5	<5	10	<5	9	0.0	0	<5	6	0	7
J01FA09	clarithromycin	29 173	24 078	18 856	15 730	13 280	2.5	1 260	5 018	5 042	1 960	2 539
J01FA10	azithromycin	77 639	69 382	61 238	49 933	43 852	8.3	2 198	23 465	14 505	3 684	7 141
J01FA15	telithromycin	<5	<5	0	0	0	0.0	0	0	0	0	0
J01FF	Lincosamides	63 250	59 149	53 932	46 587	44 856	8.4	3 977	17 412	16 340	7 127	9 329
J01FF01	clindamycin	63 250	59 149	53 932	46 587	44 856	8.4	3 977	17 412	16 340	7 127	9 329
J01G	AMINOGLYCOSIDE ANTIBACTERIALS	258	214	216	222	185	0.0	42	71	45	27	7 829
J01GA	Streptomycins	<5	0	<5	0	0	0.0	0	0	0	0	0
J01GA01	streptomycin	<5	0	<5	0	0	0.0	0	0	0	0	0
J01GB	Other aminoglycosides	257	214	215	222	185	0.0	42	71	45	27	7 829
J01GB01	tobramycin	213	177	168	172	140	0.0	35	59	28	18	6 265
J01GB03	gentamicin	34	24	32	32	33	0.0	7	7	11	8	989
J01GB06	amikacin	11	13	15	20	13	0.0	0	6	6	<5	575
J01M	QUINOLONE ANTIBACTERIALS	65 117	58 859	53 197	45 649	42 077	7.9	312	10 442	16 882	14 441	11 045
J01MA	Fluoroquinolones	65 117	58 859	53 197	45 649	42 077	7.9	312	10 442	16 882	14 441	11 045
J01MA01	ofloxacin	1 496	1 312	1 083	941	832	0.2	0	217	370	245	268
J01MA02	ciprofloxacin	63 320	56 847	51 047	43 221	39 387	7.4	312	8 369	16 482	14 224	9 044
J01MA12	levofloxacin	29	21	24	60	83	0.0	0	46	28	9	512
J01MA14	moxifloxacin	547	940	1 247	1 600	1 939	0.4	0	1 858	73	8	1 221
J01X	OTHER ANTIBACTERIALS	63 139	64 278	65 539	66 806	62 147	11.7	1 020	10 119	21 307	29 701	62 558
J01XA	Glycopeptide antibacterials	31	44	47	43	43	0.0	<5	7	21	13	522
J01XA01	vancomycin	30	44	47	42	43	0.0	<5	7	21	13	522
J01XA02	teicoplanin	<5	0	0	<5	0	0.0	0	0	0	0	0
J01XB	Polymyxins	88	94	111	111	104	0.0	9	45	36	14	3 877
J01XB01	colistin	88	94	111	111	104	0.0	9	45	36	14	3 877
J01XC	Steroid antibacterials	481	411	346	326	326	0.1	24	105	109	88	252
J01XC01	fusidic acid	481	411	346	326	326	0.1	24	105	109	88	252
J01XD	Imidazole derivatives	30	34	30	27	31	0.0	0	<5	19	9	94
J01XD01	metronidazole	30	34	30	27	31	0.0	0	<5	19	9	94
J01XE	Nitrofurantoin derivatives	36 895	36 527	36 830	37 003	30 853	5.8	882	6 686	10 923	12 362	9 077
J01XE01	nitrofurantoin	36 895	36 527	36 830	37 003	30 853	5.8	882	6 686	10 923	12 362	9 077
J01XX	Other antibacterials	31 554	33 306	34 356	35 522	36 348	6.8	137	3 921	12 073	20 217	48 735
J01XX01	fosfomycin	7	19	19	30	53	0.0	0	9	28	16	130
J01XX05	methenamine	31 313	33 030	34 039	35 183	35 980	6.8	137	3 859	11 904	20 080	43 134
J01XX08	linezolid	250	275	305	314	339	0.1	0	54	153	132	4 639

ATC group J

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
J01XX09	daptomycin	0	<5	0	0	<5	-	0	0	<5	0	28
J01XX11	tedizolid	0	0	9	18	7	0.0	0	<5	<5	<5	804
J02	ANTIMYCOTICS FOR SYSTEMIC USE	48 649	47 208	43 725	41 387	40 492	7.6	439	24 839	11 861	3 353	38 666
J02A	ANTIMYCOTICS FOR SYSTEMIC USE	48 649	47 208	43 725	41 387	40 492	7.6	439	24 839	11 861	3 353	38 666
J02AA	Antibiotics	<5	5	<5	<5	<5	-	0	0	<5	0	972
J02AA01	amphotericin B	<5	5	<5	<5	<5	-	0	0	<5	0	972
J02AB	Imidazole derivatives	0	25	11	8	8	0.0	0	<5	<5	<5	259
J02AB02	ketoconazole	0	25	11	8	8	0.0	0	<5	<5	<5	259
J02AC	Triazole derivatives	48 646	47 185	43 708	41 371	40 471	7.6	439	24 833	11 851	3 348	30 962
J02AC01	fluconazole	48 145	46 748	43 304	41 008	40 091	7.6	429	24 679	11 698	3 285	16 928
J02AC02	itraconazole	703	530	401	365	348	0.1	<5	213	105	28	581
J02AC03	voriconazole	85	103	105	97	96	0.0	<5	10	43	39	4 052
J02AC04	posaconazole	85	101	120	106	111	0.0	14	29	58	10	8 180
J02AC05	isavuconazole	0	0	0	<5	16	0.0	0	<5	9	<5	1 222
J02AX	Other antimycotics for systemic use	5	8	10	10	20	0.0	0	<5	12	<5	6 473
J02AX04	caspofungin	<5	<5	<5	<5	<5	-	0	0	<5	0	88
J02AX05	miconazole	<5	5	<5	<5	7	0.0	0	0	<5	<5	784
J02AX06	anidulafungin	0	<5	5	5	11	0.0	0	<5	6	<5	5 601
J04	ANTIMYCOBACTERIALS	2 105	1 794	1 971	1 998	1 938	0.4	160	759	591	428	7 925
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS	1 636	1 349	1 496	1 517	1 471	0.3	149	666	390	266	7 474
J04AA	Aminosalicylic acid and derivatives	0	<5	<5	0	0	0.0	0	0	0	0	0
J04AA01	4-aminosalicylic acid	0	<5	<5	0	0	0.0	0	0	0	0	0
J04AB	Antibiotics	656	636	940	1 031	1 044	0.2	132	401	278	233	3 872
J04AB01	cycloserine	0	12	13	12	10	0.0	0	9	<5	0	437
J04AB02	rifampicin	644	583	651	696	706	0.1	76	171	237	222	1 125
J04AB04	rifabutin	12	5	6	11	9	0.0	0	<5	5	<5	309
J04AB05	rifapentine	0	36	272	319	322	0.1	57	221	35	9	2 001
J04AB30	capreomycin	0	0	<5	0	0	0.0	0	0	0	0	0
J04AC	Hydrazides	78	115	336	378	377	0.1	55	251	54	17	208
J04AC01	isoniazid	78	115	336	378	377	0.1	55	251	54	17	208
J04AD	Thiocarbamide derivatives	0	6	6	11	9	0.0	0	8	<5	0	88
J04AD01	protonamide	0	6	6	11	9	0.0	0	8	<5	0	88
J04AK	Other drugs for treatment of tuberculosis	291	233	204	177	160	0.0	10	74	48	28	1 731
J04AK01	pyrazinamide	58	41	46	40	40	0.0	7	27	<5	<5	80

ATC group J

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
J04AK02	ethambutol	273	219	181	162	145	0.0	6	66	46	27	668
J04AK05	bedaquiline	<5	0	0	<5	<5	-	0	<5	<5	0	983
J04AM	Combinations of drugs for treatment of tuberculosis	976	680	529	471	407	0.1	18	263	98	28	1 575
J04AM02	rifampicin and isoniazid	915	638	466	420	370	0.1	17	241	92	20	1 077
J04AM05	rifampicin, pyrazinamide and isoniazid	178	129	126	95	76	0.0	<5	52	17	6	171
J04AM06	rifampicin, pyrazinamide, ethambutol and isoniazid	53	68	101	128	126	0.0	<5	88	28	9	326
J04B	DRUGS FOR TREATMENT OF LEPRO	470	448	475	485	473	0.1	11	95	203	164	451
J04BA	Drugs for treatment of lepra	470	448	475	485	473	0.1	11	95	203	164	451
J04BA01	clofazimine	0	<5	5	9	6	0.0	0	<5	<5	<5	36
J04BA02	dapsone	470	445	470	476	467	0.1	11	93	200	163	415
J05	ANTIVIRALS FOR SYSTEMIC USE	39 587	43 666	48 150	53 194	59 797	11.3	973	29 293	22 309	7 222	763 176
J05A	DIRECT ACTING ANTIVIRALS	39 587	43 666	48 150	53 194	59 797	11.3	973	29 293	22 309	7 222	763 176
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	33 914	37 006	40 201	43 852	47 025	8.9	786	23 444	16 512	6 283	48 364
J05AB01	aciclovir	12 720	13 191	13 449	13 519	14 000	2.6	525	7 387	4 696	1 392	5 800
J05AB06	ganciclovir	<5	<5	<5	<5	<5	-	0	<5	<5	<5	19
J05AB09	famciclovir	<5	<5	<5	<5	6	0.0	0	<5	<5	0	105
J05AB11	valaciclovir	21 583	24 259	27 263	30 907	33 684	6.3	251	16 633	11 875	4 925	33 176
J05AB14	valganciclovir	379	371	377	439	409	0.1	25	102	219	63	9 264
J05AD	Phosphonic acid derivatives	<5	<5	0	0	0	0.0	0	0	0	0	0
J05AD01	foscarnet	<5	<5	0	0	0	0.0	0	0	0	0	0
J05AE	Protease inhibitors	1 339	1 064	772	508	349	0.1	<5	166	172	10	14 870
J05AE01	saquinavir	5	<5	<5	<5	0	0.0	0	0	0	0	0
J05AE03	ritonavir	1 004	811	605	399	269	0.1	<5	132	128	8	959
J05AE08	atazanavir	1 121	850	573	353	228	0.0	<5	103	120	<5	8 992
J05AE10	darunavir	228	218	200	148	124	0.0	0	65	53	6	4 919
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	663	778	941	1 095	1 300	0.2	24	585	639	52	18 820
J05AF01	zidovudine	21	15	14	19	15	0.0	6	<5	7	0	61
J05AF02	didanosine	11	5	0	0	0	0.0	0	0	0	0	0
J05AF05	lamivudine	89	94	84	75	103	0.0	16	23	57	7	785
J05AF06	abacavir	58	67	67	58	52	0.0	15	11	23	<5	1 439
J05AF07	tenofovir disoproxil	355	421	514	557	767	0.1	0	411	333	23	3 238
J05AF08	adefovir dipivoxil	10	9	6	5	<5	-	0	<5	<5	0	128

ATC group J

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
J05AF09	emtricitabine	7	6	6	<5	<5	-	0	<5	<5	0	42
J05AF10	entecavir	210	271	343	410	410	0.1	<5	154	237	17	8 064
J05AF11	telbivudine	<5	<5	<5	0	0	0.0	0	0	0	0	0
J05AF13	tenofovir alafenamide	0	0	0	121	130	0.0	0	59	63	8	5 061
J05AG	Non-nucleoside reverse transcriptase inhibitors	346	307	246	197	230	0.0	<5	73	141	14	5 320
J05AG01	nevirapine	158	147	126	99	89	0.0	0	27	55	7	2 047
J05AG03	efavirenz	147	119	76	46	38	0.0	<5	12	19	5	947
J05AG04	etravirine	31	29	28	24	18	0.0	0	7	11	0	778
J05AG05	rilpivirine	15	14	19	31	85	0.0	0	27	56	<5	1 548
J05AH	Neuraminidase inhibitors	1 098	1 528	2 153	1 923	3 571	0.7	156	1 369	1 332	714	870
J05AH01	zanamivir	18	52	25	0	0	0.0	0	0	0	0	0
J05AH02	oseltamivir	1 080	1 477	2 129	1 923	3 571	0.7	156	1 369	1 332	714	870
J05AP	Antivirals for treatment of HCV infections	799	1 037	1 175	1 955	3 189	0.6	<5	1 437	1 707	42	255 185
J05AP01	ribavirin	696	561	754	380	88	0.0	0	17	67	<5	863
J05AP02	telaprevir	25	0	0	0	0	0.0	0	0	0	0	0
J05AP03	boceprevir	61	<5	0	0	0	0.0	0	0	0	0	0
J05AP05	simeprevir	94	69	5	<5	0	0.0	0	0	0	0	0
J05AP07	daclatasvir	32	129	235	47	0	0.0	0	0	0	0	0
J05AP08	sofosbuvir	450	360	384	101	<5	-	0	0	<5	0	1 109
J05AP09	dasabuvir	0	12	299	105	54	0.0	0	36	18	0	210
J05AP51	sofosbuvir and ledipasvir	0	534	312	29	98	0.0	<5	34	58	<5	7 216
J05AP53	ombitasvir, paritaprevir and ritonavir	0	13	312	107	55	0.0	0	36	19	0	2 418
J05AP54	elbasvir and grazoprevir	0	0	0	1 152	990	0.2	0	424	554	12	57 310
J05AP55	sofosbuvir and velpatasvir	0	0	51	504	1 988	0.4	0	930	1 036	22	172 910
J05AP56	sofosbuvir, velpatasvir and voxilaprevir	0	0	0	<5	42	0.0	0	11	30	<5	7 624
J05AP57	glecaprevir and pibrentasvir	0	0	0	<5	30	0.0	0	6	20	<5	5 525
J05AR	Antivirals for treatment of HIV infections, combinations	3 369	3 638	4 082	4 821	5 322	1.0	17	2 698	2 451	156	381 539
J05AR01	zidovudine and lamivudine	181	130	104	64	46	0.0	0	12	31	<5	1 289
J05AR02	lamivudine and abacavir	424	307	195	131	262	0.1	<5	94	151	13	2 343
J05AR03	tenofovir disoproxil and emtricitabine	1 589	1 536	1 454	1 627	2 130	0.4	<5	1 438	667	21	24 693
J05AR04	zidovudine, lamivudine and abacavir	12	11	7	5	<5	-	0	<5	<5	<5	173
J05AR06	emtricitabine, tenofovir disoproxil and efavirenz	789	732	649	467	317	0.1	0	140	165	12	20 251

ATC group J

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
J05AR08	emtricitabine, tenofovir disoproxil and rilpivirine	514	576	600	324	157	0.0	0	77	76	<5	12 862
J05AR09	emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat	135	265	259	104	52	0.0	0	25	26	<5	5 127
J05AR10	lopinavir and ritonavir	298	212	145	89	62	0.0	6	21	33	<5	1 933
J05AR13	lamivudine, abacavir and dolutegravir	91	610	968	1 200	1 230	0.2	<5	469	709	49	123 283
J05AR14	darunavir and cobicistat	0	17	48	83	383	0.1	0	175	199	9	8 926
J05AR15	atazanavir and cobicistat	0	<5	6	7	29	0.0	0	10	19	0	595
J05AR17	emtricitabine and tenofovir alafenamide	0	0	95	329	338	0.1	0	118	198	22	19 355
J05AR18	emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat	0	0	482	891	945	0.2	<5	397	510	37	108 687
J05AR19	emtricitabine, tenofovir alafenamide and rilpivirine	0	0	155	548	577	0.1	0	235	320	22	50 966
J05AR22	emtricitabine, tenofovir alafenamide, darunavir and cobicistat	0	0	0	0	14	0.0	0	<5	10	<5	1 056
J05AX	Other antivirals	601	743	836	839	1 056	0.2	11	566	447	32	38 208
J05AX05	inosine pranobex	40	25	18	13	9	0.0	0	7	<5	0	98
J05AX08	raltegravir	470	580	638	583	643	0.1	9	415	207	12	16 638
J05AX09	maraviroc	8	8	7	6	7	0.0	0	<5	5	0	586
J05AX12	dolutegravir	105	143	194	246	413	0.1	<5	151	239	20	20 887

2.12 ATC group L – Antineoplastic and immunomodulating agents

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	95 704	100 442	105 983	112 500	116 797	22.0	1 602	26 431	53 640	35 124	4 277 921
L02	ENDOCRINE THERAPY	26 977	27 821	28 869	31 639	32 537	6.1	186	5 899	10 888	15 564	412 703
L02A	HORMONES AND RELATED AGENTS	10 472	10 398	10 452	10 640	10 832	2.0	182	1 720	1 904	7 026	106 048
L02AA	Estrogens	0	<5	<5	0	0	0.0	0	0	0	0	0
L02AA02	polyestradiol phosphate	0	<5	<5	0	0	0.0	0	0	0	0	0
L02AB	Progestogens	142	138	138	130	162	0.0	0	7	56	99	397
L02AB01	megestrol	142	138	138	130	162	0.0	0	7	56	99	397
L02AE	Gonadotropin releasing hormone analogues	10 335	10 260	10 315	10 513	10 671	2.0	182	1 713	1 849	6 927	105 651
L02AE01	buserelin	724	495	387	335	252	0.1	0	248	<5	0	361
L02AE02	leuprorelin	3 477	3 139	2 786	2 467	2 236	0.4	182	491	251	1 312	22 301
L02AE03	goserelin	6 218	6 599	7 001	7 312	7 689	1.5	0	456	1 586	5 647	82 650
L02AE04	triptorelin	23	131	241	479	573	0.1	0	560	13	0	339
L02AE05	histrelin	6	0	0	0	0	0.0	0	0	0	0	0
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS	20 708	21 821	22 834	25 548	26 485	5.0	<5	4 590	10 066	11 825	306 654
L02BA	Anti-estrogens	4 417	4 609	4 958	5 439	5 544	1.0	<5	849	3 634	1 059	25 824
L02BA01	tamoxifen	4 181	4 338	4 612	4 963	5 062	1.0	<5	835	3 390	835	4 798
L02BA03	fulvestrant	263	292	376	522	521	0.1	0	14	255	252	21 026
L02BB	Anti-androgens	7 078	7 081	6 985	7 007	7 020	1.3	0	5	1 232	5 783	174 367
L02BB01	flutamide	136	108	85	82	64	0.0	0	<5	<5	60	492
L02BB03	bicalutamide	6 480	6 313	6 116	6 041	5 945	1.1	0	<5	1 026	4 915	20 970
L02BB04	enzalutamide	517	826	938	1 093	1 188	0.2	0	0	240	948	152 905
L02BG	Aromatase inhibitors	8 902	9 813	10 626	12 995	13 880	2.6	<5	3 793	5 509	4 575	38 813
L02BG03	anastrozole	1 280	1 028	843	757	652	0.1	0	25	339	288	2 600
L02BG04	letrozole	6 999	8 128	9 079	11 537	12 524	2.4	<5	3 749	4 814	3 958	32 050
L02BG06	exemestane	910	983	1 015	974	1 041	0.2	0	30	553	458	4 163
L02BX	Other hormone antagonists and related agents	1 380	1 415	1 401	1 273	1 180	0.2	0	0	241	939	67 651
L02BX02	degarelix	642	806	872	837	786	0.2	0	0	180	606	8 653
L02BX03	abiraterone	804	660	581	473	430	0.1	0	0	76	354	58 998
L03	IMMUNOSTIMULANTS	6 485	6 306	6 819	6 431	6 432	1.2	54	1 209	3 807	1 362	139 986
L03A	IMMUNOSTIMULANTS	6 485	6 306	6 819	6 431	6 432	1.2	54	1 209	3 807	1 362	139 986
L03AA	Colony stimulating factors	3 313	4 159	4 909	4 775	4 932	0.9	52	710	2 901	1 269	53 134
L03AA02	filgrastim	611	593	583	588	594	0.1	46	121	313	114	6 171
L03AA13	pegfilgrastim	2 734	3 138	3 605	3 947	1 811	0.3	<5	240	1 089	481	19 811
L03AA14	lipegfilgrastim	109	676	956	370	3 086	0.6	6	428	1 841	811	27 152

ATC group L

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
L03AB	Interferons	2 150	1 375	1 210	952	763	0.1	<5	216	474	71	51 267
L03AB01	interferon alfa natural	8	8	0	0	0	0.0	0	0	0	0	0
L03AB03	interferon gamma	11	10	13	10	9	0.0	0	9	0	0	1 796
L03AB04	interferon alfa-2a	19	19	19	21	0	0.0	0	0	0	0	0
L03AB05	interferon alfa-2b	47	34	36	40	27	0.0	0	<5	12	12	703
L03AB07	interferon beta-1a	872	592	461	372	323	0.1	<5	75	230	16	26 310
L03AB08	interferon beta-1b	489	321	211	134	95	0.0	0	25	66	<5	5 871
L03AB10	peginterferon alfa-2b	171	71	51	50	40	0.0	0	9	26	5	1 369
L03AB11	peginterferon alfa-2a	550	319	315	214	184	0.0	0	52	99	33	8 338
L03AB13	peginterferon beta-1a	<5	11	149	135	100	0.0	0	51	48	<5	6 881
L03AX	Other immunostimulants	1 058	789	723	722	761	0.1	0	289	449	23	35 585
L03AX03	BCG vaccine	13	14	13	5	8	0.0	0	0	<5	5	64
L03AX13	glatiramer acetate	1 045	775	710	717	753	0.1	0	289	446	18	35 521
L04	IMMUNOSUPPRESSANTS	57 355	61 188	64 946	68 190	71 244	13.4	1 226	18 800	36 434	14 784	2 901 871
L04A	IMMUNOSUPPRESSANTS	57 355	61 188	64 946	68 190	71 244	13.4	1 226	18 800	36 434	14 784	2 901 871
L04AA	Selective immunosuppressants	8 528	9 551	10 333	10 851	11 856	2.2	143	2 982	6 743	1 988	650 746
L04AA06	mycophenolic acid	4 425	4 668	4 925	5 164	5 375	1.0	110	1 181	3 032	1 052	46 925
L04AA10	sirolimus	215	242	272	295	297	0.1	25	34	179	59	7 824
L04AA13	leflunomide	2 006	2 142	2 225	2 256	2 238	0.4	0	218	1 401	619	12 912
L04AA18	everolimus	474	484	487	481	508	0.1	13	85	278	132	38 669
L04AA23	natalizumab	0	0	0	<5	<5	-	0	0	<5	0	17
L04AA24	abatacept	144	222	258	283	268	0.1	0	42	159	67	19 340
L04AA25	eculizumab	11	17	18	18	18	0.0	0	9	7	<5	68 700
L04AA27	fingolimod	1 110	1 238	1 329	1 411	1 380	0.3	<5	672	699	8	254 382
L04AA28	belatacept	0	0	<5	0	<5	-	0	<5	0	0	19
L04AA29	tofacitinib	0	0	0	87	835	0.2	0	166	494	175	16 931
L04AA31	teriflunomide	638	1 069	1 362	1 427	1 465	0.3	<5	602	833	29	121 182
L04AA32	apremilast	0	9	35	27	15	0.0	0	5	10	0	772
L04AA33	vedolizumab	<5	<5	0	0	0	0.0	0	0	0	0	0
L04AA37	baricitinib	0	0	0	28	56	0.0	0	15	30	11	2 562
L04AA40	cladribine	0	0	0	0	182	0.0	0	109	73	0	60 510
L04AB	Tumor necrosis factor alpha (TNF-) inhibitors	15 154	15 163	15 647	16 505	16 764	3.2	276	5 874	8 681	1 933	1 151 897
L04AB01	etanercept	5 968	5 551	5 737	7 350	8 196	1.5	159	2 592	4 337	1 108	300 676
L04AB02	infliximab	0	<5	0	<5	<5	-	0	0	<5	<5	46
L04AB04	adalimumab	5 075	4 699	4 448	4 376	4 430	0.8	120	1 757	2 141	412	445 418
L04AB05	certolizumab pegol	3 024	3 506	4 262	3 646	2 990	0.6	0	1 140	1 542	308	237 619

ATC group L

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
L04AB06	golimumab	2 086	2 040	1 848	1 684	1 514	0.3	<5	561	822	128	168 137
L04AC	Interleukin inhibitors	820	1 408	1 848	2 673	3 062	0.6	21	985	1 731	325	286 850
L04AC01	daclizumab	0	0	0	14	5	0.0	0	<5	<5	0	245
L04AC03	anakinra	148	170	189	197	208	0.0	<5	94	83	28	14 342
L04AC05	ustekinumab	555	764	830	814	805	0.2	5	283	461	56	93 276
L04AC07	tocilizumab	112	455	521	608	618	0.1	<5	150	309	157	43 030
L04AC08	canakinumab	11	13	23	24	37	0.0	12	17	7	<5	42 565
L04AC10	secukinumab	0	22	371	1 102	1 430	0.3	0	448	895	87	92 926
L04AC12	brodalumab	0	0	0	0	15	0.0	0	7	6	<5	466
L04AD	Calcineurin inhibitors	5 733	5 979	6 203	6 274	6 449	1.2	194	1 584	3 514	1 157	140 186
L04AD01	ciclosporin	3 156	3 156	3 130	2 954	2 893	0.5	81	660	1 513	639	42 238
L04AD02	tacrolimus	2 644	2 889	3 132	3 383	3 628	0.7	117	947	2 044	520	97 949
L04AX	Other immunosuppressants	39 190	41 473	43 579	45 478	47 018	8.9	911	10 936	23 589	11 582	672 192
L04AX01	azathioprine	7 650	7 896	8 280	8 280	8 214	1.6	220	3 840	3 277	877	7 566
L04AX02	thalidomide	246	238	200	90	63	0.0	<5	5	24	30	2 099
L04AX03	methotrexate	30 026	31 709	33 357	35 139	36 511	6.9	695	6 596	19 237	9 983	107 478
L04AX04	lenalidomide	308	434	612	810	987	0.2	0	11	440	536	314 566
L04AX05	pirfenidone	58	65	69	78	98	0.0	0	<5	35	62	19 277
L04AX06	pomalidomide	74	99	130	178	191	0.0	0	<5	74	115	89 752
L04AX07	dimethyl fumarate	1 054	1 273	1 235	1 160	1 213	0.2	0	565	630	18	131 454

2.13 ATC group M – Musculo-skeletal system

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
M	MUSCULO-SKELETAL SYSTEM	928 438	942 110	946 467	963 353	954 846	179.8	15 248	318 251	441 641	179 706	495 981
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	817 921	824 452	823 714	834 679	819 425	154.3	13 546	305 114	392 543	108 222	258 480
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	817 896	824 431	823 689	834 663	819 412	154.3	13 546	305 112	392 536	108 218	256 790
M01AB	Acetic acid derivatives and related substances	391 876	376 889	349 105	341 369	324 883	61.2	4 718	137 343	151 836	30 986	44 743
M01AB01	indometacin	1 232	1 179	1 220	1 282	1 302	0.3	15	519	630	138	1 452
M01AB02	sulindac	0	<5	5	5	<5	-	0	0	<5	<5	8
M01AB05	diclofenac	372 039	357 614	330 952	323 120	307 370	57.9	4 690	133 353	142 352	26 975	35 766
M01AB15	ketorolac	27	20	18	25	48	0.0	0	15	23	10	15
M01AB16	aceclofenac	0	0	<5	<5	<5	-	0	0	<5	0	6
M01AB55	diclofenac, combinations	22 213	21 482	19 774	19 896	18 773	3.5	16	4 322	10 256	4 179	7 496
M01AC	Oxicams	48 308	40 897	35 293	31 649	27 443	5.2	91	7 816	15 290	4 246	8 805
M01AC01	piroxicam	36 954	32 479	28 375	25 189	21 552	4.1	84	6 626	12 066	2 776	7 120
M01AC06	meloxicam	11 551	8 740	7 051	6 577	5 991	1.1	7	1 230	3 279	1 475	1 685
M01AE	Propionic acid derivatives	373 687	398 840	429 125	448 361	445 727	83.9	8 883	164 723	215 195	56 926	136 087
M01AE01	ibuprofen	224 042	222 341	222 755	230 829	221 288	41.7	7 447	93 013	100 027	20 801	36 978
M01AE02	naproxen	86 217	95 355	105 672	99 739	94 126	17.7	1 343	37 883	42 219	12 681	22 311
M01AE03	ketoprofen	4 975	4 492	4 252	3 766	3 559	0.7	11	788	1 967	793	2 106
M01AE14	dexibuprofen	539	200	30	24	12	0.0	0	<5	8	<5	21
M01AE17	dexketoprofen	11	9	9	17	24	0.0	0	10	11	<5	5
M01AE52	naproxen and esomeprazole	77 488	99 701	123 511	142 741	154 154	29.0	183	42 805	85 662	25 504	74 666
M01AG	Fenamates	366	417	454	494	484	0.1	<5	292	173	17	393
M01AG02	tofenamic acid	366	417	454	494	484	0.1	<5	292	173	17	393
M01AH	Coxibs	92 056	97 949	96 791	101 372	104 773	19.7	120	30 946	56 408	17 299	50 793
M01AH01	celecoxib	15 175	14 873	14 296	14 719	14 942	2.8	18	3 930	7 797	3 197	14 512
M01AH04	parecoxib	<5	<5	<5	<5	<5	-	0	<5	0	0	1
M01AH05	etoricoxib	77 854	84 192	83 452	87 661	90 827	17.1	102	27 297	49 159	14 269	36 279
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	32 661	32 466	31 596	30 244	28 000	5.3	<5	1 380	14 134	12 484	15 969
M01AX01	nabumetone	3 177	2 886	2 427	2 175	1 935	0.4	<5	325	1 048	561	1 051
M01AX05	glucosamine	28 822	28 918	28 405	27 221	25 322	4.8	<5	1 022	12 751	11 548	13 105
M01C	SPECIFIC ANTIRHEUMATIC AGENTS	77	66	64	49	35	0.0	0	<5	20	12	1 690
M01CB	Gold preparations	61	61	59	42	29	0.0	0	<5	16	12	1 652
M01CB01	sodium aurothiomalate	17	19	24	13	11	0.0	0	0	<5	8	63
M01CB03	auranofin	44	42	35	29	18	0.0	0	<5	13	<5	1 588

ATC group M

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
M01CC	Penicillamine and similar agents	9	5	5	7	6	0.0	0	<5	<5	0	38
M01CC01	penicillamine	9	5	5	7	6	0.0	0	<5	<5	0	38
M01CX	Other specific antirheumatic agents	7	0	0	0	0	0.0	0	0	0	0	0
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	64 758	72 651	73 834	77 616	80 805	15.2	1 967	21 743	34 020	23 075	17 224
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	64 751	72 643	73 830	77 611	80 800	15.2	1 967	21 742	34 017	23 074	17 223
M02AA	Antiinflammatory preparations, non-steroids for topical use	64 683	72 631	73 826	77 607	80 797	15.2	1 966	21 742	34 017	23 072	17 222
M02AA10	ketoprofen	51 400	50 447	48 193	46 996	43 249	8.1	1 085	12 431	18 616	11 117	5 695
M02AA13	ibuprofen	5 790	4 995	4 420	3 930	2 689	0.5	168	797	925	799	602
M02AA15	diclofenac	8 030	18 015	22 059	27 659	35 931	6.8	718	8 739	14 878	11 596	10 924
M02AB	Capsaicin and similar agents	<5	<5	<5	0	0	0.0	0	0	0	0	0
M02AB01	capsaicin	<5	<5	<5	0	0	0.0	0	0	0	0	0
M02AC	Preparations with salicylic acid derivatives	73	0	0	0	0	0.0	0	0	0	0	0
M02AX	Other topical products for joint and muscular pain	5	8	<5	5	<5	-	<5	0	0	<5	1
M02AX10	various	5	8	<5	5	<5	-	<5	0	0	<5	1
M03	MUSCLE RELAXANTS	6 869	7 501	8 272	8 991	10 310	1.9	154	3 504	5 341	1 311	63 378
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	5 779	5 749	5 868	5 883	6 164	1.2	151	1 362	3 517	1 134	10 116
M03BA	Carbamic acid esters	635	588	495	421	401	0.1	0	46	307	48	1 353
M03BA02	carisoprodol	635	588	495	421	401	0.1	0	46	307	48	1 353
M03BB	Oxazol, thiazine, and triazine derivatives	20	21	41	44	57	0.0	0	22	24	11	97
M03BB03	chlorzoxazone	20	21	41	44	57	0.0	0	22	24	11	97
M03BX	Other centrally acting agents	5 146	5 159	5 347	5 430	5 716	1.1	151	1 294	3 196	1 075	8 666
M03BX01	baclofen	5 080	5 075	5 269	5 357	5 637	1.1	151	1 270	3 149	1 067	8 103
M03BX02	tizanidine	93	107	105	103	108	0.0	0	31	66	11	563
M03C	MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS	0	0	0	<5	0	0.0	0	0	0	0	0
M03CA	Dantrolene and derivatives	0	0	0	<5	0	0.0	0	0	0	0	0
M03CA01	dantrolene	0	0	0	<5	0	0.0	0	0	0	0	0
M04	ANTIGOUT PREPARATIONS	50 836	53 499	56 374	59 343	61 965	11.7	24	3 974	25 508	32 459	53 326
M04A	ANTIGOUT PREPARATIONS	50 836	53 499	56 374	59 343	61 965	11.7	24	3 974	25 508	32 459	53 326
M04AA	Preparations inhibiting uric acid production	46 073	48 333	50 525	53 155	55 688	10.5	8	3 224	22 849	29 607	39 182
M04AA01	allopurinol	45 944	48 141	50 261	52 795	55 177	10.4	8	3 169	22 634	29 366	20 444

ATC group M

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15–44	45–69	≥70							
M04AA03 febuxostat	148	218	300	438	648	0.1	0	75	274	299	18 738
M04AB Preparations increasing uric acid excretion	1 942	1 924	1 878	1 788	1 752	0.3	0	91	691	970	2 512
M04AB01 probenecid	1 942	1 924	1 878	1 788	1 748	0.3	0	89	689	970	2 506
M04AB05 lesinurad	0	0	0	0	<5	-	0	<5	<5	0	6
M04AC Preparations with no effect on uric acid metabolism	6 207	7 054	8 293	9 200	9 575	1.8	16	1 123	4 217	4 219	11 632
M04AC01 colchicine	6 207	7 054	8 293	9 200	9 575	1.8	16	1 123	4 217	4 219	11 632
M05 DRUGS FOR TREATMENT OF BONE DISEASES	61 688	62 023	63 305	64 868	66 175	12.5	<5	678	24 504	40 992	87 429
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	61 688	62 023	63 305	64 868	66 175	12.5	<5	678	24 504	40 992	87 429
M05BA Bisphosphonates	57 770	57 321	57 490	57 746	57 407	10.8	<5	626	23 103	33 677	48 590
M05BA02 clodronic acid	13	10	7	<5	0	0.0	0	0	0	0	0
M05BA03 pamidronic acid	16	17	9	5	5	0.0	0	0	<5	<5	18
M05BA04 alendronic acid	53 144	52 364	52 152	51 864	50 714	9.6	0	476	20 022	30 216	25 399
M05BA06 ibandronic acid	658	659	618	597	556	0.1	0	6	230	320	1 680
M05BA07 risedronic acid	481	403	327	309	280	0.1	0	<5	99	178	722
M05BA08 zoledronic acid	3 965	4 345	4 921	5 613	6 475	1.2	<5	154	3 054	3 266	20 772
M05BB Bisphosphonates, combinations	<5	0	0	0	0	0.0	0	0	0	0	0
M05BB01 etidronic acid and calcium, sequential	<5	0	0	0	0	0.0	0	0	0	0	0
M05BX Other drugs affecting bone structure and mineralization	4 412	5 198	6 410	7 906	9 608	1.8	0	55	1 582	7 971	38 839
M05BX04 denosumab	4 412	5 198	6 410	7 906	9 608	1.8	0	55	1 582	7 971	38 839
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	40	60	166	295	120	0.0	<5	5	95	19	16 137
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	40	60	166	295	120	0.0	<5	5	95	19	16 137
M09AB Enzymes	40	58	164	292	117	0.0	0	<5	94	19	2 045
M09AB02 collagenase clostridium histolyticum	40	58	164	292	117	0.0	0	<5	94	19	2 045
M09AX Other drugs for disorders of the musculo-skeletal system	0	<5	<5	<5	<5	-	<5	<5	<5	0	14 091
M09AX03 ataluren	0	<5	<5	<5	<5	-	<5	<5	<5	0	14 091

2.14 ATC group N – Nervous system

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
N	NERVOUS SYSTEM	1 353 896	1 380 464	1 411 698	1 450 416	1 473 116	277.3	33 128	465 180	625 750	349 058	3 168 219
N02	ANALGESICS	818 063	847 882	876 882	913 160	935 571	176.1	8 653	285 423	415 653	225 842	819 563
N02A	OPIOIDS	538 389	550 473	559 406	563 551	560 703	105.6	1 699	178 795	249 739	130 470	468 891
N02AA	Natural opium alkaloids	37 640	42 022	48 789	57 193	62 111	11.7	147	10 789	26 896	24 279	108 877
N02AA01	morphine	7 145	7 572	7 951	8 200	8 068	1.5	95	836	3 457	3 680	20 418
N02AA03	hydromorphone	130	127	137	123	60	0.0	0	8	28	24	2 938
N02AA05	oxycodone	30 548	34 405	40 730	48 755	53 411	10.1	54	9 855	23 468	20 034	62 076
N02AA08	dihydrocodeine	45	35	42	37	34	0.0	0	<5	29	<5	250
N02AA51	morphine, combinations	0	0	0	<5	0	0.0	0	0	0	0	0
N02AA55	oxycodone and naloxone	5 037	5 713	6 521	7 246	7 726	1.5	<5	881	2 911	3 932	23 195
N02AB	Phenylpiperidine derivatives	12 610	12 732	12 920	12 405	11 975	2.3	10	1 748	4 961	5 256	53 696
N02AB01	ketobemidone	4 342	4 252	4 146	3 604	3 241	0.6	<5	915	1 685	640	2 950
N02AB02	pethidine	1 247	1 180	1 112	948	976	0.2	<5	251	558	166	4 193
N02AB03	fentanyl	7 490	7 753	8 058	8 180	8 036	1.5	8	641	2 870	4 517	46 553
N02AC	Diphenylpropylamine derivatives	7	12	0	0	0	0.0	0	0	0	0	0
N02AC04	dextropropoxyphene	7	12	0	0	0	0.0	0	0	0	0	0
N02AD	Benzomorphan derivatives	24	20	15	10	10	0.0	0	<5	7	<5	668
N02AD01	pentazocine	24	20	15	10	10	0.0	0	<5	7	<5	668
N02AE	Oripavine derivatives	16 731	17 814	18 354	18 403	17 999	3.4	7	1 381	4 701	11 910	52 134
N02AE01	buprenorphine	16 731	17 814	18 354	18 403	17 999	3.4	7	1 381	4 701	11 910	52 134
N02AG	Opioids in combination with antispasmodics	1 812	1 766	1 719	1 688	1 546	0.3	0	509	775	262	2 104
N02AG01	morphine and antispasmodics	134	<5	0	0	0	0.0	0	0	0	0	0
N02AG02	ketobemidone and antispasmodics	1 681	1 765	1 719	1 688	1 546	0.3	0	509	775	262	2 104
N02AJ	Opioids in combination with non-opioid analgesics	378 124	374 911	369 279	356 278	345 227	65.0	1 203	119 138	153 462	71 424	146 891
N02AJ06	codeine and paracetamol	373 346	367 454	361 371	351 291	339 932	64.0	1 186	117 354	151 170	70 222	144 559
N02AJ07	codeine and acetylsalicylic acid	20	23	20	18	21	0.0	0	<5	13	<5	44
N02AJ13	tramadol and paracetamol	6 826	10 499	10 761	6 698	6 878	1.3	17	2 365	2 924	1 572	2 289
N02AX	Other opioids	188 983	204 523	217 509	228 155	229 799	43.3	400	71 906	106 286	51 207	104 521
N02AX02	tramadol	188 470	203 294	215 712	225 070	226 103	42.6	400	71 128	104 373	50 202	87 297
N02AX06	tapentadol	851	2 006	2 822	4 613	5 304	1.0	0	1 191	2 692	1 421	17 224
N02B	OTHER ANALGESICS AND ANTIPIRETTICS	416 641	446 694	481 088	527 266	562 351	105.9	5 141	130 195	254 641	172 374	138 412
N02BA	Salicylic acid and derivatives	1 019	1 074	1 086	1 261	1 195	0.2	213	512	331	139	584
N02BA01	acetylsalicylic acid	1 017	1 071	1 082	1 257	1 191	0.2	213	512	328	138	537

ATC group N

ATC level	2014	2015	2016	2017	2018	2018	2018				2018	
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK	
	<15	15–44	45–69	≥70								
N02BA11	diflunisal	<5	<5	<5	<5	<5	-	0	0	<5	<5	47
N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	<5	<5	0	0	0	0.0	0	0	0	0	0
N02BB	Pyrazolones	1 031	1 144	1 318	1 550	1 551	0.3	11	776	540	224	492
N02BB02	metamizole sodium	41	41	49	65	59	0.0	0	6	27	26	107
N02BB51	phenazone, combinations excl. psycholeptics	990	1 103	1 269	1 485	1 492	0.3	11	770	513	198	385
N02BE	Anilides	414 896	444 981	479 273	525 156	560 287	105.5	4 924	129 244	253 956	172 163	126 930
N02BE01	paracetamol	414 754	444 764	479 030	524 901	559 985	105.4	4 915	129 063	253 880	172 127	126 832
N02BE51	paracetamol, combinations excl. psycholeptics	240	322	355	392	446	0.1	10	244	130	62	98
N02BG	Other analgesics and antipyretics	366	344	326	472	541	0.1	<5	130	360	48	10 406
N02BG07	flupirtine	<5	<5	0	0	0	0.0	0	0	0	0	0
N02BG09	methoxyflurane	0	0	0	0	<5	-	0	<5	0	0	2
N02BG10	cannabinoids	365	340	326	472	540	0.1	<5	129	360	48	10 405
N02C	ANTIMIGRAINE PREPARATIONS	101 231	105 206	107 882	115 514	119 333	22.5	2 546	57 282	53 642	5 863	212 260
N02CA	Ergot alkaloids	454	373	292	246	59	0.0	0	<5	35	21	104
N02CA52	ergotamine, combinations excl. psycholeptics	8	9	7	7	35	0.0	0	<5	19	14	82
N02CA72	ergotamine, combinations with psycholeptics	446	366	287	240	31	0.0	0	<5	19	10	22
N02CC	Selective serotonin (5HT1) agonists	97 102	101 029	103 715	111 321	114 869	21.6	2 468	56 144	50 862	5 395	201 168
N02CC01	sumatriptan	50 676	52 591	51 695	58 093	59 989	11.3	2 072	32 457	22 986	2 474	90 769
N02CC02	naratriptan	1 941	2 109	2 242	2 485	2 847	0.5	8	1 377	1 338	124	7 391
N02CC03	zolmitriptan	15 840	16 229	20 268	19 321	19 236	3.6	325	8 705	9 226	980	43 367
N02CC04	rizatriptan	26 829	27 936	30 355	31 217	32 744	6.2	288	16 475	14 610	1 371	31 488
N02CC05	almotriptan	3 056	2 889	2 916	2 934	3 022	0.6	5	1 371	1 508	138	6 245
N02CC06	eletriptan	11 871	12 332	12 796	13 275	13 650	2.6	38	5 837	7 142	633	21 612
N02CC07	frovatriptan	20	180	223	192	230	0.0	<5	149	76	<5	297
N02CX	Other antimigraine preparations	4 524	4 622	4 762	4 844	5 722	1.1	84	1 628	3 509	501	10 988
N02CX01	pizotifen	62	58	50	45	35	0.0	0	8	22	5	121
N02CX02	clonidine	4 463	4 567	4 714	4 802	5 308	1.0	82	1 423	3 322	481	3 671
N02CX07	erenumab	0	0	0	0	399	0.1	<5	204	177	16	7 196
N03	ANTIPILEPTICS	118 788	122 561	127 262	131 955	136 190	25.6	3 650	38 977	62 574	30 989	467 840
N03A	ANTIPILEPTICS	118 788	122 561	127 262	131 955	136 190	25.6	3 650	38 977	62 574	30 989	467 840
N03AA	Barbiturates and derivatives	2 246	2 175	2 087	2 006	1 901	0.4	52	176	933	740	4 451
N03AA02	phenobarbital	1 920	1 829	1 744	1 630	1 519	0.3	51	126	780	562	3 480

ATC group N

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
N03AA03	primidone	338	358	355	385	391	0.1	<5	51	155	184	971
N03AB	Hydantoin derivatives	1 541	1 436	1 281	1 118	1 022	0.2	19	112	516	375	2 223
N03AB02	phenytoin	1 541	1 436	1 281	1 118	1 022	0.2	19	112	516	375	2 223
N03AB05	fosphenytoin	<5	<5	0	0	0	0.0	0	0	0	0	0
N03AD	Succinimide derivatives	227	224	266	289	294	0.1	148	122	20	<5	3 366
N03AD01	ethosuximide	227	224	266	289	294	0.1	148	122	20	<5	3 366
N03AE	Benzodiazepine derivatives	10 909	9 856	8 702	7 198	6 416	1.2	136	1 387	3 254	1 639	3 619
N03AE01	clonazepam	10 909	9 856	8 702	7 198	6 416	1.2	136	1 387	3 254	1 639	3 619
N03AF	Carboxamide derivatives	16 205	15 671	15 310	14 894	14 432	2.7	730	3 563	7 082	3 057	42 961
N03AF01	carbamazepine	13 396	12 723	12 256	11 495	10 461	2.0	143	2 153	5 682	2 483	11 758
N03AF02	oxcarbazepine	2 518	2 635	2 703	2 968	3 387	0.6	579	1 054	1 220	534	12 030
N03AF03	rufinamide	98	96	94	90	83	0.0	19	49	14	<5	2 227
N03AF04	eslicarbazepine	332	383	461	590	783	0.2	9	406	286	82	16 946
N03AG	Fatty acid derivatives	15 285	15 211	15 249	15 197	15 072	2.8	1 463	5 634	6 247	1 728	51 048
N03AG01	valproic acid	15 200	15 137	15 167	15 118	15 014	2.8	1 443	5 622	6 226	1 723	50 340
N03AG03	aminobutyric acid	20	8	16	14	8	0.0	0	<5	5	0	11
N03AG04	vigabatrin	90	85	85	87	78	0.0	40	16	17	5	536
N03AG06	tiagabine	9	9	9	9	7	0.0	0	<5	<5	<5	161
N03AX	Other antiepileptics	85 807	91 243	97 526	104 042	109 602	20.6	2 198	32 332	49 865	25 207	360 173
N03AX03	sultiame	239	238	277	323	343	0.1	264	77	<5	0	3 090
N03AX09	lamotrigine	27 569	28 531	29 235	30 145	30 746	5.8	917	14 093	12 209	3 527	112 569
N03AX10	felbamate	17	22	18	19	21	0.0	<5	13	5	<5	428
N03AX11	topiramate	3 649	3 954	4 174	4 617	4 814	0.9	198	2 580	1 830	206	12 648
N03AX12	gabapentin	32 203	35 539	39 417	42 711	46 051	8.7	138	9 207	23 037	13 669	71 260
N03AX14	levetiracetam	7 934	8 529	9 244	9 761	10 306	1.9	895	3 356	3 614	2 441	49 032
N03AX15	zonisamide	633	638	639	623	611	0.1	53	320	187	51	8 892
N03AX16	pregabalin	20 230	20 712	21 852	23 571	24 468	4.6	18	5 317	12 329	6 804	77 522
N03AX17	stiripentol	25	27	30	33	34	0.0	17	17	0	0	2 602
N03AX18	lacosamide	500	555	625	703	770	0.1	53	370	271	76	11 194
N03AX21	retigabine	36	20	17	<5	<5	-	0	<5	0	0	13
N03AX22	perampanel	220	254	303	360	361	0.1	22	193	118	28	5 535
N03AX23	brivaracetam	0	0	89	201	289	0.1	10	168	92	19	5 387
N04	ANTI-PARKINSON DRUGS	20 072	20 745	21 511	22 269	23 072	4.3	37	1 690	9 299	12 046	156 713
N04A	ANTICHOLINERGIC AGENTS	2 348	2 252	2 119	2 071	1 990	0.4	20	413	1 235	322	1 495
N04AA	Tertiary amines	2 322	2 236	2 103	2 055	1 979	0.4	20	413	1 226	320	1 474
N04AA01	trihexyphenidyl	41	44	52	54	39	0.0	17	9	10	<5	253
N04AA02	biperiden	2 279	2 189	2 049	2 000	1 939	0.4	<5	404	1 215	317	1 220

ATC group N

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
N04AA04	procyclidine	<5	<5	<5	<5	<5	-	0	0	<5	0	1
N04AB	Ethers chemically close to antihistamines	32	17	17	17	11	0.0	0	0	9	<5	21
N04AB02	orphenadrine (chloride)	32	17	17	17	11	0.0	0	0	9	<5	21
N04B	DOPAMINERGIC AGENTS	17 785	18 546	19 443	20 262	21 150	4.0	18	1 280	8 090	11 762	155 218
N04BA	Dopa and dopa derivatives	9 033	9 331	9 663	10 093	10 586	2.0	15	132	2 938	7 501	99 361
N04BA02	levodopa and decarboxylase inhibitor	8 339	8 701	9 055	9 513	10 003	1.9	15	129	2 736	7 123	85 877
N04BA03	levodopa, decarboxylase inhibitor and COMT inhibitor	1 391	1 350	1 392	1 387	1 380	0.3	0	8	529	843	13 484
N04BB	Adamantane derivatives	158	166	191	207	178	0.0	<5	38	97	42	716
N04BB01	amantadine	158	166	191	207	178	0.0	<5	38	97	42	716
N04BC	Dopamine agonists	11 676	12 154	12 849	13 281	13 773	2.6	<5	1 147	6 467	6 157	38 557
N04BC01	bromocriptine	<5	<5	<5	<5	<5	-	0	0	0	<5	18
N04BC04	ropinirole	2 869	2 930	2 957	2 923	2 914	0.6	0	152	1 385	1 377	13 557
N04BC05	pramipexole	8 469	8 906	9 577	10 013	10 581	2.0	<5	987	4 994	4 598	15 216
N04BC06	cabergoline	109	88	91	80	61	0.0	0	5	27	29	108
N04BC07	apomorphine	26	30	45	62	60	0.0	0	0	29	31	3 557
N04BC09	rotigotine	560	533	537	552	521	0.1	0	32	218	271	6 102
N04BD	Monoamine oxidase B inhibitors	3 868	4 011	4 134	4 304	4 302	0.8	0	47	1 858	2 397	15 264
N04BD01	selegiline	2 257	2 318	2 400	2 439	2 465	0.5	0	26	1 078	1 361	4 273
N04BD02	rasagiline	1 648	1 739	1 778	1 887	1 807	0.3	0	21	777	1 009	9 890
N04BD03	safinamide	0	0	10	101	86	0.0	0	0	36	50	1 102
N04BX	Other dopaminergic agents	111	105	127	142	157	0.0	0	0	61	96	1 319
N04BX01	tolcapone	6	8	9	8	6	0.0	0	0	<5	<5	247
N04BX02	entacapone	105	98	118	134	151	0.0	0	0	57	94	1 072
N05	PSYCHOLEPTICS	630 363	631 424	638 090	645 060	647 068	121.8	14 320	158 342	273 027	201 379	684 161
N05A	ANTIPSYCHOTICS	109 198	113 430	118 840	124 611	129 459	24.4	1 097	48 737	56 801	22 824	320 172
N05AA	Phenothiazines with aliphatic side-chain	18 907	17 572	16 472	15 331	13 921	2.6	9	3 280	7 357	3 275	5 529
N05AA01	chlorpromazine	201	167	168	202	202	0.0	0	123	57	22	507
N05AA02	levomepromazine	18 724	17 418	16 313	15 135	13 727	2.6	9	3 160	7 304	3 254	5 022
N05AB	Phenothiazines with piperazine structure	11 104	10 514	9 382	9 108	8 690	1.6	13	1 979	3 636	3 062	7 617
N05AB02	fluphenazine	17	17	14	9	7	0.0	0	0	<5	<5	26
N05AB03	perphenazine	1 758	1 707	1 659	1 577	1 507	0.3	0	233	952	322	6 064
N05AB04	prochlorperazine	9 346	8 803	7 715	7 529	7 185	1.4	13	1 750	2 683	2 739	1 527
N05AB06	trifluoperazine	<5	<5	0	<5	0	0.0	0	0	0	0	0

ATC group N

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15–44	45–69	≥70							
N05AC Phenothiazines with piperidine structure	46	44	38	35	31	0.0	0	<5	16	14	94
N05AC01 periciazine	<5	<5	<5	<5	<5	-	0	0	<5	0	3
N05AC02 thioridazine	43	41	36	33	30	0.0	0	<5	15	14	92
N05AC04 pipotiazine	<5	<5	<5	<5	0	0.0	0	0	0	0	0
N05AD Butyrophenone derivatives	4 030	3 878	3 998	3 835	3 628	0.7	5	264	1 250	2 109	1 176
N05AD01 haloperidol	4 023	3 871	3 987	3 822	3 608	0.7	5	262	1 245	2 096	1 149
N05AD03 melperone	6	7	11	11	18	0.0	0	<5	<5	12	24
N05AD08 droperidol	<5	<5	<5	<5	5	0.0	0	0	<5	<5	4
N05AE Indole derivatives	870	963	1 013	1 006	1 091	0.2	<5	549	478	62	9 075
N05AE03 sertindole	100	110	96	79	72	0.0	0	23	45	<5	817
N05AE04 ziprasidone	766	677	639	586	550	0.1	<5	193	309	47	4 010
N05AE05 lurasidone	5	189	291	347	476	0.1	<5	337	127	11	4 247
N05AF Thioxanthene derivatives	21 600	20 893	20 308	19 329	17 745	3.3	12	5 696	8 810	3 227	13 889
N05AF01 flupentixol	4 185	3 902	3 744	3 486	3 171	0.6	0	757	1 546	868	2 701
N05AF03 chlorprothixene	15 115	14 811	14 499	13 822	12 619	2.4	12	4 530	6 063	2 014	8 308
N05AF05 zuclopenthixol	2 914	2 729	2 561	2 470	2 314	0.4	0	522	1 408	384	2 880
N05AG Diphenylbutylpiperidine derivatives	114	112	112	104	101	0.0	0	43	44	14	342
N05AG01 fluspirilene	0	<5	<5	<5	0	0.0	0	0	0	0	0
N05AG02 pimozide	114	111	109	101	97	0.0	0	43	41	13	309
N05AG03 penfluridol	0	0	<5	<5	<5	-	0	0	<5	<5	32
N05AH Diazepines, oxazepines, thiazepines and oxepines	50 380	56 873	64 650	72 723	80 292	15.1	145	35 545	34 747	9 855	151 437
N05AH01 loxapine	0	<5	0	0	0	0.0	0	0	0	0	0
N05AH02 clozapine	2 571	2 576	2 610	2 651	2 700	0.5	0	1 078	1 469	153	9 679
N05AH03 olanzapine	16 701	16 920	16 990	17 421	17 673	3.3	41	6 595	8 158	2 879	53 863
N05AH04 quetiapine	33 528	39 948	47 818	55 638	63 125	11.9	106	29 476	26 431	7 112	87 886
N05AH05 asenapine	50	28	29	29	<5	-	0	<5	0	0	9
N05AL Benzamides	600	657	608	629	641	0.1	0	290	324	27	4 139
N05AL01 sulpiride	0	0	0	<5	<5	-	0	0	<5	0	6
N05AL03 tiapride	<5	7	<5	<5	<5	-	0	<5	<5	0	21
N05AL05 amisulpride	597	650	604	624	637	0.1	0	288	322	27	4 113
N05AN Lithium	7 559	7 580	7 570	7 628	7 639	1.4	0	2 287	3 964	1 388	17 025
N05AN01 lithium	7 559	7 580	7 570	7 628	7 639	1.4	0	2 287	3 964	1 388	17 025
N05AX Other antipsychotics	14 019	14 345	14 612	14 943	14 999	2.8	960	6 610	5 322	2 107	109 849
N05AX07 prothipendyl	<5	<5	<5	<5	0	0.0	0	0	0	0	0
N05AX08 risperidone	8 329	8 264	8 305	8 141	8 040	1.5	821	2 751	2 727	1 741	26 125
N05AX12 aripiprazole	5 399	5 731	5 910	6 375	6 530	1.2	192	3 669	2 323	346	45 457

ATC group N

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
N05AX13	paliperidone	832	860	887	936	973	0.2	0	530	407	36	38 267
N05B	ANXIOLYTICS	267 746	262 535	258 101	252 789	247 153	46.5	2 520	58 022	109 820	76 791	107 313
N05BA	Benzodiazepine derivatives	241 318	236 275	233 577	229 065	223 638	42.1	2 201	49 046	100 499	71 892	95 724
N05BA01	diazepam	116 561	109 998	105 594	100 854	95 870	18.1	1 897	21 236	43 437	29 300	40 633
N05BA02	chlordiazepoxide	0	<5	<5	<5	7	0.0	0	<5	<5	<5	3
N05BA04	oxazepam	134 599	135 729	137 340	136 950	135 934	25.6	78	30 046	60 807	45 003	49 065
N05BA06	lorazepam	54	70	98	142	148	0.0	<5	51	77	19	445
N05BA08	bromazepam	6	7	7	<5	<5	-	0	0	<5	<5	11
N05BA09	clobazam	752	779	836	896	936	0.2	329	416	177	14	2 688
N05BA12	alprazolam	3 535	3 206	2 895	2 587	2 409	0.5	0	886	1 201	322	2 878
N05BB	Diphenylmethane derivatives	34 711	34 044	31 107	29 716	29 178	5.5	326	10 638	11 977	6 237	7 871
N05BB01	hydroxyzine	34 711	34 044	31 107	29 716	29 178	5.5	326	10 638	11 977	6 237	7 871
N05BE	Azapirodecanedione derivatives	2 230	2 273	2 248	2 119	2 053	0.4	0	758	903	392	3 717
N05BE01	buspirone	2 230	2 273	2 248	2 119	2 053	0.4	0	758	903	392	3 717
N05C	HYPNOTICS AND SEDATIVES	423 732	424 789	431 014	435 943	437 472	82.4	11 998	91 108	181 336	153 030	256 677
N05CA	Barbiturates, plain	<5	0	0	0	0	0.0	0	0	0	0	0
N05CA04	barbital	<5	0	0	0	0	0.0	0	0	0	0	0
N05CC	Aldehydes and derivatives	6	10	7	13	12	0.0	<5	6	<5	<5	73
N05CC01	chloral hydrate	6	10	7	13	12	0.0	<5	6	<5	<5	73
N05CD	Benzodiazepine derivatives	28 276	27 282	26 877	26 433	25 703	4.8	2 831	5 334	9 176	8 362	32 305
N05CD01	flurazepam	17	15	11	9	8	0.0	0	0	<5	6	25
N05CD02	nitrazepam	23 303	21 518	20 328	19 139	17 915	3.4	305	3 103	7 630	6 877	10 946
N05CD03	flunitrazepam	1 119	961	790	645	559	0.1	<5	103	277	178	1 468
N05CD05	triazolam	74	67	62	49	49	0.0	0	8	20	21	123
N05CD08	midazolam	4 255	5 220	6 217	7 125	7 702	1.5	2 745	2 291	1 327	1 339	19 743
N05CF	Benzodiazepine related drugs	358 302	354 753	355 844	350 093	345 210	65.0	43	52 358	154 033	138 776	137 547
N05CF01	zopiclone	304 071	298 583	296 755	290 210	283 705	53.4	34	38 955	125 133	119 583	111 807
N05CF02	zolpidem	65 751	67 382	70 628	70 841	72 357	13.6	10	15 833	33 650	22 864	25 740
N05CH	Melatonin receptor agonists	68 793	76 032	82 748	94 753	101 659	19.1	9 585	42 806	34 102	15 166	83 786
N05CH01	melatonin	68 793	76 032	82 748	94 753	101 659	19.1	9 585	42 806	34 102	15 166	83 786
N05CM	Other hypnotics and sedatives	2 150	2 145	2 122	1 961	1 948	0.4	<5	148	483	1 316	2 965
N05CM02	clomethiazole	1 939	1 971	1 945	1 835	1 824	0.3	0	115	429	1 280	2 826
N05CM05	scopolamine	110	61	65	41	25	0.0	0	<5	<5	22	42
N05CM06	propiomazine	100	108	105	77	97	0.0	0	32	52	13	96
N05CM09	Valerianae radix	5	5	9	9	<5	-	0	0	0	<5	0

ATC group N

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
N05CM11	bromides	0	0	0	0	<5	-	<5	0	0	0	1
N06	PSYCHOANALEPTICS	359 882	367 511	376 408	382 158	385 557	72.6	12 161	133 612	155 582	84 202	735 595
N06A	ANTIDEPRESSANTS	317 158	322 941	329 608	332 397	333 229	62.7	616	108 705	149 779	74 129	309 943
N06AA	Non-selective monoamine reuptake inhibitors	67 286	68 350	69 403	70 267	71 207	13.4	77	18 731	37 464	14 935	30 013
N06AA02	imipramine	16	16	16	13	10	0.0	0	<5	5	<5	34
N06AA04	clomipramine	2 488	2 342	2 216	2 122	1 953	0.4	<5	305	1 031	614	1 698
N06AA05	opipramol	9	7	8	7	8	0.0	0	<5	<5	<5	17
N06AA06	trimipramine	9 406	8 837	8 128	7 521	7 105	1.3	<5	1 205	3 334	2 564	5 157
N06AA07	lofepramine	6	6	5	5	6	0.0	0	<5	<5	<5	29
N06AA09	amitriptyline	51 933	53 891	55 869	57 811	59 416	11.2	69	16 691	32 024	10 632	20 845
N06AA10	nortriptyline	2 178	2 192	2 251	2 143	2 422	0.5	5	730	1 107	580	1 313
N06AA12	doxepin	2 016	1 846	1 641	1 454	1 133	0.2	0	77	362	694	921
N06AA21	maprotiline	<5	0	0	0	0	0.0	0	0	0	0	0
N06AB	Selective serotonin reuptake inhibitors	185 867	186 025	186 321	183 597	180 025	33.9	516	66 061	76 179	37 269	124 764
N06AB03	fluoxetine	11 117	12 142	12 232	12 055	11 817	2.2	125	7 000	3 908	784	16 197
N06AB04	citalopram	23 517	22 312	20 210	18 571	17 008	3.2	0	3 302	8 602	5 104	9 759
N06AB05	paroxetine	14 246	13 797	13 122	12 510	12 050	2.3	0	2 241	6 354	3 455	10 596
N06AB06	sertraline	30 840	30 095	32 444	34 076	35 157	6.6	377	15 677	13 106	5 997	33 977
N06AB08	fluvoxamine	543	554	542	505	488	0.1	<5	176	237	74	882
N06AB10	escitalopram	110 767	113 703	112 762	110 559	107 723	20.3	29	39 763	45 387	22 544	53 354
N06AF	Monoamine oxidase inhibitors, non-selective	89	88	89	93	97	0.0	0	24	47	26	1 427
N06AF01	isocarboxazid	0	<5	<5	<5	0	0.0	0	0	0	0	0
N06AF03	phenelzine	83	83	85	88	89	0.0	0	20	43	26	650
N06AF04	tranylcypromine	7	6	<5	8	9	0.0	0	<5	5	0	777
N06AG	Monoamine oxidase A inhibitors	707	721	668	634	569	0.1	0	143	269	157	1 349
N06AG02	moclobemide	707	721	668	634	569	0.1	0	143	269	157	1 349
N06AX	Other antidepressants	103 291	107 779	112 616	115 819	118 415	22.3	33	35 423	52 312	30 647	152 389
N06AX01	oxitriptan	280	203	95	90	78	0.0	<5	31	36	8	155
N06AX02	tryptophan	18	9	32	17	18	0.0	0	<5	12	<5	22
N06AX03	mianserin	26 388	25 419	24 219	23 176	22 033	4.2	5	4 526	10 317	7 185	10 954
N06AX05	trazodone	17	19	18	24	16	0.0	0	7	8	<5	43
N06AX06	nefazodone	30	31	28	26	25	0.0	0	<5	21	<5	390
N06AX11	mirtazapine	38 608	40 915	43 265	45 123	46 334	8.7	15	11 479	18 005	16 835	42 317
N06AX12	bupropion	11 691	12 123	12 100	11 958	11 934	2.3	<5	5 636	5 308	989	26 291
N06AX14	tianeptine	0	7	6	9	10	0.0	0	6	<5	0	156

ATC group N

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
N06AX16	venlafaxine	31 307	32 625	32 903	32 906	32 734	6.2	8	10 785	15 720	6 221	27 818
N06AX18	reboxetine	338	329	286	263	262	0.1	0	95	142	25	534
N06AX21	duloxetine	3 958	4 664	5 361	6 119	7 206	1.4	0	2 232	3 867	1 107	18 234
N06AX22	agomelatine	17	12	19	16	13	0.0	0	7	<5	<5	191
N06AX26	vortioxetine	25	1 381	5 041	7 126	8 703	1.6	<5	3 970	3 808	924	25 284
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	37 098	39 627	42 365	45 899	48 609	9.2	11 694	30 052	6 641	222	377 163
N06BA	Centrally acting sympathomimetics	36 710	39 231	41 988	45 520	48 281	9.1	11 692	29 896	6 525	168	369 845
N06BA01	amfetamine	419	378	315	348	327	0.1	<5	189	122	15	15 695
N06BA02	dexamfetamine	1 886	2 009	2 282	2 589	2 861	0.5	192	1 814	828	27	53 958
N06BA04	methylphenidate	32 335	34 062	35 618	37 698	38 784	7.3	9 986	23 926	4 780	92	184 114
N06BA07	modafinil	486	548	582	678	704	0.1	9	444	220	31	7 795
N06BA09	atomoxetine	3 635	3 630	3 669	3 707	3 621	0.7	1 253	2 082	284	<5	33 357
N06BA12	lisdexamfetamine	388	2 115	3 908	5 884	8 217	1.6	2 225	5 026	960	6	74 925
N06BC	Xanthine derivatives	311	321	304	300	269	0.1	<5	130	96	42	204
N06BC01	caffeine	311	321	304	300	269	0.1	<5	130	96	42	204
N06BX	Other psychostimulants and nootropics	89	93	92	98	78	0.0	<5	40	25	12	7 113
N06BX03	piracetam	73	72	75	81	64	0.0	0	28	24	12	293
N06BX13	idebenone	16	21	17	17	14	0.0	<5	12	<5	0	6 820
N06C	PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	0	0	<5	0	<5	-	0	0	<5	0	1
N06CA	Antidepressants in combination with psycholeptics	0	0	<5	0	<5	-	0	0	<5	0	1
N06CA02	melitracen and psycholeptics	0	0	<5	0	<5	-	0	0	<5	0	1
N06D	ANTI-DEMENTIA DRUGS	15 427	15 170	15 233	15 281	15 356	2.9	<5	10	1 614	13 731	48 488
N06DA	Anticholinesterases	12 805	12 597	12 572	12 630	12 729	2.4	0	5	1 394	11 330	38 657
N06DA02	donepezil	7 701	7 479	7 360	7 449	7 546	1.4	0	<5	834	6 711	19 589
N06DA03	rivastigmine	5 212	5 239	5 344	5 380	5 404	1.0	0	<5	617	4 783	18 006
N06DA04	galantamine	257	224	193	172	139	0.0	0	0	15	124	1 063
N06DX	Other anti-dementia drugs	3 729	3 646	3 821	3 818	3 685	0.7	<5	5	430	3 249	9 831
N06DX01	memantine	3 729	3 646	3 821	3 818	3 685	0.7	<5	5	430	3 249	9 831
N07	OTHER NERVOUS SYSTEM DRUGS	44 934	41 860	40 271	38 745	37 137	7.0	37	10 823	22 561	3 716	286 130
N07A	PARASYMPATHOMIMETICS	784	781	837	874	928	0.2	8	166	371	383	4 933
N07AA	Anticholinesterases	619	621	692	737	770	0.1	8	155	291	316	3 163
N07AA01	neostigmine	0	0	0	<5	0	0.0	0	0	0	0	0

ATC group N

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
N07AA02 pyridostigmine	617	620	688	733	767	0.1	8	153	291	315	3 147
N07AA30 ambenonium	<5	<5	<5	<5	<5	-	0	<5	<5	<5	17
N07AA51 neostigmine, combinations	<5	0	<5	<5	0	0.0	0	0	0	0	0
N07AB Choline esters	32	21	9	0	0	0.0	0	0	0	0	0
N07AB01 carbachol	32	21	9	0	0	0.0	0	0	0	0	0
N07AX Other parasympathomimetics	134	140	139	137	158	0.0	0	11	80	67	1 769
N07AX01 pilocarpine	134	140	135	130	152	0.0	0	11	76	65	1 033
N07AX03 cevimeline	0	0	<5	7	6	0.0	0	0	<5	<5	736
N07B DRUGS USED IN ADDICTIVE DISORDERS	41 853	38 602	36 830	35 133	33 381	6.3	13	10 198	20 466	2 704	215 774
N07BA Drugs used in nicotine dependence	17 794	17 104	16 961	16 000	14 701	2.8	<5	3 305	9 708	1 686	24 433
N07BA01 nicotine	931	993	1 191	1 168	1 284	0.2	<5	143	719	420	992
N07BA03 varenicline	16 911	16 175	15 833	14 902	13 506	2.5	0	3 175	9 048	1 283	23 441
N07BB Drugs used in alcohol dependence	16 397	13 682	12 143	11 498	11 158	2.1	10	3 537	6 675	936	12 995
N07BB01 disulfiram	4 233	4 225	4 247	4 146	4 003	0.8	0	1 251	2 415	337	2 619
N07BB03 acamprostate	469	465	472	435	384	0.1	0	120	237	27	725
N07BB04 naltrexone	10 488	8 189	6 840	6 483	6 407	1.2	10	2 057	3 807	533	8 965
N07BB05 nalmefene	1 615	1 162	921	695	583	0.1	0	192	344	47	687
N07BC Drugs used in opioid dependence	8 017	8 117	8 010	7 933	7 791	1.5	<5	3 431	4 271	88	178 346
N07BC01 buprenorphine	2 894	3 037	3 168	3 321	3 485	0.7	0	1 819	1 658	8	63 815
N07BC02 methadone	3 604	3 548	3 424	3 346	3 295	0.6	<5	1 037	2 179	78	85 937
N07BC05 levomethadone	<5	6	14	16	16	0.0	0	9	6	<5	1 421
N07BC51 buprenorphine, combinations	2 265	2 198	2 018	1 774	1 455	0.3	0	851	602	<5	27 172
N07C ANTIVERTIGO PREPARATIONS	682	708	732	719	704	0.1	<5	156	368	177	1 661
N07CA Antivertigo preparations	682	708	732	719	704	0.1	<5	156	368	177	1 661
N07CA01 betahistine	649	674	698	673	652	0.1	0	130	346	176	1 576
N07CA03 flunarizine	33	34	34	44	48	0.0	<5	25	19	<5	80
N07CA52 cinnarizine, combinations	0	0	0	<5	6	0.0	0	<5	<5	0	5
N07X OTHER NERVOUS SYSTEM DRUGS	2 076	2 153	2 210	2 300	2 388	0.5	14	323	1 559	492	63 762
N07XX Other nervous system drugs	2 076	2 153	2 210	2 300	2 388	0.5	14	323	1 559	492	63 762
N07XX02 riluzole	290	301	336	353	359	0.1	0	15	194	150	4 321
N07XX04 sodium oxybate	96	103	116	142	141	0.0	10	100	28	<5	12 639
N07XX05 amifampridine	7	11	14	8	13	0.0	<5	<5	7	<5	4 172
N07XX06 tetrabenazine	52	48	41	44	57	0.0	<5	11	25	18	725

ATC group N

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
N07XX07 fampridine	1 631	1 690	1 703	1 751	1 796	0.3	0	184	1 297	315	37 093
N07XX08 tafamidis	0	0	0	0	<5	-	0	0	0	<5	1 262
N07XX11 pitolisant	0	0	0	6	29	0.0	<5	20	6	<5	2 126
N07XX59 dextromethorphan, combinations	0	0	0	8	9	0.0	0	<5	8	0	1 422

2.15 ATC group P – Antiparasitic products, insecticides and repellents

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
P	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	97 581	94 700	93 310	93 329	94 332	17.8	4 509	41 622	35 657	12 544	30 006
P01	ANTIPROTOZOALS	92 914	89 211	87 278	86 800	87 630	16.5	2 865	37 875	34 643	12 247	24 757
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES	59 261	57 467	55 655	53 658	52 535	9.9	686	20 939	21 502	9 408	6 434
P01AB	Nitroimidazole derivatives	59 259	57 467	55 655	53 655	52 529	9.9	685	20 938	21 499	9 407	6 278
P01AB01	metronidazole	59 238	57 451	55 641	53 649	52 508	9.9	685	20 930	21 488	9 405	6 181
P01AB02	tinidazole	27	22	26	16	27	0.0	<5	14	11	<5	19
P01AB03	ornidazole	0	<5	<5	<5	0	0.0	0	0	0	0	0
P01AB06	nimorazole	<5	0	<5	<5	<5	-	0	0	<5	<5	77
P01AC	Dichloroacetamide derivatives	5	0	0	0	0	0.0	0	0	0	0	0
P01AC01	diloxanide	5	0	0	0	0	0.0	0	0	0	0	0
P01AX	Other agents against amoebiasis and other protozoal diseases	0	0	0	<5	9	0.0	<5	<5	<5	<5	156
P01AX05	mepacrine	0	0	0	<5	5	0.0	0	<5	<5	0	40
P01AX06	atovaquone	0	0	0	<5	<5	-	<5	0	<5	<5	88
P01AX11	nitazoxanide	0	0	0	0	<5	-	0	0	<5	0	27
P01B	ANTIMALARIALS	34 230	32 306	32 165	33 624	35 594	6.7	2 183	17 165	13 349	2 897	18 267
P01BA	Aminoquinolines	6 041	6 216	6 288	6 280	6 298	1.2	38	1 662	3 343	1 255	4 031
P01BA01	chloroquine	13	12	11	11	9	0.0	0	<5	5	<5	15
P01BA02	hydroxychloroquine	6 020	6 199	6 258	6 260	6 279	1.2	38	1 658	3 331	1 252	4 000
P01BA03	primaquine	9	11	22	10	10	0.0	0	<5	7	<5	16
P01BB	Biguanides	25 262	23 467	23 563	25 145	27 088	5.1	1 833	14 579	9 267	1 409	13 149
P01BB01	proguanil	<5	<5	0	<5	0	0.0	0	0	0	0	0
P01BB51	proguanil, combinations	25 260	23 465	23 563	25 144	27 088	5.1	1 833	14 579	9 267	1 409	13 149
P01BC	Methanolquinolines	3 086	2 769	2 436	2 323	2 336	0.4	319	989	786	242	1 072
P01BC01	quinine	350	368	331	286	253	0.1	0	14	89	150	268
P01BC02	mefloquine	2 737	2 401	2 105	2 037	2 083	0.4	319	975	697	92	803
P01BD	Diaminopyrimidines	0	<5	<5	<5	<5	-	0	<5	0	0	1
P01BD01	pyrimethamine	0	<5	<5	<5	<5	-	0	<5	0	0	1
P01BE	Artemisinin and derivatives, plain	0	<5	0	0	0	0.0	0	0	0	0	0
P01BE03	artesunate	0	<5	0	0	0	0.0	0	0	0	0	0
P01BF	Artemisinin and derivatives, combinations	5	<5	6	13	16	0.0	0	10	6	0	16
P01BF01	artemether and lumefantrine	5	<5	6	13	16	0.0	0	10	6	0	16

ATC group P

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
P01C	AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS	<5	<5	0	<5	6	0.0	0	<5	<5	<5	55
P01CX	Other agents against leishmaniasis and trypanosomiasis	<5	<5	0	<5	6	0.0	0	<5	<5	<5	55
P01CX01	pentamidine isethionate	<5	<5	0	<5	6	0.0	0	<5	<5	<5	55
P02	ANTHELMINTICS	2 775	2 960	3 066	3 231	3 438	0.7	1 289	1 550	467	132	2 531
P02B	ANTITREMATODALS	52	66	65	56	63	0.0	8	48	7	0	125
P02BA	Quinoline derivatives and related substances	52	66	65	56	63	0.0	8	48	7	0	125
P02BA01	praziquantel	52	66	65	56	63	0.0	8	48	7	0	125
P02C	ANTINEMATODAL AGENTS	2 713	2 894	2 991	3 167	3 370	0.6	1 281	1 499	459	131	2 396
P02CA	Benzimidazole derivatives	2 432	2 612	2 626	2 696	2 457	0.5	1 190	843	327	97	1 048
P02CA01	mebendazole	2 272	2 277	2 261	2 294	2 065	0.4	1 021	676	281	87	479
P02CA03	albendazole	172	345	376	415	405	0.1	174	171	48	12	569
P02CF	Avermectines	125	124	217	324	769	0.1	25	593	124	27	1 322
P02CF01	ivermectin	125	124	217	324	769	0.1	25	593	124	27	1 322
P02CX	Other antinematodals	176	186	174	177	167	0.0	74	72	13	8	27
P02CX01	pyrvinium	176	186	174	177	167	0.0	74	72	13	8	27
P02D	ANTICESTODALS	20	10	22	22	16	0.0	5	8	<5	<5	9
P02DA	Salicylic acid derivatives	20	10	22	22	16	0.0	5	8	<5	<5	9
P02DA01	niclosamide	20	10	22	22	16	0.0	5	8	<5	<5	9
P03	ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS	2 157	2 779	3 211	3 561	3 681	0.7	376	2 494	624	187	2 719
P03A	ECTOPARASITICIDES, INCL. SCABICIDES	2 157	2 779	3 211	3 561	3 681	0.7	376	2 494	624	187	2 719
P03AC	Pyrethrines, incl. synthetic compounds	2 092	2 706	3 148	3 507	3 622	0.7	371	2 452	613	186	2 676
P03AC04	permethrin	2 092	2 706	3 148	3 507	3 622	0.7	371	2 452	613	186	2 676
P03AX	Other ectoparasiticides, incl. scabicides	72	87	69	71	73	0.0	6	53	13	<5	42
P03AX01	benzyl benzoate	32	36	37	44	73	0.0	6	53	13	<5	42
P03AX03	malathion	41	51	32	27	0	0.0	0	0	0	0	0

2.16 ATC group R – Respiratory system

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
R	RESPIRATORY SYSTEM	1 259 843	1 296 996	1 330 147	1 374 981	1 397 861	263.2	159 019	507 225	508 602	223 015	1 779 464
R01	NASAL PREPARATIONS	405 387	416 923	428 436	460 559	470 847	88.6	39 071	212 624	170 655	48 497	158 293
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	349 590	357 048	366 599	395 123	405 551	76.4	37 534	178 401	145 406	44 210	143 119
R01AA	Sympathomimetics, plain	3 606	3 691	3 702	3 300	3 983	0.8	1 408	1 356	844	375	437
R01AA05	oxymetazoline	2 000	2 101	2 047	1 563	2 241	0.4	1 115	628	376	122	268
R01AA07	xylometazoline	1 618	1 596	1 671	1 745	1 746	0.3	296	728	469	253	169
R01AB	Sympathomimetics, combinations excl. corticosteroids	427	495	480	435	382	0.1	7	162	142	71	33
R01AB06	xylometazoline	427	495	480	435	382	0.1	7	162	142	71	33
R01AC	Antiallergic agents, excl. corticosteroids	47 317	42 319	42 169	46 164	45 902	8.6	12 880	20 164	10 521	2 337	12 153
R01AC01	cromoglicic acid	8 651	7 724	7 457	7 607	4 927	0.9	1 132	1 910	1 514	371	1 093
R01AC02	levocabastine	38 754	34 707	34 878	38 774	41 371	7.8	11 864	18 361	9 135	2 011	11 060
R01AC03	azelastine	214	101	0	0	0	0.0	0	0	0	0	0
R01AD	Corticosteroids	305 163	316 586	325 942	351 612	361 610	68.1	24 728	159 599	135 668	41 615	129 329
R01AD04	flunisolide	12	12	12	12	11	0.0	0	0	8	<5	25
R01AD05	budesonide	28 577	26 320	25 023	25 004	20 345	3.8	651	6 463	9 865	3 366	8 216
R01AD08	fluticasone	21 841	21 422	21 199	21 209	20 341	3.8	969	6 471	9 611	3 290	11 004
R01AD09	mometasone	160 714	160 156	161 114	171 090	176 300	33.2	11 705	73 262	68 734	22 599	42 342
R01AD11	triamcinolone	6 975	6 357	6 023	5 719	5 523	1.0	171	1 886	2 596	870	2 308
R01AD12	fluticasone furoate	92 012	88 454	87 374	92 014	91 495	17.2	8 855	43 992	30 546	8 102	18 629
R01AD58	fluticasone, combinations	7 848	31 102	42 588	55 895	67 751	12.8	3 262	36 540	22 333	5 616	46 805
R01AX	Other nasal preparations	1 224	1 332	1 482	1 923	2 047	0.4	149	798	595	505	1 168
R01AX03	ipratropium bromide	615	600	585	791	910	0.2	<5	156	318	434	778
R01AX06	mupirocin	609	732	899	1 134	1 137	0.2	147	642	277	71	390
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE	84 739	92 556	97 245	105 358	106 138	20.0	2 229	55 352	41 622	6 935	15 174
R01BA	Sympathomimetics	84 739	92 556	97 245	105 358	106 138	20.0	2 229	55 352	41 622	6 935	15 174
R01BA01	phenylpropanolamine	84 735	92 554	97 241	105 358	106 138	20.0	2 229	55 352	41 622	6 935	15 174
R01BA51	phenylpropanolamine, combinations	0	<5	<5	0	0	0.0	0	0	0	0	0
R01BA52	pseudoephedrine, combinations	<5	<5	0	0	0	0.0	0	0	0	0	0
R02	THROAT PREPARATIONS	231	601	860	959	718	0.1	41	405	200	72	79
R02A	THROAT PREPARATIONS	231	601	860	959	718	0.1	41	405	200	72	79
R02AA	Antiseptics	0	0	113	242	174	0.0	7	102	53	12	17
R02AA03	dichlorobenzyl alcohol	0	0	113	242	174	0.0	7	102	53	12	17
R02AX	Other throat preparations	231	601	748	721	547	0.1	34	306	147	60	62

ATC group R

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
R02AX01	flurbiprofen	0	0	14	90	105	0.0	<5	63	29	11	15
R02AX03	benzydamine	231	601	735	639	456	0.1	32	254	121	49	47
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	430 210	437 223	448 102	457 872	462 106	87.0	67 331	114 893	174 656	105 226	1 201 084
R03A	ADRENERGICS, INHALANTS	370 805	379 576	395 846	410 441	414 624	78.1	56 627	104 878	158 807	94 312	739 485
R03AA	Alpha- and beta-adrenoreceptor agonists	157	122	68	52	55	0.0	38	11	6	0	161
R03AA01	epinephrine	157	122	68	52	55	0.0	38	11	6	0	161
R03AC	Selective beta-2-adrenoreceptor agonists	278 642	283 525	297 047	308 927	310 331	58.4	54 562	83 583	111 647	60 539	149 011
R03AC02	salbutamol	231 841	239 798	255 957	270 499	274 663	51.7	53 974	74 919	95 446	50 324	97 383
R03AC03	terbutaline	29 663	28 386	27 455	25 686	23 882	4.5	557	7 636	10 993	4 696	9 356
R03AC04	fenoterol	17	16	11	11	13	0.0	0	0	12	<5	37
R03AC12	salmeterol	8 614	8 427	8 185	8 238	8 111	1.5	231	1 009	3 490	3 381	12 723
R03AC13	formoterol	12 919	12 162	11 282	10 731	9 958	1.9	132	1 678	4 718	3 430	15 697
R03AC18	indacaterol	9 391	7 525	6 114	5 163	4 402	0.8	0	47	1 869	2 486	11 716
R03AC19	olodaterol	131	817	927	1 029	1 070	0.2	0	27	512	531	2 098
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	183 306	187 960	192 942	196 252	196 886	37.1	7 893	47 352	88 112	53 529	463 081
R03AK06	salmeterol and fluticasone	92 173	88 214	83 967	78 843	73 827	13.9	6 053	16 856	29 856	21 062	145 449
R03AK07	formoterol and budesonide	83 643	82 839	80 791	78 736	75 825	14.3	759	18 176	36 374	20 516	168 540
R03AK08	formoterol and beclometa-sone	5 526	8 761	13 249	17 061	20 625	3.9	143	5 304	9 905	5 273	51 919
R03AK10	vilanterol and fluticasone furoate	5 049	12 816	20 372	26 166	30 321	5.7	949	7 591	13 808	7 973	84 904
R03AK11	formoterol and fluticasone	3 733	3 673	4 045	4 482	4 765	0.9	183	1 460	2 153	969	12 268
R03AL	Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	4 849	10 887	17 031	22 168	28 395	5.4	<5	385	12 013	15 995	127 233
R03AL02	salbutamol and ipratropium bromide	0	0	0	<5	0	0.0	0	0	0	0	0
R03AL03	vilanterol and umeclidinium bromide	137	2 442	4 546	6 634	8 310	1.6	<5	113	3 625	4 571	34 934
R03AL04	indacaterol and glycopyrro-nium bromide	4 720	7 447	7 618	7 435	6 766	1.3	0	47	2 742	3 977	31 325
R03AL05	formoterol and aclidinium bromide	0	919	2 538	2 823	2 679	0.5	0	44	1 195	1 440	10 718
R03AL06	olodaterol and tiotropium bromide	0	440	3 086	5 969	7 631	1.4	0	97	3 105	4 429	29 373
R03AL08	vilanterol, umeclidinium bromide and fluticasone furoate	0	0	0	0	1 802	0.3	0	26	756	1 020	5 476

ATC group R

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
R03AL09	formoterol, glycopyrronium bromide and beclometasone	0	0	0	337	3 221	0.6	<5	75	1 350	1 795	15 407
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS	159 015	159 605	162 051	165 633	164 441	31.0	40 903	26 535	52 825	44 178	261 574
R03BA	Glucocorticoids	96 580	97 203	99 473	103 028	102 566	19.3	40 451	22 438	27 049	12 628	84 200
R03BA01	beclometasone	3 822	3 692	3 652	3 817	3 889	0.7	721	1 016	1 383	769	2 837
R03BA02	budesonide	18 785	17 790	17 063	16 579	15 784	3.0	1 761	3 885	6 443	3 695	21 066
R03BA05	fluticasone	64 166	63 633	64 979	67 460	67 034	12.6	38 079	12 434	11 504	5 017	35 008
R03BA07	mometasone	578	431	392	348	348	0.1	9	107	155	77	474
R03BA08	ciclesonide	11 093	13 598	15 260	16 702	17 330	3.3	659	5 390	8 015	3 266	24 815
R03BB	Anticholinergics	68 515	68 644	69 233	69 975	69 276	13.0	1 068	5 607	28 775	33 826	177 317
R03BB01	ipratropium bromide	28 642	29 167	30 118	30 696	31 013	5.8	1 056	4 579	12 438	12 940	28 327
R03BB04	tiotropium bromide	40 771	40 059	38 667	37 851	36 257	6.8	28	1 137	15 151	19 941	124 385
R03BB05	acridinium bromide	2 631	2 976	3 048	2 929	2 575	0.5	0	40	1 146	1 389	7 459
R03BB06	glycopyrronium bromide	2 874	2 251	1 905	1 705	1 506	0.3	0	17	666	823	5 213
R03BB07	umeclidinium bromide	0	214	1 854	3 072	3 589	0.7	0	64	1 673	1 852	11 933
R03BC	Antiallergic agents, excl. corticosteroids	364	326	210	10	28	0.0	<5	9	11	7	56
R03BC01	cromoglicic acid	364	326	210	10	28	0.0	<5	9	11	7	56
R03C	ADRENERGICS FOR SYSTEMIC USE	23 347	20 578	13 869	4 772	3 573	0.7	1 651	571	906	445	1 324
R03CA	Alpha- and beta-adrenoreceptor agonists	8 918	7 538	4 389	3 636	2 745	0.5	1 358	485	663	239	846
R03CA02	ephedrine	8 918	7 538	4 389	3 636	2 745	0.5	1 358	485	663	239	846
R03CC	Selective beta-2-adrenoreceptor agonists	14 831	13 283	9 634	1 161	845	0.2	301	88	249	207	478
R03CC02	salbutamol	3 141	2 693	3 741	483	377	0.1	279	41	38	19	194
R03CC03	terbutaline	11 582	10 517	6 105	536	342	0.1	22	38	156	126	152
R03CC12	bambuterol	218	172	145	150	145	0.0	0	11	68	66	127
R03CC13	clenbuterol	0	<5	<5	<5	<5	-	0	<5	0	0	6
R03D	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	40 854	39 982	39 686	39 924	39 922	7.5	5 389	9 827	16 782	7 924	198 701
R03DA	Xanthines	3 049	2 677	2 316	2 017	1 873	0.4	0	89	871	913	2 417
R03DA02	choline theophyllinate	6	5	0	0	0	0.0	0	0	0	0	0
R03DA04	theophylline	3 039	2 667	2 305	2 006	1 864	0.4	0	86	865	913	2 374
R03DA05	aminophylline	12	13	15	16	12	0.0	0	<5	8	0	44
R03DC	Leukotriene receptor antagonists	37 473	36 610	36 321	36 373	36 185	6.8	5 340	9 000	15 292	6 553	28 556
R03DC01	zafirlukast	20	17	15	16	15	0.0	0	0	7	8	173

ATC group R

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
R03DC03	montelukast	37 454	36 593	36 306	36 357	36 171	6.8	5 340	9 000	15 286	6 545	28 383
R03DX	Other systemic drugs for obstructive airway diseases	1 452	1 764	2 147	2 691	3 066	0.6	69	966	1 277	754	167 727
R03DX05	omalizumab	413	752	1 122	1 519	1 812	0.3	69	911	716	116	129 128
R03DX07	roflumilast	1 039	1 012	977	997	981	0.2	0	<5	386	591	4 532
R03DX08	reslizumab	0	0	0	<5	17	0.0	0	<5	12	<5	1 163
R03DX09	mepolizumab	0	0	61	197	247	0.1	0	43	162	42	31 237
R03DX10	benralizumab	0	0	0	0	34	0.0	0	14	17	<5	1 667
R05	COUGH AND COLD PREPARATIONS	356 030	387 311	390 932	389 149	385 115	72.5	22 224	123 108	158 873	80 910	97 910
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	104 508	106 877	103 679	101 730	98 295	18.5	4 546	18 295	38 621	36 833	45 442
R05CA	Expectorants	5 185	5 302	6 010	5 064	4 035	0.8	819	1 209	1 230	777	383
R05CA03	guaifenesin	0	0	<5	0	0	0.0	0	0	0	0	0
R05CA10	combinations	5 185	5 302	6 007	5 064	4 035	0.8	819	1 209	1 230	777	383
R05CB	Mucolytics	100 034	102 335	98 519	97 444	95 089	17.9	3 766	17 284	37 689	36 350	45 058
R05CB01	acetylcysteine	96 331	98 794	94 871	93 303	90 768	17.1	1 393	16 585	36 951	35 839	35 110
R05CB02	bromhexine	4 351	4 157	4 300	4 689	4 926	0.9	2 349	769	1 013	795	845
R05CB13	dornase alfa (desoxyribonuclease)	145	155	156	165	182	0.0	58	101	18	5	9 103
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	246 923	271 828	275 066	273 933	271 068	51.0	15 808	95 055	115 099	45 106	43 228
R05DA	Opium alkaloids and derivatives	246 923	271 828	275 066	273 933	271 068	51.0	15 808	95 055	115 099	45 106	43 228
R05DA01	ethylmorphine	238 540	262 841	266 227	265 341	262 514	49.4	15 302	92 478	111 327	43 407	39 809
R05DA03	hydrocodone	441	493	395	364	284	0.1	<5	50	142	90	119
R05DA04	codeine	6 709	7 208	7 015	6 853	6 858	1.3	38	2 235	3 248	1 337	2 295
R05DA07	noscapine	1 771	1 818	2 177	2 270	2 102	0.4	493	672	626	311	248
R05DA09	dextromethorphan	0	0	0	0	<5	-	0	<5	<5	<5	3
R05DA20	combinations	2 619	2 746	2 532	2 369	2 265	0.4	24	541	1 204	496	754
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	44 505	51 620	55 023	55 933	56 945	10.7	2 635	20 121	24 142	10 047	9 240
R05FA	Opium derivatives and expectorants	44 505	51 620	55 023	55 933	56 945	10.7	2 635	20 121	24 142	10 047	9 240
R05FA02	opium derivatives and expectorants	44 505	51 620	55 023	55 933	56 945	10.7	2 635	20 121	24 142	10 047	9 240
R06	ANTIHISTAMINES FOR SYSTEMIC USE	615 581	618 418	642 752	683 165	706 540	133.0	86 467	287 541	249 338	83 194	248 197
R06A	ANTIHISTAMINES FOR SYSTEMIC USE	615 581	618 418	642 752	683 165	706 540	133.0	86 467	287 541	249 338	83 194	248 197

ATC group R

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
R06AA Aminoalkyl ethers	44	50	2 581	8 784	9 372	1.8	17	4 178	3 981	1 196	4 468
R06AA02 diphenhydramine	5	8	11	10	28	0.0	<5	10	13	<5	13
R06AA04 clemastine	20	13	20	13	27	0.0	<5	7	9	7	38
R06AA09 doxylamine	0	0	2 535	8 741	9 303	1.8	12	4 158	3 953	1 180	4 297
R06AA52 diphenhydramine, combinations	19	29	17	20	14	0.0	0	<5	6	5	120
R06AB Substituted alkylamines	18 231	11 594	5 868	5 347	4 573	0.9	984	1 345	1 503	741	5 281
R06AB02 dexchlorpheniramine	18 231	11 594	5 868	5 347	4 573	0.9	984	1 345	1 503	741	5 281
R06AD Phenothiazine derivatives	69 771	71 388	72 539	72 702	74 509	14.0	3 317	28 174	31 499	11 519	59 943
R06AD01 alimemazine	63 783	65 271	66 312	66 923	68 852	13.0	3 282	25 550	29 363	10 657	57 455
R06AD02 promethazine	6 509	6 681	6 799	6 324	6 186	1.2	40	2 888	2 347	911	2 489
R06AD03 thiethylperazine	5	6	<5	0	0	0.0	0	0	0	0	0
R06AE Piperazine derivatives	297 671	285 596	285 951	291 357	288 008	54.2	32 385	107 006	107 098	41 519	67 103
R06AE03 cyclizine	837	947	1 076	1 098	475	0.1	9	103	235	128	613
R06AE05 meclozine	2 983	3 202	3 378	3 838	4 355	0.8	131	3 338	580	306	599
R06AE07 cetirizine	293 687	281 318	281 412	286 302	283 122	53.3	32 222	103 614	106 189	41 097	65 348
R06AE09 levocetirizine	619	597	600	612	602	0.1	32	253	255	62	544
R06AX Other antihistamines for systemic use	268 418	285 917	311 620	343 951	369 107	69.5	53 659	163 249	119 700	32 499	111 402
R06AX02 cyproheptadine	32	35	29	25	20	0.0	<5	5	5	6	44
R06AX13 loratadine	62 810	57 895	55 508	54 389	52 598	9.9	1 454	21 303	22 083	7 758	15 483
R06AX17 ketotifen	7	7	11	11	11	0.0	0	5	<5	<5	28
R06AX22 ebastine	9 554	11 024	11 836	12 808	13 182	2.5	229	5 541	5 880	1 532	7 969
R06AX26 fexofenadine	34 434	36 385	39 227	42 308	44 851	8.4	820	22 300	17 182	4 549	16 485
R06AX27 desloratadine	169 031	188 292	212 900	243 334	267 221	50.3	51 554	118 751	77 509	19 407	71 378
R06AX28 rupatadine	0	38	130	122	<5	-	<5	<5	0	0	5
R06AX29 bilastine	<5	10	12	23	25	0.0	0	14	7	<5	10
R07 OTHER RESPIRATORY SYSTEM PRODUCTS	15	18	39	49	57	0.0	18	32	7	0	73 853
R07A OTHER RESPIRATORY SYSTEM PRODUCTS	15	18	39	49	57	0.0	18	32	7	0	73 853
R07AX Other respiratory system products	8	10	26	41	45	0.0	10	31	<5	0	73 698
R07AX02 ivacaftor	8	10	11	13	15	0.0	<5	8	<5	0	29 542
R07AX30 ivacaftor and lumacaftor	0	0	15	28	30	0.0	6	23	<5	0	44 157

2.17 ATC group S – Sensory organs

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
S	SENSORY ORGANS	653 581	643 475	646 492	668 750	674 467	127.0	104 833	192 838	215 644	161 152	427 356
S01	OPHTHALMOLOGICALS	578 242	569 996	572 678	596 365	600 667	113.1	90 242	168 456	190 282	151 687	411 304
S01A	ANTIINFECTIVES	252 458	246 271	240 135	243 441	238 050	44.8	55 309	70 713	73 727	38 301	50 751
S01AA	Antibiotics	249 383	243 185	236 834	239 977	234 627	44.2	55 196	69 575	72 320	37 536	49 089
S01AA01	chloramphenicol	193 008	190 250	187 623	193 942	193 278	36.4	40 988	59 397	61 771	31 122	43 276
S01AA02	chlortetracycline	6	<5	<5	<5	<5	-	0	0	<5	0	1
S01AA10	natamycin	0	0	<5	<5	<5	-	0	<5	<5	0	2
S01AA11	gentamicin	42	37	31	17	24	0.0	<5	10	11	<5	4
S01AA12	tobramycin	1 629	1 431	1 413	1 293	1 260	0.2	153	358	442	307	125
S01AA13	fusidic acid	60 942	55 781	51 375	48 485	41 986	7.9	15 832	10 135	10 070	5 949	3 542
S01AA26	azithromycin	6 944	6 268	5 796	5 330	4 876	0.9	1 281	1 395	1 415	785	586
S01AA27	cefuroxime	0	<5	0	0	0	0.0	0	0	0	0	0
S01AA30	combinations of different antibiotics	5 579	5 758	6 263	6 446	8 651	1.6	485	2 152	3 355	2 659	1 435
S01AD	Antivirals	3 287	2 915	3 300	3 375	3 300	0.6	114	891	1 338	957	835
S01AD02	trifluridine	0	0	0	<5	<5	-	0	<5	<5	0	7
S01AD03	aciclovir	3 287	2 915	3 300	3 374	3 299	0.6	114	890	1 338	957	828
S01AE	Fluoroquinolones	2 669	2 844	2 926	3 082	3 016	0.6	116	1 100	1 227	573	767
S01AE03	ciprofloxacin	2 669	2 844	2 926	3 082	3 016	0.6	116	1 100	1 227	573	767
S01AX	Other antiinfectives	8	8	<5	5	7	0.0	0	<5	<5	0	60
S01AX09	chlorhexidine	<5	<5	<5	<5	<5	-	0	<5	<5	0	55
S01AX15	propamidine	<5	<5	<5	<5	<5	-	0	<5	<5	0	3
S01AX18	povidone-iodine	<5	<5	<5	<5	<5	-	0	<5	<5	0	2
S01B	ANTIINFLAMMATORY AGENTS	53 602	59 749	62 824	67 149	70 182	13.2	2 563	11 539	24 110	31 970	26 910
S01BA	Corticosteroids, plain	35 407	37 698	42 473	48 920	53 707	10.1	2 518	10 664	19 365	21 160	15 940
S01BA01	dexamethasone	21 838	23 155	29 392	36 013	37 430	7.1	697	5 618	13 746	17 369	11 391
S01BA02	hydrocortisone	0	0	0	60	4 618	0.9	202	1 067	1 953	1 396	1 573
S01BA04	prednisolone	14 636	15 448	16 479	17 943	18 288	3.4	1 784	5 959	6 731	3 814	2 924
S01BA07	fluorometholone	9	9	25	17	16	0.0	0	<5	7	7	20
S01BA09	clobetasone	13	12	12	14	13	0.0	<5	<5	7	<5	31
S01BA13	rimexolone	4 105	4 322	2 440	83	0	0.0	0	0	0	0	0
S01BC	Antiinflammatory agents, non-steroids	21 212	26 341	27 895	28 399	29 077	5.5	57	1 211	8 402	19 407	10 970
S01BC03	diclofenac	6 025	7 512	7 688	7 732	7 782	1.5	40	692	2 522	4 528	1 847
S01BC10	nepafenac	9 786	12 825	15 204	17 423	17 752	3.3	11	322	4 980	12 439	8 216
S01BC11	bromfenac	5 715	6 465	5 400	3 545	4 061	0.8	6	205	1 052	2 798	907

ATC group S

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	58 553	55 148	49 893	43 762	43 173	8.1	1 153	7 509	15 491	19 020	8 785
S01CA	Corticosteroids and antiinfectives in combination	58 553	55 148	49 893	43 762	43 173	8.1	1 153	7 509	15 491	19 020	8 785
S01CA01	dexamethasone and antiinfectives	58 553	55 148	49 893	43 762	43 173	8.1	1 153	7 509	15 491	19 020	8 785
S01E	ANTI GLAUCOMA PREPARATIONS AND MIOTICS	72 872	73 682	74 978	76 099	76 868	14.5	285	2 398	21 121	53 064	155 029
S01EA	Sympathomimetics in glaucoma therapy¹⁾	5 140	5 386	4 901	4 787	4 647	0.9	10	181	1 205	3 251	4 183
S01EA03	apraclonidine	193	238	169	205	178	0.0	<5	25	62	90	68
S01EA05	brimonidine	4 998	5 196	4 772	4 633	4 492	0.9	9	159	1 149	3 175	4 115
S01EB	Parasympathomimetics	955	907	917	910	841	0.2	<5	64	247	528	1 308
S01EB01	pilocarpine	955	907	917	910	841	0.2	<5	64	247	528	1 308
S01EC	Carbonic anhydrase inhibitors	11 093	11 520	12 539	13 374	13 984	2.6	156	855	3 433	9 540	22 456
S01EC01	acetazolamide	1 822	1 623	1 687	2 065	2 107	0.4	55	579	758	715	1 136
S01EC02	diclofenamide	0	0	0	0	7	0.0	0	6	<5	0	2 172
S01EC03	dorzolamide	2 430	2 567	2 840	3 152	3 443	0.7	28	103	875	2 437	5 303
S01EC04	brinzolamide	7 266	7 478	7 486	7 290	7 108	1.3	81	147	1 477	5 403	8 990
S01EC05	methazolamide	<5	0	0	0	0	0.0	0	0	0	0	0
S01EC54	brinzolamide, combinations	0	614	1 554	2 062	2 594	0.5	<5	64	669	1 859	4 855
S01ED	Beta blocking agents¹⁾	50 197	50 544	51 182	51 703	52 160	9.8	194	1 323	14 268	36 375	74 832
S01ED01	timolol	21 495	21 519	21 391	21 098	20 510	3.9	149	537	6 131	13 693	23 541
S01ED02	betaxolol	1 150	960	834	723	651	0.1	6	8	125	512	384
S01ED51	timolol, combinations	29 552	30 224	31 281	32 044	33 251	6.3	57	880	8 700	23 614	50 907
S01EE	Prostaglandin analogues¹⁾	37 948	38 603	38 866	38 665	38 696	7.3	44	742	9 982	27 928	52 250
S01EE01	latanoprost	23 693	24 167	24 533	24 257	24 309	4.6	32	457	6 131	17 689	23 986
S01EE03	bimatoprost	2 344	2 584	2 380	2 444	2 425	0.5	0	80	601	1 744	4 337
S01EE04	travoprost	6 454	5 844	5 206	4 520	4 026	0.8	<5	46	839	3 140	6 846
S01EE05	tafluprost	6 577	7 156	7 675	8 197	8 698	1.6	11	173	2 601	5 913	17 081
S01F	MYDRIATICS AND CYCLOPLEGICS	5 397	5 208	5 556	4 995	4 918	0.9	312	1 328	2 272	1 006	1 065
S01FA	Anticholinergics	5 384	5 201	5 540	4 976	4 910	0.9	312	1 327	2 266	1 005	1 060
S01FA01	atropine	2 033	1 851	1 553	1 336	1 120	0.2	229	266	422	203	257
S01FA02	scopolamine	<5	<5	<5	<5	<5	-	0	0	<5	0	68
S01FA04	cyclopentolate	3 401	3 373	4 059	3 749	3 907	0.7	80	1 102	1 904	821	706

ATC group S

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15-44	45-69	≥70							
S01FA06	tropicamide	168	162	128	86	93	0.0	7	29	48	9	25
S01FA54	cyclopentolate, combinations	0	<5	<5	<5	9	0.0	0	<5	<5	<5	4
S01FB	Sympathomimetics excl. antiglaucoma preparations	46	39	46	51	30	0.0	0	5	20	5	5
S01FB01	phenylephrine	46	39	46	51	30	0.0	0	5	20	5	5
S01G	DECONGESTANTS AND ANTIALLERGICS	195 587	184 820	185 939	201 407	202 110	38.1	34 918	87 127	63 015	17 050	63 847
S01GA	Sympathomimetics used as decongestants	21 906	20 455	19 535	20 161	19 732	3.7	1 851	8 582	7 512	1 787	5 712
S01GA01	naphazoline	0	0	5	12	11	0.0	0	<5	5	<5	2
S01GA52	tetryzoline, combinations	21 906	20 455	19 530	20 152	19 723	3.7	1 851	8 579	7 508	1 785	5 709
S01GX	Other antiallergics	177 610	167 905	169 762	185 118	186 023	35.0	33 716	80 159	56 650	15 498	58 135
S01GX01	cromoglicic acid	25 240	23 575	23 034	23 718	22 328	4.2	3 304	8 586	8 115	2 323	8 027
S01GX02	levocabastine	91 780	86 161	87 921	97 537	98 785	18.6	19 357	43 161	28 705	7 562	24 759
S01GX04	nedocromil	1 168	0	0	0	0	0.0	0	0	0	0	0
S01GX06	emedastine	384	380	398	413	430	0.1	93	154	128	55	146
S01GX07	azelastine	615	118	0	0	0	0.0	0	0	0	0	0
S01GX08	ketotifen	21 010	20 747	21 391	23 557	24 107	4.5	4 211	10 151	7 595	2 150	9 580
S01GX09	olopatadine	43 210	41 899	41 694	45 550	45 755	8.6	8 179	20 009	13 670	3 897	15 624
S01X	OTHER OPHTHALMOLOGICALS	52 955	61 071	69 033	79 807	88 992	16.8	779	9 194	34 699	44 320	104 678
S01XA	Other ophthalmologicals	52 955	61 071	69 033	79 807	88 992	16.8	779	9 194	34 699	44 320	104 678
S01XA03	sodium chloride, hypertonic	23	24	34	39	63	0.0	0	<5	24	37	95
S01XA08	acetylcysteine	0	0	0	<5	<5	-	0	<5	0	0	32
S01XA18	ciclosporin	601	784	1 823	2 697	3 881	0.7	63	637	1 831	1 350	26 504
S01XA20	artificial tears and other indifferent preparations	52 768	60 852	68 604	79 216	87 932	16.6	735	8 974	34 245	43 978	74 200
S01XA21	mercaptamine	0	0	0	6	10	0.0	<5	7	0	0	3 439
S01XA25	lifitegrast	0	0	0	0	6	0.0	0	<5	<5	<5	180
S02	OTOLOGICALS	23 042	24 528	22 510	20 226	22 924	4.3	4 959	7 160	7 622	3 183	4 170
S02A	ANTIINFECTIVES	7 549	6 437	5 536	5 224	4 986	0.9	1 690	1 479	1 321	496	859
S02AA	Antiiinfectives	7 549	6 437	5 536	5 224	4 986	0.9	1 690	1 479	1 321	496	859
S02AA01	chloramphenicol	11	13	11	0	0	0.0	0	0	0	0	0
S02AA03	boric acid	<5	<5	8	20	5	0.0	0	0	<5	<5	8
S02AA15	ciprofloxacin	7 537	6 423	5 520	5 204	4 982	0.9	1 690	1 479	1 318	495	851
S02B	CORTICOSTEROIDS	10 853	12 168	7 855	1 355	1 429	0.3	18	310	738	363	280
S02BA	Corticosteroids	10 853	12 168	7 855	1 355	1 429	0.3	18	310	738	363	280
S02BA07	betamethasone	10 853	12 168	7 855	1 355	1 429	0.3	18	310	738	363	280

ATC group S

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
								<15	15-44	45-69	≥70	
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	5 664	7 030	10 163	14 369	17 171	3.2	3 386	5 560	5 793	2 432	3 028
S02CA	Corticosteroids and antiinfectives in combination	5 664	7 030	10 163	14 369	17 171	3.2	3 386	5 560	5 793	2 432	3 028
S02CA02	flumetasone and antiinfectives	101	74	62	59	<5	-	0	0	<5	0	1
S02CA05	fluocinolone acetonide and antiinfectives	5 565	6 964	10 104	14 314	17 169	3.2	3 386	5 560	5 791	2 432	3 027
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	75 987	72 113	74 436	74 488	73 692	13.9	13 449	23 020	25 844	11 379	11 882
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	75 987	72 113	74 436	74 488	73 692	13.9	13 449	23 020	25 844	11 379	11 882
S03CA	Corticosteroids and antiinfectives in combination	75 987	72 113	74 436	74 488	73 692	13.9	13 449	23 020	25 844	11 379	11 882
S03CA01	dexamethasone and antiinfectives	12 881	10 738	10 956	10 854	9 588	1.8	717	2 571	4 224	2 076	1 387
S03CA04	hydrocortisone and antiinfectives	65 069	63 009	65 134	65 319	65 568	12.3	12 837	20 889	22 272	9 570	10 495

2.18 ATC-group V – Various

ATC level		2014	2015	2016	2017	2018	2018	2018				2018
		Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
		<15	15–44	45–69	≥70							
V	VARIOUS	27 786	30 050	32 694	35 372	37 093	7.0	5 420	12 581	11 428	7 664	187 635
V01	ALLERGENS	10 346	11 619	12 876	14 582	16 203	3.1	2 847	10 393	2 858	105	125 642
V01A	ALLERGENS	10 346	11 619	12 876	14 582	16 203	3.1	2 847	10 393	2 858	105	125 642
V01AA	Allergen extracts	10 346	11 619	12 876	14 582	16 203	3.1	2 847	10 393	2 858	105	125 642
V01AA02	grass pollen	7 480	8 644	9 845	11 002	12 021	2.3	2 042	8 005	1 926	48	76 816
V01AA03	house dust mites	552	556	514	933	1 544	0.3	176	1 034	322	12	10 910
V01AA05	tree pollen	5 287	5 535	5 791	6 259	6 585	1.2	1 210	4 010	1 318	47	30 402
V01AA07	insects	148	165	149	144	136	0.0	19	36	70	11	1 095
V01AA10	flowers	120	96	43	<5	10	0.0	0	<5	5	<5	104
V01AA11	animals	526	570	555	513	581	0.1	98	369	112	<5	6 314
V03	ALL OTHER THERAPEUTIC PRODUCTS	3 015	3 294	3 530	3 868	4 210	0.8	95	491	1 643	1 981	51 302
V03A	ALL OTHER THERAPEUTIC PRODUCTS	3 015	3 294	3 530	3 868	4 210	0.8	95	491	1 643	1 981	51 302
V03AB	Antidotes	108	100	120	82	122	0.0	<5	45	55	18	223
V03AB01	ipecacuanha	8	<5	<5	8	5	0.0	0	<5	<5	<5	2
V03AB03	edetates	0	0	<5	0	0	0.0	0	0	0	0	0
V03AB06	thiosulfate	<5	<5	<5	0	<5	-	0	0	0	<5	56
V03AB09	dimercaprol	8	12	6	6	<5	-	0	0	<5	0	10
V03AB14	protamine	0	0	<5	0	<5	-	0	0	0	<5	1
V03AB15	naloxone	14	12	20	11	27	0.0	<5	12	9	<5	18
V03AB16	ethanol	<5	<5	0	<5	<5	-	0	<5	<5	0	7
V03AB17	methylthionium chloride	0	0	<5	<5	<5	-	0	<5	0	0	2
V03AB19	physostigmine	<5	0	0	<5	<5	-	0	0	<5	0	1
V03AB21	potassium iodide	<5	<5	<5	11	41	0.0	<5	18	16	6	16
V03AB22	amyl nitrite	0	0	<5	<5	<5	-	0	0	<5	0	1
V03AB25	flumazenil	<5	<5	5	<5	<5	-	0	<5	<5	0	5
V03AB32	glutathione	61	63	72	34	26	0.0	0	5	16	5	88
V03AB33	hydroxocobalamin	0	<5	0	0	<5	-	0	0	<5	0	6
V03AC	Iron chelating agents	127	122	139	144	157	0.0	25	47	43	42	17 765
V03AC01	deferoxamine	36	31	30	31	26	0.0	10	9	<5	<5	530
V03AC02	deferiprone	26	23	22	21	23	0.0	<5	8	5	6	986
V03AC03	deferasirox	83	82	105	109	122	0.0	16	38	35	33	16 249
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia	2 486	2 699	2 813	2 965	3 072	0.6	8	263	1 218	1 583	29 611
V03AE01	polystyrene sulfonate	727	846	881	951	876	0.2	5	57	325	489	1 941
V03AE02	sevelamer	1 746	1 790	1 862	1 987	2 014	0.4	<5	191	856	964	13 253

ATC group V

ATC level	2014	2015	2016	2017	2018	2018	2018				2018
	Number of individuals					Prevalence per 1 000	Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
V03AE03 lanthanum carbonate	473	603	644	562	590	0.1	0	62	253	275	9 339
V03AE04 calcium acetate and magnesium carbonate	96	94	19	12	5	0.0	0	<5	<5	<5	24
V03AE05 sucroferric oxyhydroxide	0	0	63	122	115	0.0	0	7	65	43	1 340
V03AE09 patiomer calcium	0	0	0	<5	257	0.1	<5	27	116	113	3 708
V03AE10 sodium zirconium cyclosilicate	0	0	0	0	<5	-	0	<5	0	0	7
V03AF Detoxifying agents for antineoplastic treatment	66	57	61	61	38	0.0	11	10	12	5	366
V03AF01 mesna	7	<5	9	10	12	0.0	0	<5	10	0	17
V03AF03 calcium folinate	59	55	52	51	26	0.0	11	8	<5	5	349
V03AG Drugs for treatment of hypercalcemia	163	280	371	579	736	0.1	34	113	277	312	853
V03AH Drugs for treatment of hypoglycemia	20	28	24	28	28	0.0	10	8	6	<5	2 222
V03AH01 diazoxide	20	28	24	28	28	0.0	10	8	6	<5	2 222
V03AX Other therapeutic products	<5	15	6	16	63	0.0	0	<5	37	22	253

Noen forkortelser og definisjoner

ATC	Anatomisk Terapeutisk Kjemisk (klassifikasjonssystem for legemidler)
DDD	Definert døgndose
FHI	Folkehelseinstituttet
HELFO	Helseøkonomiforvaltningen
MA	Markedsføringstillatelse
NOK	Norske kroner
NorPD	Reseptregisteret
OTC	Reseptfritt
SPC	Preparatomtale
SSB	Statistisk sentralbyrå
WHO	Verdens helseorganisasjon

Some abbreviations and definitions

ATC	Anatomical Therapeutic Chemical (classification system for medicines)
DDD	Defined Daily Doses
HELFO	The Norwegian Health Economics Administration
MA	Marketing Authorisation
NIPH	Norwegian Institute of Public Health
NOK	Norwegian kroner
NorPD	Norwegian Prescription Database
OTC	Over The Counter, non prescription
SPC	Summary of Product Characteristics
SSB	Statistics Norway
WHO	World Health Organization

Definisjoner

Prevalens

Brukere (individer) defineres som personer som har hentet minst én resept på apotek i perioden. Prevalens er definert som antall brukere per 100 (%) eller per 1000 (promille) innbyggere i det definerte befolkningsutvalget.

Insidens (nye brukere)

Insidens er antall brukere av et bestemt legemiddel eller en legemiddelgruppe i en definert tidsperiode som ikke var brukere i en tidligere, definert periode. Insidens kan også uttrykkes som andel (%) i forhold til antallet potensielle nye brukere i det definerte befolkningsutvalget.

Definitions

Prevalence

Users (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 (%) or 1000 (promille) inhabitants in the defined population sample.

Incidence (new users)

Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample.

Folkemengde i Norge 2014–2018 (per 1. juli)
Population in Norway 2014–2018 (as of 1st July)

Year	2014	2015	2016	2018	2018
Population	5 137 321	5 189 984	5 236 624	5 276 847	5 311 797

Folkemengde etter alder i 2018 (per 1. juli)
Population by age in 2018 (as of 1st July)

Age groups	<15	15–44	45–69	≥70
Population	905 749	2 093 866	1 650 202	661 981

Kilde: Statistisk sentralbyrå / Source: Statistics Norway

Liste over vitenskapelige publikasjoner basert på data fra Reseptregisteret per 21.02.2019

List of publications based on data from the Norwegian Prescription Database (NorPD) as of 21.02.2019

2018:

- Andersson J, Hofslid M, Gade UL, Heegaard S, Pottegard A. Use of topical ocular antibiotics in young children: a Scandinavian drug utilization study. *Acta Ophthalmol (Oxf)* 2018;96(8):789-94.
- Antonazzo IC, Riise T, Cortese M, Berge LI, Engeland A, Fasmer OB, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. *Cephalalgia* 2018;38(11):1759-64.
- Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilization and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. *Epilepsy Res* 2018;139:35-42.
- Bateman BT, Heide-Jørgensen U, Einarsdottir K, Engeland A, Furu K, Gissler M, Hernandez-Diaz S, Huybrechts K, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Selmer R, Zoega H. Beta-blocker use in pregnancy and the risk of congenital malformations: An international cohort study. *Ann Intern Med* 2018; 169: 665-73.
- Benko R, Matuz M, Silva A, Ferreira J, Machado MC, Furtado C, Fungie G, Bordas R, Blix HS. Cross-national comparison of paediatric antibiotic use in Norway, Portugal and Hungary. *Basic Clin Pharmacol Toxicol*. 2018 Dec 27. doi: 10.1111/bcpt.13198.
- Bergene EH, Nordeng H, Ro TB, Steinsbekk A. Register-based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. *Acta Paediatr* 2018;22:22.
- Bergene EH, Nordeng H, Ro TB, Steinsbekk A. Requests for new oral antibiotic prescriptions in children within 2 days: a Norwegian population-based study. *Fam Pract* 2018;35(6):690-7.
- Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong-van den Berg LTW, Jordan S, Klungsøyr K, Neville AJ, Pierini A, Puccini A, Sinclair M, Thayer D, Dolk H. The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. *Eur J Pharmacol* 2018; 74:513-20
- Cohen JM, Wood ME, Hernandez-Diaz S, Nordeng H. Agreement between paternal self-reported medication use and records from a national prescription database. *Pharmacoepidemiol Drug Saf* 2018;27(4):413-21.
- Cortese M, Riise T, Engeland A, Ascherio A, Bjørnevik K. Urate and the risk of Parkinson's disease in men and women. *Parkinsonism Relat Disord* 2018;52:76-82.
- Dalen DM, Locatelli M, Strom S. An Equilibrium Model Estimated on Pharmaceutical Data. *Atl Econ J* 2018;46(3):281-96.
- Danielsson KC, Borthen I, Morken NH, Gilhus NE. Hypertensive pregnancy complications in women with epilepsy and antiepileptic drugs: a population-based cohort study of first pregnancies in Norway. *BMJ Open* 2018;8(4):e020998.
- Diaz E, Omland G, Hannestad Y, Ruths S. Use of hormonal contraceptives among immigrant women and their daughters in Norway: Data from the Norwegian Prescription Database. *Acta Obstetrica et Gynecologica Scandinavica* 2018.
- Egeland GM, Skurtveit S, Staff AC, Eide GE, Daltveit AK, Klungsøyr K, et al. Pregnancy-Related Risk Factors Are Associated With a Significant Burden of Treated Hypertension Within 10 Years of Delivery: Findings From a Population-Based Norwegian Cohort. *J Am Heart Assoc* 2018;7(10):13.
- Engeland A, Borge T, Klungsøyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. *Pharmacoepidemiol Drug Saf* 2018;27(9):995-1004.
- Fossum GH, Gjelstad S, Kvaerner KJ, Lindbaek M. Prescribing antibiotics when the stakes are higher - do GPs prescribe less when patients are pregnant? A retrospective observational study. *BJGP open* 2018;2(2):bjgpopen18X101505.
- Fossum GH, Lindbaek M, Gjelstad S, Kvaerner KJ. Relationship between Maternal and First Year of Life Dispensations of Antibiotics and Antiasthmatics. *Antibiotics (Basel)* 2018;7(3):17.
- Frank AS, Lupattelli A, Matteson DS, Nordeng H. Maternal use of thyroid hormone replacement therapy before, during, and after pregnancy: agreement between self-report and prescription records and group-based trajectory modeling of prescription patterns. *Clin Epidemiol* 2018;10:1801-16.
- Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. *Pain* 2018;07:07.
- Gulati S, Solheim O, Carlsen SM, Oie LR, Jensberg H, Gulati AM, et al. Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. *PLoS ONE* 2018;13(8):e0202575.
- Hegvik TA, Instanes JT, Haavik J, Klungsøyr K, Engeland A. Associations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. *Eur Child Adolesc Psychiatry*. 2018 May;27(5):663-675.
- Heldal AT, Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG. Use of drugs for alcohol use disorder in Norway 2004-16. *Tidsskrift for Den Norske Lægeforening* 2018;138(18):13.
- Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, et al. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. *Osteoporos Int* 2018;29(8):1875-85.
- Huybrechts KF, Bröms G, Christensen LB, Einarsdottir K, Engeland A, Furu K, Gissler M, Hernandez-Diaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between Methylphenidate and Amphetamine use in Pregnancy and Risk of Congenital Malformations: A cohort study from the International Pregnancy Safety Study (InPreSS) Consortium. *JAMA Psychiatry* 2018;75(2):167-75
- Jakobsen GS, Smastuen MC, Sandbu R, Nordstrand N, Hofso D, Lindberg M, et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities. *Jama* 2018;319(3):291-301.
- Johannsdottir IM, Loge JH, Kiserud CE, Karlstad O, Skurtveit S. Increased prescription rates of anxiolytics and hypnotics to survivors of cancer in childhood, adolescence, and young adulthood-A population-based study. *Pediatr Blood Cancer* 2018;65(2).
- Kasciuskeviciute S, Gumbrevicius G, Vendzelyte A, Sciupokas A, Petrikonis K, Kadusevicius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study. *Medicina (Kaunas)* 2018;54(2):11.
- Kjerpeseth L, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. *Eur J Clin Pharmacol* 2018;74:1653-62.
- Kleppang AL, Hartz I, Thurston M, Hagquist C. Leisure-time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. *Eur Child Adolesc Psychiatry* 2018;02:02.
- Knudsen-Baas KM, Johannesen TB, Myklebust TA, Aarseth JH, Owe JF, Gilhus NE, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. *J Neurooncol* 2018;140(3):739-48.
- Kolberg ES, Tranung M, Aasarod KM. Increased prescribing of ursodeoxycholic acid in Norway. *Int J Clin Pharm* 2018;40(6):1454-7.
- Lossius AK, Magnus MC, Lunde J, Stordal K. Prospective Cohort Study of Breast-feeding and the Risk of Childhood Asthma. *J Pediatr* 2018;195:182-9.e2.
- Magnus MC, Karlstad Ø, Parr CL, Page CM, Nafstad P, Magnus P, London SJ, Wilcox AJ, Nystad W, Håberg SE. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. *Thorax*. 2019;74(2):106-13.
- Magnus MC, Wright RJ, Røysamb E, Parr CL, Karlstad Ø, Page CM, Nafstad P, Håberg SE, London SJ, Nystad W. Association of Maternal Psychosocial Stress With Increased Risk of Asthma Development in Offspring. *Am J Epidemiol*. 2018;187(6):1199-209.
- Mauseth SA, Skurtveit S, Langhammer A, Spigset O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 2018;29(4):489-95.

- Mauseth SA, Skurtveit S, Skovlund E, Langhammer A, Spigset O. Medication use and association with urinary incontinence in women: Data from the Norwegian Prescription Database and the HUNT study. *NeuroUrol Urodyn* 2018;37(4):1448-57.
- Meijer M, Thygesen LC, Green A, Emneus M, Brasso K, Iversen P, Pukkala E, Bolin K, Stavem K, Ersbøll AK. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. *Cancer Med*. 2018;7:254-260.
- Mikalsen IB, Karlstad Ø, Furu K, Øymar K. Prescribing of asthma drugs for children 2004–2015 [Forskrivning av legemidler mot astma til barn i perioden 2004-15]. *Tidsskr Nor Legeforen* 2018; 138:345-51.
- CH, Blix HS, Halvorsen JA, Nafstad P, Valberg M, Lagerlov P. Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway. *JAMA netw* 2018;1(7):e184145.
- Nakken O, Lindstrom JC, Tysnes OB, Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. *Amyotroph Lateral Scler Frontotemporal Degener* 2018;19(3-4):303-10.
- Nechanská B, Moravcik V, Skurtveit S, Lund IO, Gabrhelík R, Engeland A, Handal M. Neonatal Outcomes after Fetal Exposure to Methadone and Buprenorphine: National Registry Studies from the Czech Republic and Norway. *Addiction* 2018.
- Nesvag R, Bramness JG, Handal M, Hartz I, Hjellvik V, Skurtveit S. The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents. *Eur Psychiatry* 2018;49:16-22.
- Parr CL, Magnus MC, Karlstad O, Holvik K, Lund-Blix NA, Haugen M, et al. Vitamin A and D intake in pregnancy, infant supplementation, and asthma development: the Norwegian Mother and Child Cohort. *Am J Clin Nutr* 2018;107(5):789-98.
- Pasternak B, Wintzell V, Furu K, Engeland A, Neovius M, Stephansson O. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death. *JAMA* 2018.
- Raknes G, Simonsen P, Smabrekke L. The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study. *J Crohns Colitis* 2018;12(6):677-86.
- Raman SR, Man K, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell GA, Crystal S, Furu K, Yang Yea-Huei Kao, Karlstad Ø; Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Saint-Gerons DM, Stürmer T, Su CC, Zoega H, Sturkenbroom M, Chan EW, Coghill D, Ip P, Wong I. Regional and national trends in attention-deficit/hyperactivity disorder (ADHD) medication use: a multinational study in North America, Europe, Asia and Australia. *Lancet Psychiatry* 2018; 5(10):824-835.
- Reset A, Skurtveit S, Furu K, Skovlund E. Effect of the market withdrawal of dextropropoxyphene on use of other prescribed analgesics. *Scand J Pain* 2018;18(4):667-74.
- Roksvaag I, Skjeldestad FE. Decreasing trends in number of depot medroxyprogesterone acetate starters in Norway - a cross-sectional study. *Acta Obstet Gynecol Scand* 2018;97(2):151-7. .
- Ruiz PLD, Tapia G, Bakken IJ, Hasberg SE, Hungnes O, Gulseth HL, et al. Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study. *Diabetologia* 2018;61(9):1996-2004.
- Rutherford OW, Jonasson C, Ghanima W, Holst R, Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. *Open Heart* 2018;5(2):e000931.
- Skurtveit S, Bramness JG, Hjellvik V, Hartz I, Nesvag R, Hauge LJ, et al. Increase in diagnosis of depressive disorders contributes to the increase in antidepressant use in adolescents. *Acta Psychiatr Scand* 2018;137(5):413-21.
- Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway. *J Eur Acad Dermatol Venereol* 2018;32(5):776-82.
- Solberg BS, Halmøy A, Engeland A, Iglund J, Haavik J, Klungsoyr K. Gender differences in Psychiatric Comorbidity in Adults with Attention Deficit/Hyperactivity Disorder. *Acta Psychiatr Scand* 2018; 137: 176–186.
- Suren P, Thorstensen AG, Tørstad M, Emhjellen PE, Furu K, Biele G, Aase H, Stoltenberg C, Zeiner P, Bakken IJ, Reichborn-Kjennerud T. [Diagnosis of hyperkinetic disorder among children in Norway]. *Diagnostikk av hyperkinetisk forstyrrelse hos barn i Norge*. *Tidsskr Nor Legeforen* 2018;138:1924-9. Norwegian, English.
- Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? *Eur J Clin Pharmacol* 2018;74(4):497-504.
- Vederhus J-K, Bramness JG, Skurtveit S, Heldal AT, Lobmaier PPK. Bruk av medikamenter for alkoholbrukslidelser i Norge 2004–16. *Tidsskrift for Den Norske Laegeforening* 2018;138(18):1710-5.
- Vie TL, Hufthammer KO, Holmen TL, Meland E, Breidablik HJ. Is self-rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Trøndelag Health Study and the Norwegian Prescription Database. *SSM Popul Health* 2018;4:144-52.
- Walle-Hansen MM, Høye S. Geographic Variation in Antibiotic Consumption- Is It Due to Doctors' Prescribing or Patients' Consulting? *Antibiotics (Basel)* 2018;7(1):20.
- Wastesson JW, Martikainen JE, Zoëga H, Schmidt M, Karlstad Ø, Pottegård A. Trends in Use of Paracetamol in the Nordic Countries. *Basic Clin Pharmacol Toxicol*. 2018;123(3):301–7.
- Winje BA, White R, Syre H, Skutlberg DH, Oftung F, Mengshoel AT, et al. Stratification by interferon-gamma release assay level predicts risk of incident TB. *Thorax* 2018;05:05.
- 2017:**
- Antonazzo IC, Riise T, Cortese M, Berge LI, Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. *Cephalalgia* 2017;33:102417748573.
- Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. *Epilepsy Res* 2017;139:35-42.
- Bakken IJ, Wensaas K-A, Furu K, Grøneng GM, Stoltenberg C, Överland S, et al. General practice consultations and use of prescription drugs after changes to school absence policy. *Tidsskr Nor Laegeforen* 2017;137(16):1178-84.
- Beisland C, Johannesen TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. *OncoTargets and therapy*. 2017;10:371-385
- Beriwan Ezat, Lasse Pihlstrøm, Jan Aasly, Ole-Bjørn Tysnes, Arild Egge, Espen Dietrichs Bruk av avansert behandling ved Parkinsons sykdom i Norge *Tidsskr Nor Legeforen* 2017 137:619-23 <http://tidsskriftet.no/en/2017/05/original-article/use-advanced-therapies-parkinsons-disease-norway>
- Bjelland EK, Owe KM, Nordeng HME, Engdahl BL, Kristiansson P, Vangen S, et al. Does progestin-only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective population study. *PLoS One* 2017;12(9):14.
- Blandhol M, Tysland T, Blix HS, Høye S. Antibiotic switch during treatment with antibiotics against respiratory tract infections in ambulatory care in Norway. *Infect Dis (Lond)* 2017;49(11-12):854-8.
- Brakedal B, Flones I, Reiter SF, Torkildsen O, Dolle C, Assmus J, et al. Glitazone Use Associated With Reduced Risk of Parkinson's Disease. *Mov Disord* 2017;32(11):1594-9.
- But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A, Starup-Linde J, Schmidt MK, Furu K, de Vries F, Karlstad Ø, Ekstrøm, N, Haukka J. Cancer Risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. *Diabetologia* 2017;60:1691-703. doi: 10.1007/s00125-017-4312-5
- Efjestad AS, Ihle-Hansen H, Hjellvik V, Blix HS. Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors. *Dement Geriatr Cogn Dis Extra* 2017;7(1):30-40.
- Egeland GM, Skurtveit S, Sakshaug S, Daltveit AK, Vikse BE, Haugen M. Low Calcium Intake in Midpregnancy Is Associated with Hypertension Development within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study. *Journal of Nutrition* 2017;147(9):1757-63.
- Engeland A, Borge T, Klungsoyr K, Skurtveit S, Furu K. Preterm births and use of medication in early adulthood: a population-based registry study. *Pharmacoepidemiology and Drug Safety* 2017;26(7):742-51.
- Evandt J, Oftedal B, Krog NH, Skurtveit S, Nafstad P, Schwarze PE, et al. Road traffic noise and registry based use of sleep medication. *Environ Health* 2017;16:12.
- Ezat B, Pihlstrom L, Aasly J, Tysnes OB, Egge A, Dietrichs E. Use of advanced therapies for Parkinson's disease in Norway. *Tidsskr Nor Laegeforen* 2017;137(9):619-23.
- Fadnes LT, Diaz E. Primary healthcare usage and use of medications among immigrant children according to age of arrival to Norway: a population-based study. *BMJ Open* 2017;7:e014641 <http://bmjopen.bmj.com/content/7/2/e014641.long>

- Fredheim OMS, Brelin S, Hjernstad MJ, Loge JH, Aass N, Johannessen TB, et al. Prescriptions of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five-year period 2005-2009. *European Journal of Pain* 2017;21(3):530-40.
- Fredheim OMS, Skurtveit S, Borchgrevink PC. Provision of analgesics to children before and after the new recommendations on codeine. *Tidsskr Nor Laegeforen* 2017;137(12-13):881-4.
- Furu K, Karlstad Ø, Zoega H, Martikainen J, Bahmanyar S, Kieler H, Pottegård A. Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 million Children Using Population-based Longitudinal Data. *Basic & Clin Pharmacol & Toxicol* 2017;120:373-9.
- Gjerden P, Bramness JG, Tvette IF, Slordal L. The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015. *Eur J Clin Pharmacol* 2017;73(9):1173-9.
- Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Håberg SE, Mølgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy, and the risk of adverse neonatal outcomes and congenital malformations-A population based European register study. *BMJ* 2017. Mar 1;356:j629. <http://www.bmj.com/content/356/bmj.j629.long>
- Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. *Immun Ageing* 2017;14:7.
- Haaland GS, Falk RS, Straume O, Lorens JB. Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. *JAMA Intern Med* 2017;177(12):1774-80.
- Halvorsen S, Ghanima W, Tvette IF, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. *Eur Heart J-Cardiovasc Pharmacother* 2017;3(1):28-36.
- Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, et al. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. *Osteoporos Int* 2017;28(10):2935-44. 25. Hognert H1, Skjeldstad FE2, Gemzell-Danielsson K3, Heikinheimo O4, Milsom I1, Lidegaard Ø5, Lindh I1. High birth rates despite easy access to contraception and abortion: a cross-sectional study. *Acta Obstet Gynecol Scand*. 2017 Dec;96(12):1414-1422. doi: 10.1111/aogs.13232. Epub 2017 Oct 30. <https://www.ncbi.nlm.nih.gov/pubmed/28921518>
- Holdo I, Bramness JG, Handal M, Torgersen L, Reichborn-Kjennerud T, Ystrom E, et al. Hypnotics use in children 0-18 months: moderate agreement between mother-reported survey data and prescription registry data. *J* 2017;10:28.
- Johannsdottir IM, Karlstad O, Loge JH, Fossa SD, Kiserud C, Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. *J Adolesc Young Adult Oncol* 2017;6(1):120-6.
- Jorgensen SB, Soraas A, Sundsfjord A, Liestol K, Leegaard TM, Jenum PA. Fecal carriage of extended spectrum beta-lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* after urinary tract infection - A three year prospective cohort study. *PLoS One* 2017;12(3):16.
- Karlstad Ø, Furu K, Stoltenberg C, Håberg SE, Bakken IJ. ADHD Diagnosis and Treatment in Relation to Children's Birth Month: Nationwide Study from Norway. *Scand J Public Health*. 2017 Jun;45:343-9.
- Kaspersen SL, Pape K, Carlsen F, Ose SO, Bjørngaard JH. Employees' drug purchases before and after organizational downsizing: a natural experiment on the Norwegian working population (2004-2012). *Scand J Work Environ Health* 2017;43(4):307-15.
- Kjerpeseth L, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. *Eur J Clin Pharmacol* 2017;73:1417-25.
- Krøvdal Ø, Grundy E, Skirbekk V. Fertility history and use of antidepressant medication in late mid-life: a register-based analysis of Norwegian women and men. *Aging Ment Health*. 2017 May;21(5):477-486. doi: 10.1080/13607863.2015.1118010. Epub 2015 Dec 8. <https://www.ncbi.nlm.nih.gov/pubmed/26644174>
- Lindh I, Skjeldstad FE, Gemzell-Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use in the Nordic countries. *Acta Obstet Gynecol Scand* 2017; 96:19-28. <http://onlinelibrary.wiley.com/doi/10.1111/aogs.13055/abstract>
- Mauseth SA, Skurtveit S, Langhammer A, Spigset O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 2017;04:04.
- Milenkovic M, Haavik S. Recording of pharmaceutical interventions of potential clinical importance in Norwegian pharmacies. *Norsk Farmaceutisk Tidsskrift* 2017;125(6):26-30.
- Modalsli EH, Asvold BO, Romundstad PR, Langhammer A, Hoff M, Forsmo S, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. *Br J Dermatol* 2017;176(5):1162-9.
- Modalsli EH, Asvold BO, Snekvik I, Romundstad PR, Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depressive symptoms: the HUNT Study, Norway. *J Eur Acad Dermatol Venereol* 2017;31(12):2062-8.
- Mårdal K, Blix HS, Størdal K. Use of antibiotics in children during the period 2005-16. *Tidsskr Nor Laegeforen* 2017;137(18):1414-9.
- Nakken O, Lindstrom JC, Tysnes OB, Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. *Amyotrophic Lateral sclerosis & Frontotemporal Degeneration* 2017:1-8.
- Odsbu I, Selmer R, Lundborg CS, Blix HS. Increased prescribing of systemic tetracyclines and isotretinoin for treatment of acne. *J Antimicrob Chemother* 2017;72(5):1510-5.
- Parr CL, Magnus MC, Karlstad O, Haugen M, Refsum H, Ueland PM, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population-based Cohort. *Am J Respir Crit Care Med* 2017;195(2):221-8.
- Preus HR, Fredriksen KW, Vogsland AE, Sandvik L, Grytten JI. Antibiotic-prescribing habits among Norwegian dentists: a survey over 25 years (1990-2015). *Eur J Oral Sci* 2017;125(4):280-7.
- Raknes G, Smabrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study. *PLoS One* 2017;12(11):13.
- Raknes G, Smabrekke L. Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. *Pharmacoepidemiology and Drug Safety* 2017;26(6):685-93.
- Raknes G, Smabrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. *Pharmacoepidemiology and Drug Safety* 2017;26(2):136-42.
- Rebndor, E.W., Strand, E., Midttun, Ø. et al. The kynurenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. *Diabetologia* 2017; 60: 1712.
- Reigstad MM, Storeng R, Myklebust TA, Oldereid NB, Omland AK, Røsbak TE, et al. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. *Cancer Epidemiology Biomarkers & Prevention* 2017;26(6):953-62.
- Sakshaug S, Handal M, Hjellevik V, Berg C, Ripel A, Gustavsen I, et al. Long-term Use of Z-Hypnotics and Co-medication with Benzodiazepines and Opioids. *Basic Clin Pharmacol Toxicol* 2017;120(3):292-8.
- Salvatore S, Roislien J, Baz-Lomba JA, Bramness JG. Assessing prescription drug abuse using functional principal component analysis (FPCA) of wastewater data. *Pharmacoepidemiology and Drug Safety* 2017;26(3):320-6.
- Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug A, Svendsen K, Eggen AE. Pain sensitivity and analgesic use among 10,486 adults: the Tromsø study. *BMC Pharmacol Toxicol* 2017;18(1):45.
- Stormorken E, Jason LA, Kirkevold M. From good health to illness with post-infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. *BMC family practice* 2017;18(1):49.
- Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non-refugees from War-Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. *Journal of Immigrant and Minority Health* 2017;19(3):582-9.
- Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? *Eur J Clin Pharmacol* 2017;18:18.
- Svendsen T, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI, Landmark CJ. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability. *Neurochemical Research* 2017;42(7):2077-83. 55. Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Landmark CJ. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome. *Epilepsy Research* 2017;129:125-31.
- Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, et al. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome. *Epilepsy Res* 2017;129:125-31.

- Sverdrup Efestad A, Ihle-Hansen H, Hjellvik V, Blix HS. Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors. *Dement Geriatr Cogn Dis Extra* 2017;7(1):30-40.
- Tevik K, Selbaek G, Engedal K, Seim A, Krokstad S, Helvik AS. Use of alcohol and drugs with addiction potential among older women and men in a population-based study. The Nord-Trøndelag Health Study 2006-2008 (HUNT3). *PLoS One* 2017;12(9):14.
- Tvete IF, Bjorner T, Skomedal T. New benzodiazepine and Z-hypnotic users and disability pension: an eight-year nationwide observational follow-up study. *Scand J Prim Health Care* 2017;35(3):240-6.
- Urbaniak AM, Strom BO, Krøntveit R, Svanqvist KH. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database. *Drugs Aging* 2017;34(8):635-45.
- Vie TL, Hufthammer KO, Holmen TL, Meland E, Breidablik HJ. Is self-rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Trøndelag Health Study and the Norwegian Prescription Database. *SSM Popul Health*. 2017 Dec 9;4:144-152. doi: 10.1016/j.ssmph.2017.11.010. eCollection 2018 Apr
- Youngster I, Avorn J, Belleudi V, Cantarutti A, Díez-Domingo J, Kirchmayer U, Byung-Joo Park, Peiró S, Sanfeliu-Gimeno G, Schröder H, Schüssler K, Shin JY, Shin SM, Simonsen GS, Blix HS, Tong A, Trifirò G, Ziv-Baran T, Kim SK. Antibiotic Use in Children – A Cross-National Analysis of 6 Countries. *J Pediatr* 2017;182:239-44.
- 2016:**
- Andenaes R, Helseth S, Misvaer N, Småstuen MC, Ribu L. Psychosocial factors are strongly associated with insomnia in users and nonusers of prescribed sleep medication: Evidence from the HUNT3 study. *J Multidisciplinary Healthcare* 2016;9:547-55.
- Baftiu A, Johannessen Landmark C, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications. *Eur J Clin Pharmacol* 2016;72(10):1245-54.
- Bains SJ, Mahic M, Myklebust TA, Smastuen MC, Yaqub S, Dorum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: An unselected population-based study. *J Clin Oncol* 2016;34(21):2501-8.
- Bakken MS, Schjøtt J, Engeland A, Engesaeter LB, Ruths S. Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. *J Am Geriatr Soc* 2016;64(6):1203-9.
- Blagestad T, Nordhus IH, Gronli J, Engesaeter LB, Ruths S, Ranhoff AH, et al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressants, and anxiolytics: Results from a population of total hip arthroplasty patients. *Pain* 2016;157(3):643-51.
- Brelis S, Fredheim OM, Loge JH, Skurtveit S, Johannesen TB, Aass N, et al. Opioids for outpatients with cancer in their last year of life: A nationwide pharmacoepidemiological study. *Journal of Opioid Management* 2016;12(1):25-36.
- Charlton RA, Klungsøyr K, Neville AJ, Jordan S, Pierini A, de Jong-van den Berg LTW, et al. Prescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regions. *PLoS One* 2016; May 18;11(5): e0155737. doi: 10.1371/journal.pone.0155737.
- Charlton RA, Pierini A, Klungsøyr K, Neville AJ, Jordan S, de Jong-van den Berg LT, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. *BMJ Open* 2016 Jan 19;6(1):e009237.
- leiner HF, Bjoro T, Midthjell K, Grill V, Asvold BO. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes: The population-based hunt study in Norway. *J Clin Endocrinol Metab* 2016;101(2):669-77.
- Gabrhelik R, Nechanska B, Mravcic V, Skurtveit S, Lund IO, Handal M. A Unique Opportunity to Study Short and Long Term Consequences in Children Prenatally Exposed to Illicit Drugs and Opioid Maintenance Treatment Using Czech and Scandinavian Registers. *Cent Eur J Public Health* 2016;24(3):248-51.
- Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungsøyr K, Engeland A, et al. Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy - a cohort linkage study. *BJOG* 2016;123(10):1609-18.
- Gimeno-Feliu LA, Calderon-Larranaga A, Prados-Torres A, Revilla-Lopez C, Diaz E. Patterns of pharmaceutical use for immigrants to Spain and Norway: a comparative study of prescription databases in two European countries. *International Journal for Equity in Health* 2016;15.
- Halvorsen S, Jortveit J, Hasvold P, Thuresson M, Øie E. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. *BMC Cardiovasc Disord* 2016;16:115.
- Hartz I, Skurtveit S, Hjellvik V, Furu K, Nesvåg R, Handal M. Antidepressant drug use among adolescents during 2004-2013: a population-based register linkage study. *Acta Psychiatr Scand* 2016;134(5):420-9.
- Hartz I, Skurtveit S, Steffenak AK, Karlstad Ø, Handal M. Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. *BMC Psychiatry* 2016;16:12.
- Johannsdottir IM, Karlstad Ø, Loge JH, Fossa SD, Kiserud C, Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. *J Adolesc Young Adult Oncol* 2016;14:14.
- Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM, et al. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. *PLoS One* 2016;11(12):e0165122.
- Karlstad Ø, Zoega H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. *Eur J Clin Pharmacol* 2016;72(12):1507-14.
- Kaspersen SL, Pape K, Ose SO, Gunnell D, Bjorngaard JH. Unemployment and initiation of psychotropic medication: a case-crossover study of 2 348 552 Norwegian employees. *Occup Environ Med* 2016;73(11):719-26.
- Kjaerulf TM, Ersboll AK, Green A, Emneus M, Pukkala E, Bolin K, et al. Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study. *Scand J Urol* 2016;50(3):220-7.
- Knudsen-Baas KM, Engeland A, Gilhus NE, Storstein AM, Owe JF. Does the choice of antiepileptic drug affect survival in glioblastoma patients? *J Neurooncol* 2016;129(3):461-9.
- Kravdal Ø, Grundy E. Health effects of parental deaths among adults in Norway: Purchases of prescription medicine before and after bereavement. *SSM - Population Health* 2016;2:868-75.
- Magnus MC, Håberg SE, Magnus P, Engeland A, Nafstad P, Karlstad Ø, et al. Pre-eclampsia and childhood asthma. *Eur Respir J* 2016;48(6):1622-30.
- Magnus MC, Karlstad Ø, Håberg SE, Nafstad P, Davey Smith G, Nystad W. Prenatal and infant paracetamol exposure and development of asthma: The Norwegian Mother and Child Cohort Study. *Int J Epidemiol* 2016;45(2):512-22.
- Magnus MC, Karlstad Ø, Midtun O, Håberg SE, Tunheim G, Parr CL, et al. Maternal plasma total neopterin and kynurenine/tryptophan levels during pregnancy in relation to asthma development in the offspring. *J Allergy Clin Immunol* 2016;138(5):1319-25.e4.
- Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M, Haugen M, Høise G, Knudsen GP, Paltiel L, Schreuder P, Tambs K, Vold L, Stoltenberg C. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol*. 2016;45(2):382-8.
- Mellbye A, Borchgrevink PC, Skurtveit S, Fredheim OMS. Hva vet vi om bruken av opioider ved ikke-malign smerte? *Norsk farmaceutisk tidsskrift* 2016;(3):25-30.
- Mellbye A, Karlstad Ø, Skurtveit S, Borchgrevink PC, Fredheim OMS. The duration and course of opioid therapy in patients with chronic non-malignant pain. *Acta Anaesthesiol Scand* 2016;60:128-37.
- Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. *PLoS One* 2016;11(11):e0166451.
- Nesvåg R, Hartz I, Bramness JG, Hjellvik V, Handal M, Skurtveit S. Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. *Eur Neuropsychopharmacol* 2016;26:1412-8.
- Olah KS, Kim TH, Lee HH, Kim JM. Re: Use of hormonal contraceptives among immigrant and native women in Norway: data from the Norwegian Prescription Database The contraceptive situation in Korea. *BJOG* 2016;123(5):840.
- Roman M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, et al. Postmenopausal hormone therapy and breast cancer prognostic characteristics: A linkage between nationwide registries. *Cancer Epidemiology Biomarkers and Prevention* 2016;25(11):1464-73.
- Roman M, Sakshaug S, Graff-Iversen S, Vangen S, Weiderpass E, Ursin G, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. *Int J Cancer* 2016;138(3):584-93.

- Samuelsen PJ, Svendsen K, Wilsgaard T, Stubhaug A, Nielsen CS, Eggen AE. Persistent analgesic use and the association with chronic pain and other risk factors in the population—a longitudinal study from the Tromsø Study and the Norwegian Prescription Database. *Eur J Clin Pharmacol* 2016;72:977-85.
- Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. *Pharmacoepidemiol Drug Saf* 2016;25(10):1160-9.
- Skipenes VP, Skjeldstad FE. Prevalence of combined contraceptive vaginal rings in Norway. *Acta Obstet Gynecol Scand* 2016;95(9):1027-33.
- Sørensen M, Arneberg F, Line TM, Berg TJ. Cost of diabetes in Norway 2011. *Diabetes Res Clin Pract* 2016;122:124-32.
- Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non-refugees from War-Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. *J Immigr Minor Health* 2016;21:21.
- Tjagvad C, Skurtveit S, Bramness JG, Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. *Journal of Substance Use* 2016;21(5):515-20.
- Tvete IF, Bjørner T, Skomedal T. A 5-year follow-up study of users of benzodiazepine: Starting with diazepam versus oxazepam. *Br J Gen Pract* 2016;66(645):e241-e7.
- Øvre-Eide V, Skjeldstad FE. Use pattern for contraceptive implants in Norway. *Acta Obstet Gynecol Scand* 2016;95(11):1244-50.
- 2015:**
- Berg C, Skurtveit S, Sakshaug S, Hjellvik V, Handal M. Reduced Prescribing of Benzodiazepines in Denmark and Norway. *Basic Clin Pharmacol Toxicol*. 2015;116(6):457-8.
- Blix HS, Vestrheim DF, Hjellvik V, Skaare D, Christensen A, Steinbakk M. Antibiotic prescriptions and cycles of *Mycoplasma pneumoniae* infections in Norway: can a nationwide prescription register be used for surveillance? *Epidemiology and Infection*. 2015;143(9):1884-92. doi: 10.1017/S0950268814002908
- Bukten A, Lund IO, Rognli EB, Stavseth MR, Lobmaier P, Skurtveit S, Clausen T, Kunøe N. The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study. *Subst Abuse*. 2015;9(Suppl 2):59-66. doi: 10.4137/SaRt.S23546. eCollection 2015.
- Charlton R, Garne E, Wang H, Klungsøyr K, Jordan S, Neville A, Pierini A, Hansen A, Engeland A et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. *Pharmacoepidemiol Drug Saf*. 2015 Nov;24(11):1144-54. doi: 10.1002/pds.3847.
- Dale O, Borchgrevink PC, Fredheim OM, Mahic M, Romundstad P, Skurtveit S. Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids. *BMC Public Health*. 2015;15:461. doi: 10.1186/s12889-015-1774-6
- de Jonge L, Garne E, Gini R, Jordan SE, Klungsøyr K, Loane M, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmedICAT Study. *Drug safety*. 2015;38(11):1083-93. doi: 10.1007/s40264-015-0321-9
- Engeland A, Bjørge T, Klungsøyr K, Skjaerven R, Skurtveit S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. *European Journal of Epidemiology*. 2015;30(6):501-8. doi: 10.1007/s10654-015-0018-5.
- Fredheim OMS, Mahic M, Skurtveit S, Borchgrevink PC. Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study. *Palliative Medicine*. 2015;29(7):661-6. doi: 10.1177/0269216315575252
- Fride Tvete I, Bjørner T, Skomedal T. Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway. *Scand J Prim Health Care*. 2015;33(4):252-9. doi: 10.3109/02813432.2015.
- Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir U, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M. Serotonin-Reuptake Inhibitors and Venlafaxine in early pregnancy and risk of birth defects – a population based cohort study and sibling design. *BMJ* 2015. Apr 17;350:h1798.
- Hagen TP, Hakkinen U, Iversen T, Klitkou So T, Moger TA. Socio-economic inequality in the use of procedures and mortality among AMI patients: Quantifying the effects along different paths. *Health Econ*. 2015;24:102-15. doi: 10.1002/hec.3269.
- Halvorsen T, Martinussen PE. Benzodiazepine use in COPD: empirical evidence from Norway. *Int J Chron Obstruct Pulmon Dis* 2015;10:1695-702. doi: 10.2147/COPD.S83107
- Hansen AB, Skurtveit S, Borchgrevink PC, Dale O, Romundstad PR, Mahic M, et al. Consumption of and satisfaction with health care among opioid users with chronic non-malignant pain. *Acta Anaesthesiologica Scandinavica*. 2015;59(10):1355-66. doi: 10.1111/aas.12645
- Hartz I, Handal M, Tverdal A, Skurtveit S. Paediatric Off-Label Use of Melatonin - A Register Linkage Study between the Norwegian Prescription Database and Patient Register. *Basic Clin Pharmacol Toxicol* 2015;117(4):267-73. doi: 10.1111/bcpt.12411
- Hermann M, Waade RB, Molden E. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. *Therapeutic Drug Monitoring*. 2015;37(4):546-9. doi: 10.1097/FTD.000000000000169.
- Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sjøgaard AJ, Syversen U, et al. Use of anti-osteoporotic drugs in central Norway after a forearm fracture. *Archives of Osteoporosis*. 2015;10:30. doi: 10.1007/s11657-015-0235-2.
- Høiseith G, Middelkoop G, Mørland J, Gjerde H. Has Previous Abuse of Flunitrazepam Been Replaced by Clonazepam? *European Addiction Research*. 2015;21(4):217-21. DOI:10.1159/000377628
- Iversen MM, Nefs G, Tell GS, Espehaug B, Midthjell K, Graue M, et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine-year follow-up of the Nord-Trøndelag Health Study, Norway. *Journal of Psychosomatic Research*. 2015;79(4):309-15.
- Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Vejrup K, et al. Hormonal contraceptive use before and after conception in relation to preterm birth and small for gestational age: An observational cohort study. *BJOG* 2015;122(10):1349-61. DOI: 10.1111/1471-0528.13114
- Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. *Seizure*. 2015;28:88-91. doi:10.1016/j.seizure.2015.02.017
- Kann IC, Lundqvist C, Lurås H. Polypharmacy Among the Elderly in a List-Patient System. *Drugs - Real World Outcomes*. 2015;2(3):193-8. doi: 10.1007/s40801-015-0036-3
- Kelly E, Lu CY, Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. *Journal of Clinical Pharmacy and Therapeutics*. 2015;40(1):76-82. doi: 10.1111/jcpt.12227
- Kieler H, Malm H, Artama M, Engeland A, Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. *BJOG-an International Journal of Obstetrics and Gynaecology*. 2015;122(12):1618-24. DOI: 10.1111/1471-0528.13164
- Krævdal Ø, Grundy E, Skirbekk V. Fertility history and use of anti-depressant medication in late mid-life: a register-based analysis of Norwegian women and men. *Aging & mental health*. 2015;1-10. doi: 10.1080/13607863.2015.1118010
- Lund IO, Skurtveit S, Handal M. Commentary on Raitasalo et al: the great potential in nation-wide registers to study prescription drug use and abuse. *Addiction (Abingdon, England)*. 2015;110(4):644-5. DOI: 10.1111/add.12856
- Lund IO, Bukten A, Storvoll EE, Moan IS, Skurtveit S, Handal M, Nordfjaern T, Brunborg GS, Rossow I. A Cohort Study on Long-Term Adverse Effects of Parental Drinking: Background and Study Design. *Subst Abuse*. 2015 Dec 15;9(Suppl 2):77-83. doi: 10.4137/SaRt.S23329.
- Mahic M, Fredheim OM, Borchgrevink PC, Skurtveit S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. *Eur J Pain*. 2015 Sep;19(8):1095-100. doi: 10.1002/ejp.632.
- Magnus MC, Håberg SE, Karlstad O, Nafstad P, London SJ, Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Study. *Thorax*. 2015;70(3):237-43. doi: 10.1136/thoraxjnl-2014-206438.
- Neutel CI, Johansen HL. Association between hypnotics use and increased mortality: causation or confounding? *European Journal of Clinical Pharmacology*. 2015;71(5):637-42. doi: 10.1007/s00228-015-1841-z.
- Rossow I, Bramness JG. The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study. *BMC Public Health*. 2015;15. doi: 10.1186/s12889-015-1615-7.
- Ruths S, Bakken MS, Ranhoff AH, Hunskaar S, Engesaeter LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study. *BMC Geriatrics*. 2015;15. doi: 10.1186/s12877-015-0154-5

Skrede S, Tivete IF, Tanum L, Steen VM, Bramness JG. Incident Users of Antipsychotic Agents and Future Use of Cholesterol-Lowering Drugs: An Observational, Pharmacoepidemiologic Study. *Journal of Clinical Psychiatry*. 2015;76(1):E111-E6. doi: 10.4088/JCP.14m08996.

Suhrke P, Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register-based cohort study. *Cancer Medicine*. 2015;4(8):1303-8. doi: 10.1002/cam4.474

Tivete IF, Bjørner T, Skomedal T. Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway. *Scand J Primary Health Care*. 2015;33(4):252-9. doi: 10.3109/02813432.2015.1117282

Øymar K, Mikalsen IB, Furu K, Nystad W, Karlstad Ø. Prescription patterns of inhaled corticosteroids for preschool children - A Norwegian register study. *Pediatric Allergy and Immunology*. 2015;26(7):655-61. doi: 10.1111/pai.12429

Zoega H, Kieler H, Nørgaard M, Furu K, Valdimarsdóttir U, Brandt L, et al. Use of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and Sweden. *Plos One*. 2015;10(12). DOI: 10.1371/journal.pone.0144474

2014:

Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. *Acta Neurol Scand Suppl*. 2014;129:26-31

Andersen JB, Owe JF, Engeland A, Gilhus NE. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. *Eur J Neurol* 2014;21:948-955

Bakken MS, Engeland A, Engesaeter LB, Ranhoff AH, Hunskaar S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. *Eur J Clin Pharmacol* 2014;70:873-880

Berg-Hansen P, Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. *Mult Scler* 2014;20:1780-1782

Ferrer P, Rafaniello C, Sabate M, Ballarín E, Coma A, Zara C, et al. Cross-national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007-2011. *Epidemiology Biostatistics and Public Health*. 2014;11:e9405-1.

Fredheim OM, Mahic M, Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemiological study from the Norwegian prescription database and the Nord-Trøndelag health study (HUNT). *Pain* 2014;155:1213-1221

Gjelsvik B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self-poisoning: a multilevel approach. *PLoS One*. 2014;e98086.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association Between Use of β -Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. *European Urology* 2014;65:635-641.

Halvorsen T, Martinussen PE. The geography of chronic obstructive pulmonary disease: A population-based study of Norway. *Soc Sci Med* 2014;21:25-34.

Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offspring overweight or obesity. *Int J Obes*. 2014;38:1275-81.

Kalseth J, Halvorsen T, Kalseth B, Sarheim Anthun K, Peltola M, Kautiainen K, Häkkinen U, Medin E, Lundgren J, Rehnberg C, Másdóttir BB, Heimisdóttir M, Bjarnadóttir HH, Kjøtlum JE, Kilsmark J, Halsteinli V. Cross-country comparisons of health-care costs: The case of cancer treatment in the Nordic countries. *Health Policy* 2014;115:172-179.

Kann IC, Lundqvist C, Luras H. Prescription of addictive and non-addictive drugs to home-dwelling elderly. *Drugs Aging*. 2014 Jun;31(6):453-9.

Karlstad Ø, Furu K, Skurtveit S, Selmer R. Prescribing of Drugs for Attention-Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. *Eur Addict Res* 2014;20:59-65.

Kieler H, Malm H, Artama M, Engeland A, Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. *BJOG*. 2014 Nov 14;[Epub ahead of print]:doi: 10.1111/1471-0528.13164.

Kielland KB, Amundsen EJ, Dalgard O. HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. *Scand J Gastroenterol*. 2014 Dec;49(12):1465-72.

Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short- and Long-Term Mortality Risk Associated with the Use of Antipsy-

chotics Among 26,940 Dementia Outpatients: A Population-Based Study. *Am J Geriatr Psychiatry* 2014;22:321-331.

Mahic M, Fredheim OM, Borchgrevink PC, Skurtveit S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. *Eur J Pain*. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ejp.632.

Mellbye A, Karlstad O, Skurtveit S, Borchgrevink PC, Fredheim OM. Co-morbidity in persistent opioid users with chronic non-malignant pain in Norway. *Eur J Pain*. 2014;18:1083-1093

Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41-80 year old Norwegians, 2005-2010. *Eur J Pain*. 2014 Mar;18(3):438-46.

Nordfjærn T, Bjerkeset O, Bratberg G, Moylan S, Berk M, Grawe R. Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. *Nord J Psychiatry* 2014;68:107-116.

Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study. *Glob J Health Sci*. 2014 Jul;6(4):155-62.

Omland G, Ruths S, Diaz E. Use of hormonal contraceptives among immigrants and native women in Norway: data from the Norwegian Prescription Database. *BJOG* 2014;121:1221-1228

Riska BS, Skurtveit S, Furu K, Engeland A, Handal M. Dispensing of benzodiazepines and benzodiazepine-related drugs to pregnant women: a population-based cohort study. *Eur J Clin Pharmacol*. 2014 Nov;70(11):1367-74.

Skrivarhaug T, Stene LC, Drivvoll AK, Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Childhood Diabetes Registry. *Diabetologia* 2014;57:57-62.

Skurtveit S, Selmer R, Odsbu I, Handal M. Self-reported data on medicine use in the Norwegian mother and child cohort study compared to data from the Norwegian prescription database. *Norsk Epidemiologi*. 2014;24(1-2).

Strøm H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study. *BMC Public Health*. 2014;14:520.

Svendsen K, Fredheim OM, Romundstad P, Borchgrevink PC, Skurtveit S. Persistent opioid use and socio-economic factors: a population-based study in Norway. *Acta Anaesthesiol Scand*. 2014;58:437-445.

Sørås A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing *Escherichia coli*. *PLoS One*. 2014;9:e85889.

2013:

Bakken MS, Engeland A, Engesaeter LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. *Age Ageing* 2013;42:514-20.

Berge LI, Riise T, Iversen M. Co-morbidity between diabetes, migraine and depression. *Norsk Epidemiologi* 2013;23:2013.

Berge LI, Riise T, Fasmer OB, Hundal O, Oedegaard KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? *Epidemiology* 2013;24:129-34.

Bjorner T, Tivete IF, Aursnes I, Skomedal T. [Dispensing of benzodiazepines and Z drugs by Norwegian pharmacies 2004-2011]. *Tidsskr Nor Laegeforen* 2013;133:2149-53.

Brelin S, Loge JH, Skurtveit S, Johannesen TB, Aass N, Ottesen S, et al. Antidepressants to cancer patients during the last year of life--a population-based study. *Psychooncology* 2013;22:506-14.

Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. *Osteoporos Int* 2013;24:1225-33.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. *British Journal of Clinical Pharmacology* 2013;75:1134-41.

Fossum GH, Lindbaek M, Gjelstad S, Dalen I, Kvaerner KJ. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway. *BMJ Open* 2013;3:e002285.

Fredheim OM, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonma-

- lignant pain: a study from the Norwegian Prescription Database. *Pain* 2013;154:2487-93.
- Holdø I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. *Arch Dis Child* 2013;98:732-6.
- Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. *Br J Gen Pract*. 2013;63:e777-86.
- Jonasson C, Tvette IF, Hatlebakk JG. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. *Scand J Gastroenterol* 2013;48:1010-7.
- Klovstad H, Natas O, Tverdal A, Aavitsland P. Systematic screening with information and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. *BMC Infectious Diseases* 2013;13:30.
- Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? *Social Science and Medicine* 2013;81:42-52.
- Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. *J Vet Pharmacol Ther* 2013;36:285-91.
- Kyrudal AE, Dahl AA, Hernes E, Smastuen MC, Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. *BJU Int* 2013;111:221-32.
- Lillefjell M, Haugan T, Martinussen P, Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. *Journal of Musculoskeletal Pain* 2013;21:311-319.
- Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. *Eur J Clin Pharmacol* 2013;69:111-8.
- Lund IO, Skurtveit S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. *Addiction* 2013;108:367-76.
- Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. *Acta Obstet Gynecol Scand* 2013;92:1208-1215.
- Neutel CI, Skurtveit S, Berg C, Sakshaug S. Multiple prescribers in older frequent opioid users--does it mean abuse? *J Popul Ther Clin Pharmacol* 2013;20:e397-e405.
- Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. *Eur J Epidemiol* 2013;28:759-69.
- Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. *Obstetrics and Gynecology* 2013;121:306-13.
- Nordfjaern T, Bjerkeset O, Moylan S, Berk M, Grawe RW. Clusters of personality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. *Addict Behav* 2013;38:2575-80.
- Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. *Hum Psychopharmacol* 2013;28:248-57.
- Persheim MS, Helland A, Spigset O, Slordal L. Potensielt vanedannende legemidler på blåresept ved kroniske sterke smerter. [Potentially addictive drugs on reimbursable prescription for chronic severe pain]. *Tidsskrift for den Norske Laegeforening* 2013;133:150-4.
- Rognstad S, Brekke M, Fetveit A, Dalen I, Straand J. Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. *Br J Gen Pract*. 2013;63:e554-62.
- Skogar O, Nilsson M, Tornhage CJ, Løkk J. National surveys: a way to manage treatment strategies in Parkinson's disease? *Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease*. *J Multidiscip Healthc* 2013;6:239-47.
- Skollerud LM, Fredheim OM, Svendsen K, Skurtveit S, Borchgrevink PC. Laxative prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. *Supportive Care in Cancer* 2013;21:67-73.
- Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. *J Clin Epidemiol* 2013;66:964-72.
- Stene LE, Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. *Journal of Women's Health* 2013;22:250-8.
- Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. *JAMA* 2013;309:48-54.
- Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. *Heart* 2013;99:1755-60.
- Tvette IF, Bjørner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. *BMJ Open* 2013;3:e003296.
- Westin AA, Bramness JG, Chalabianloo F, Rynestad T, Slordal L. [Pregabalin should be moved to the prescription group B]. *Tidsskr Nor Laegeforen* 2013;133:615-6.
- 2012:**
- Berge LI, Riise T, Fasmer OB, Lund A, Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. *Diabet Med* 2012;29:509-14.
- Blix HS, Hjellvik V. Økt bruk av antibiotika blant 19-åringene i mai. [Increased use of antibiotics among nineteen-year-olds in May]. *Tidsskr Nor Laegeforen* 2012;132:1084-8.
- Blix HS, Landmark K, Selmer R, Reikvam Å. Forskrivning av antihypertensive legemidler 1975-2010. [Patterns in the prescription of antihypertensive drugs in Norway, 1975-2010] *Tidsskr Nor Laegeforen* 2012;132:1224-8.
- Bramness JG, Furu K, Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. *Clin Pharmacol Therap* 2012;91:438-41.
- Bramness JG, Skurtveit S, Mørland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. *Addiction* 2012;107:967-72.
- Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, Sjøgård AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. *Pharmacoepidemiol Drug Saf* 2012;21:297-304.
- Devold HM, Sjøgaard AJ, Tverdal A, Falck JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. *Osteoporosis International* 2012;24:1225-33.
- Fasmer OB, Riise T, Lund A, Dilsaver SC, Hundal O, Ødegaard KJ. Comorbidity of migraine with ADHD. *J Attend Disord* 2012;16:339-45.
- Fredheim OMS, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: A pharmacoepidemiological study from a national prescription database. *Palliative Medicine* 2012;26:804-12.
- Fredheim OM, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: a pharmacoepidemiological study from a national prescription database. *Palliat Med* 2012;26:804-812.
- Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. *Pharmacoepidemiol Drug Saf* 2012;21:881-5.
- Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. *J Clin Psychiatry*. 2012;73:e548-54.
- Handal M, Skurtveit S, Mørland JG. Samtidig bruk av ulike benzodiazepiner. [Co-medication with benzodiazepines]. *Tidsskr Nor Laegeforen*. 2012;132:526-30.
- Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nationwide prescription database study. *Scandinavian Journal of Public Health* 2012;40:704-11.
- Hjellvik V, Mahic M, Tverdal A. Utdanning og legemiddelbruk. [Education and use of drugs in Norway]. *Tidsskr Nor Laegeforen* 2012;132:2166-70.
- Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Comorbidities in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2012;21:1045-52.
- Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nørgaard M, Nielsen RB, Stephansson O, Valdimarsdóttir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries *BMJ* 2012;344:d8012.

- Kjome RL, Roraas T, Granas AG, Sandberg S. [Regional differences in sales of glucometer strips and antidiabetics]. *Tidsskr Nor Laegeforen* 2012;132:1453-7.
- Kjosavik SR, Ruths S, Hunskaar S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. *Eur J Clin Pharmacol* 2012;68:311-9.
- Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: Participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Medical Research Methodology* 2012;12:143.
- Lillemoen PKS, Kjosavik SR, Hunskaar S, Ruths S. [Prescriptions for ADHD medication, 2004–08]. *Tidsskr Nor Laegeforen* 2012;132:1856-60.
- Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non-malignant pain. *Acta Anaesthesiologica Scandinavica* 2012;56:1267-76.
- Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. *Sleep Medicine* 2012;13:893-7.
- Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. *Pharmacoepidemiol Drug Saf* 2012;21:199-206
- Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z-hypnotic use in Norwegian elderly, aged 65-79. *Norsk Epidemiologi* 2012;22:203-8.
- Nordbø A, Skurtveit S, Borchgrevink PC, Kaasa S, Fredheim OM. Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs. *Acta Anaesthesiol Scand.* 2012;56:88-94.
- Nordfjærn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. *Addictive Behaviors* 2012;37:1151-7.
- Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? *European Journal of Clinical Pharmacology* 2012;68:1085-94.
- Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Borchgrevink PC, Fredheim OMS. [Reimbursement of analgesics for chronic pain]. *Tidsskr Nor Laegeforen* 2012;132:2489-93.
- Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. *British Journal of Clinical Pharmacology* 2012;74:1053-62.
- Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. *Neuro-Oncology* 2012;14:1178-84.
- Selmer R, Blix HS, Landmark K, Reikvam Å. Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up of 78,453 incident users. *Eur J Clin Pharmacol* 2012;68:1435-42.
- Skjeldestad FE. [Prescribing contraception for young women]. *Tidsskr Nor Laegeforen.* 2012;132:292-4.
- Steffenak AKM, Wilde-Larsson B, Skurtveit S, Furu K, Nordström G, Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents - a prospective register linkage study. *J Adolescent Health* 2012;50:578-87
- Steffenak AKM, Wilde-Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. *Clinical Epidemiology* 2012;4:225-31.
- Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. *BMJ Open.* 2012 Apr 5;2(2):e000614.
- Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: A nationwide population-based study with focus on gender differences. *BMC Medicine* 2012;10:148.
- Svendsen K, Skurtveit S, Romundstad P, Borchgrevink PC, Fredheim OM. Differential patterns of opioid use: defining persistent opioid use in a prescription database. *Eur J Pain* 2012;16:359-69.
- Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. *Scand J Rheum* 2012;41:196-201.
- Von Soest T, Bramness JG, Pedersen W, Wichstrøm L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. *Epidemiology and Psychiatric Sciences* 2012;21:87-95.
- Åsvold BO, Vatten LJ, Midthjell K, Bjørø T. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the HUNT Study in Norway. *J Clin Endocrinol Metab.* 2012;97:93-9.
- 2011:**
Berg C, Sakshaug S, Handal M, Skurtveit S. Z-hypnotika - Sovemidlene som dominerer markedet i Norge. *Norsk Farmaceutisk Tidsskrift* 2011;4:20-23.
- Blix H, Hjellevik V, Litleskare I, Rønning M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. *J Antimicrob Chemother* 2011;66:2159-67.
- Bramness JG, Sexton JA. The basic pharmacoepidemiology of benzodiazepine use in Norway 2004-9. *Norsk Epidemiologi* 2011; 21: 35-42
- Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. *BMC Public Health.* 2011;11:144.
- Dalen DM, Furu K, Locatelli M, Strøm S. Generic substitution: micro evidence from register data in Norway. *Eur J Health Econ* 2011;12:49-59.
- Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. *Eur J Epidemiol* 2011;26:157-63.
- Espnes MG, Bjørge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2011;20:243-8.
- Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal Ø, Ødegaard KJ. Comorbidity of asthma with ADHD. *J Atten Disord* 2011;15:564-71.
- Fredheim OM, Borchgrevink P, Nordstrand B, Clausen T, Skurtveit S. Prescription of analgesics to patients in opioid maintenance therapy: A pharmacoepidemiological study. *Drug Alcohol Depend* 2011;116:158-62.
- Furu K, Karlstad Ø, Skurtveit S, Håberg SE, Nafstad P, London SJ, Nystad W. High validity of mother-reported use of antiasthmatics among children: a comparison with a population-based prescription database. *J Clin Epidemiol* 2011;64:878-84.
- Furu K, Skurtveit S. Legemidler forskrevet til barn og ungdom i alderen 0-17 år i Norge. En studie basert på data fra Reseptregisteret. *Norsk Farmaceutisk Tidsskrift* 2011;119:14-7.
- Ghaderi S, Nordbø SA, Bakken IJ. Chlamydiainfeksjon i Sør-Trøndelag – behandling og oppfølging. [Chlamydia infections in South Trøndelag – treatment and follow-up]. *Tidsskr Nor Laegeforen* 2011;131:461-3.
- Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. *Expert Rev Pharmacoecon Outcomes Res.* 2011;11:121-9.
- Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, Lonsdale J, Malmström R, Martikainen J, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay F, Vlahovic-Palcevski V, Wendykowska K, Wettermark B, Zara Corinne Gustafsson L. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Front Pharmacol* 2011;1:141.
- Gjelstad S, Straand J, Dalen I, Fetveit A, Strøm H, Lindbæk M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? *J Antimicrob Chemother* 2011;66:2425-33.
- Hancock D, Håberg SE, Furu K, Whitworth KV, Nafstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. *Pediatr Allergy Immunol* 2011;22:528-36.
- Handal M, Engeland A, Rønning M, Skurtveit S, Furu K. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. *Eur J Clin Pharmacol* 2011;67:953-60
- Harman C, Reid M, Thomas KV. In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. *Environ Sci Technol.* 2011;45:5676-82.
- Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance therapy – a pharmacoepidemiological study *Norsk Epidemiologi* 2011;21:77-83.
- Hartz I, Tverdal, Aa, Skurtveit S. Langtidsbruk av benzodiazepiner i kombinasjon med opioider og z-hypnotika blant uføretrygdte i Norge. *Norsk Farmaceutisk Tidsskrift* 2011; 119, 24-28

- Hjellvik V, Tverdal A, Strøm H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. *Epidemiology* 2011;22:418-21.
- Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway –explained by hormone therapy or mammographic screening? *International Journal of Cancer* 2011;95:51-9.
- Karlstad Ø, Tverdal A, Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. *Pharmacoepidemiol Drug Saf* 2011;20:370-7.
- Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of anti-psychotics and antidepressants in general practice and specialist care in Norway. *Acta Psychiatr Scand* 2011;123:459-65.
- Kvaale MK, Grave K, Bangen M, Norström M. Forskrivning av antibakterielle midler til hund og katt i Norge i perioden 2005-2008. *Norsk Veterinærtidsskrift* 2011;123:76-79.
- Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. *Epilepsy Res.* 2011;95:51-9.
- Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti-dementia drugs with psychotropic drugs in Norway--a population-based study. *Pharmacoepidemiol Drug Saf.* 2011;20:1319-26.
- Log T, Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults – a population-based cohort study. *Pharmacoepidemiol Drug Saf* 2011;20:90-8.
- Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. *Scand J Pain* 2011;2:36-44.
- Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009. *Pharmacoepidemiol Drug Saf.* 2011;20:457-63.
- Neubert A, Hsia Y, de Jong-van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, Nørgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. *Br J Clin Pharmacol.* 2011;72:969-77.
- Skurtveit S, Furu K, Handal M, Borchgrevink P, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? *Pain* 2011;152:1555-61.
- Zoega H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: A population-based comparison study. *Acta Psychiatr Scand* 2011;123:360-7.
- Ødegaard KJ, Dilsaver SC, Hundal O, Riise T, Lund A, Akiskal HS, Fasmer OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the Norwegian Prescription Database. *J Clin Psychopharmacol.* 2011;31:734-9.
- Ødegaard KJ, Riise T, Dilsaver S, Lund A, Akiskal H, Fasmer OB, Hundal Ø. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. *J Affective Disorders* 2011;129:198-204.
- 2010:**
- Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. *Pharm World Sci.* 2010;32:752-8.
- Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. *Pharmacoepidemiol Drug Saf* 2010;19:273-9.
- Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. *Eur J Neurol* 2010;17:1445-50.
- Berg A, Furu K, Einen, M, Spigseth O: Bør barn behandles med efedrin mikstur? [Should children be treated with ephedrine mixture?]. *Tidsskr Nor Lægeforen* 2010;24: 2474-5.
- Berge HM, Gjelstad S, Furu K, Straand J. Glukosaminbruk reduserer ikke behovet for analgetika [Use of glucosamine does not reduce the need for other pain-relieving drugs]. *Tidsskr Nor Lægeforen* 2010;130:1463-6.
- Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. *Drugs: Education, Prevention, and Policy* 2010;17:168-80.
- Bramness J, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. *Basic Clin Pharmacol Toxicol* 2010;107:883-6.
- Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sjøgaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 – a nationwide register study in Norway. *Eur J Clin Pharmacol* 2010;66:299-306.
- Fredheim OM, Skurtveit S, Breivik H, Borchgrevink P. Increasing use of opioids from 2004 to 2007 – Pharmacoepidemiological data from a complete national prescription database in Norway. *Eur J Pain* 2010;14:289-294.
- Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen Ø, Borchgrevink P. Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. *Pediatric Anesthesia* 2010;20:537-544.
- Furu K, Skurtveit S, Strøm H, Rønning M. Reseptregisteret 2004-2009 - en kilde til informasjon. *Norsk Farmaceutisk Tidsskrift* 2010;12:29-31.
- Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic Countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106:86-94.
- Gjerden P, Slørddal L, Bramness JG. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. *Eur J Clin Pharmacol* 2010;66:911-7.
- Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. *Soc Sci Med* 2010;70:921-5.
- Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. *Scand J Public Health* 2010;38:465-73.
- Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. *Eur Resp J* 2010;35:1235-42.
- Hunskaar S, Welle-Nilsen LK. The market lifecycle of duloxetine for urinary incontinence in Norway. *Acta Obstet Gynecol Scand.* 2010;89:217-22.
- Kann IC, Bjørn E, Lurås H. Competition in general practice: prescriptions to the elderly in a list patient system. *J Health Econ.* 2010;29:751-64.
- Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. *Eur J Clin Pharmacol* 2010;66:399-406.
- Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population-based study. *Eur J Clin Pharmacol* 2010;66:1151-60.
- Kjome RL, Granas AG, Nerhus K, Roraas TH, Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. *Diabetes Technol Ther* 2010;12:701-5.
- Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG. Bruk av benzodiazepiner og cannabis blant unge voksne [Use of benzodiazepines and cannabis in young adults]. *Tidsskr Nor Lægeforen* 2010 ;130:928-31.
- Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids-- a follow-up study of 17 074 men and women. *Pain Med* 2010;11:805-14.
- Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. *Ann Epidemiol* 2010;20:890-7.
- Vandraas K, Spigset O, Mahic M, Slørddal S. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. *Eur J Clin Pharmacol* 2010;66:823-9.
- 2009:**
- Bachs LC, Engeland A, Mørland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. *Clin Pharmacol Ther* 2009;85:596-9.
- Bramness JG. Bruk av litium i Oslo og i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. *Tidsskr Nor Lægeforen* 2009;129:855-7.
- Bramness JG. Ungdom og dagliglivets smerter. [Adolescents and everyday life pains]. *Tidsskr Nor Lægeforen* 2009; 129:1444.
- Bramness JG, Grøholt B, Engeland A, Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 – a prescription database study. *J Affect Disord* 2009; 117:208-11.
- Bramness JG, Skurtveit S, Neutel I, Mørland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? *Pharmacoepidemiol Drug Saf* 2009;18:492-6.

- Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. *J Affect Disord* 2009;118:224-8.
- Devold H, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. *Brit J Clin Pharmacol* 2009;67:234-41.
- Engeland A, Bjørge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. *Acta Obstet Gynecol Scand* 2009;88:1083-9.
- Fredheim OM, Skurtveit S, Moroz A, Breivik H, Borchgrevink P. Prescription pattern of codeine for non-malignant pain in Norway- a pharmacoepidemiological study from The Norwegian Prescription Database. *Acta Anaesthesiol Scand* 2009;53:627-33.
- Gjerden P, Bramness JG, Slørdaal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. *Br J Clin Pharmacol* 2009;67:228-33.
- Gjerden P, Slørdaal L, Bramness JG. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. *Eur J Clin Pharmacol* 2009;65:1229-35.
- Gjerden P, Slørdaal L, Bramness JG. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine. *Br J Clin Pharmacol* 2009;68:238-42.
- Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. *Scand J Public Health* 2009;37:320-6.
- Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. *Nor J Epidemiol* 2009;19:169-172.
- Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway – use among disability pensioners. *Nor J Epidemiol* 2009;19:209-218.
- Hauge S, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. *Virology* 2009;6:54.
- Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. *Eur J Clin Pharmacol* 2009;65:295-301.
- Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Samtidig bruk av warfarin, analgetika og antiinflammatoriske midler. [Concomitant use of warfarin, analgesics and anti-inflammatory drugs]. *Tidsskr Nor Lægeforen* 2009;129:1217-20.
- Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2009;18:572-8.
- Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population-based study of prescriptions. *Epilepsy Res* 2009; 87: 31-9.
- Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. *Brit J Clin Pharmacol* 2009;67:355-62.
- Skurtveit S, Furu K, Kaasa S, Borchgrevink P. Introduction of low dose transdermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? *Eur J Pain* 2009;13:949-53.
- Skurtveit S, Strøm H, Skriverhaug T, Mørland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up study. *Diabet Med* 2009; 26:404-08.
- Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study. *Pharmacoepidemiol Drug Saf* 2009;18:737-42.
- Winther RB, Bramness JG. Legemiddelshopping av vanedannende medikamenter i Norge [Prescription shopping of addictive drugs in Norway]. *Tidsskr Nor Lægeforen* 2009;129:517-20.
- 2008:**
- Bachs LC, Bramness JG, Engeland A, Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. *Nor J Epidemiol* 2008;18:185-90.
- Berg A, Furu K, Spigset O. Slimhinneavsvellende nesedråper og nesesypray hos barn [Nasal decongestants and nasal sprays in children]. *Tidsskr Nor Lægeforen* 2008;128:2582-3.
- Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. *Nor J Epidemiol* 2008;18:167-72.
- Bramness JG, Skurtveit S. Carisoprodol should be taken off the market. *South Med J* 2008;101:1074-5.
- Bramness JG, Skurtveit S, Neutel CI, Mørland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. *J Clin Psych* 2008; 69:1099-1103.
- Brekke M, Rognstad, Straand J, Furu K, Gjelstad S, Bjørner T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. *Scand J Prim Health Care* 2008;26:80-5.
- Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. *Br J Clin Pharmacol* 2008;65:653-60.
- Engeland A, Bramness JG, Mørland J, Skurtveit S. Veitrafikkulykker knyttet til forskrivning av legemidler: en registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] *Nor J Epidemiol* 2008;18: 159-66.
- Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008; 18:129-36.
- Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel CI, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. *Sleep Med* 2008;9:818-22.
- Hagen K, Stovner LJ, Skorpen F, Pettersen E, Zwart JA. COMT genotypes and use of antipsychotic medication: linking population-based prescription database to the HUNT study. *Pharmacoepidemiol Drug Saf* 2008;17:372-7.
- Litleskare I, Blix H, Rønning M. Antibiotikaforbruk i Norge [Antibiotic use in Norway]. *Tidsskr Nor Lægeforen* 2008;128:2324-9.
- Olsen AS, Ottesen S. Varierende forskrivning av opioider til norske kreftpasienter [Variable prescription of opioids to cancer patients in Norway]. *Tidsskr Nor Lægeforen* 2008;128:1271-4.
- Skurtveit S, Furu K, Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later – a follow-up study of 13 390 men and women aged 40-42 years. *Pharmacoepidemiol Drug Saf* 2008;17:926-933.
- Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. *J Clin Epidemiol* 2008;61:714-17.
- Strøm H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. *Nor J Epidemiol* 2008;18:191-94.
- 2007:**
- Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. *J Antimicrob Chemother* 2007;59:1161-6.
- Blix HS, Engeland A, Litleskare I, Rønning M. Age- and gender-specific antibacterial prescribing in Norway. *J Antimicrob Chemother* 2007;59:971-6.
- Bramness JG, Engeland A, Furu K. Antidepressiver hos barn og ungdom – førte advarsler til færre forskrivninger? [The use of antidepressants amongst children and adolescents – did the warnings lead to fewer prescriptions?] *Tidsskr Nor Lægeforen* 2007;127:2653-5.
- Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. *Br J Clin Pharmacol* 2007;64: 210-8.
- Bramness JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. *Drug Alcohol Depend* 2007;90:203-9.
- Bramness JG, Skurtveit S, Mørland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. *Accid Anal Prev* 2007;39:1050-5.
- Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. *Ann Epidemiol* 2007;17:597-602.
- Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. *Eur J Clin Pharmacol* 2007;63:693-8.
- Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njølstad I, Skurtveit S. Aspects of statin prescribing in Norwegian counties with high, average and

low statin consumption - an individual-level prescription database study. *BMC Clin Pharmacol* 2007;7:14.

Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P. A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. *BMC Public Health* 2006;6:141.

Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. *Br J Clin Pharmacol* 2007;64:476-81.

Torkildsen O, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. *Acta Neurol Scand Suppl* 2007;187:46-50.

Åsheim H, Nilsen KB, Johansen K, Furu K. [Prescribing of stimulants for ADHD in Nordland county]. *Tidsskr Nor Laegeforen* 2007;127:2360-2.

2006:

Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M. [Changes in the sale and use of flunitrazepam in Norway, 1999 – 2004]. *Tidsskr Nor Laegeforen* 2006;126:589-90.

Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. *BMC Health Serv Res* 2006;6:75.

Mellingsæter T, Bramness JG, Slørdal L. [Are z-hypnotics better and safer sleeping pills than benzodiazepines?] *Tidsskr Nor Laegeforen* 2006; 126: 2954-6.

Straand J, Fetveit A, Rognstad S, Gjelstad S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. *BMC Health Serv Res* 2006;6:72.

Strøm H, Engeland A, Eriksen E, Sakshaug S, Rønning M. [How many and who are receiving medication for diabetes mellitus?] *Tidsskr Nor Laegeforen* 2006;126:768-70.

2005:

Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Rønning M. [Prescription of selective serotonin reuptake inhibitors 1990–2004]. *Tidsskr Nor Laegeforen* 2005;125:2470-3.

2004:

Strøm H. Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk [The Norwegian Prescription Database: An important tool for detailed information on drug use]. *Nor J Epidemiol* 2004;14:53-56.

2001:

Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. *Nor J Epidemiol* 2001;11:55-60.

Utgitt av Folkehelseinstituttet
Published by Norwegian Institute of Public Health
June 2019

Bestilling/Order:
Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no
Only available as PDF from www.fhi.no

ISBN: 978-82-8406-014-9 elektronisk utgave / electronic version
ISSN: 1890-9647